Genetically-modified bacterial cells and uses thereof

Genetically-modified bacterial cells with targeted gene modifications enhance transformation efficiency and plasmid yield, addressing limitations in current methods and accelerating biotechnology processes.

WO2026236259A1PCT designated stage Publication Date: 2026-11-12NOVEL BIOTECHNOLOGY USA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026741
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-02-02
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current bacterial transformation methods are limited by low efficiency and plasmid yield, which hinder molecular cloning and recombinant DNA workflows.

Method used

Genetically-modified bacterial cells with targeted genetic modifications, such as reduced expression of specific genes like mltG and increased expression of oxyR, enhance transformation efficiency and plasmid yield, and improve growth kinetics.

Benefits of technology

The modified bacterial cells achieve significantly higher transformation efficiency, faster replication rates, and enhanced plasmid production, accelerating biotechnology processes and improving laboratory and industrial productivity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026741_12112026_PF_FP_ABST
    Figure US2026026741_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides engineered bacterial cells having one or more genetic modifications that result in increased transformation efficiency of a transformed plasmid. Also disclosed herein are engineered bacterial cells having one or more genetic modifications that result in increased or constitutive production of bacterial stress proteins that result in increased yield of transformed plasmid. Also disclosed herein are expressions systems containing an engineered bacterial cell as described herein.
Need to check novelty before this filing date? Find Prior Art

Description

Docket No. 212391-704601GENETICALLY-MODIFIED BACTERIAL CELLS AND USES THEREOFCROSS-REFERENCE

[0001] This application claims the benefit of U.S. Provisional Application No.63 / 800,665 filed May 6, 2025, and U.S. Provisional Application No. 63 / 974,132 filed February 2, 2026, the entire contents of which are incorporated herein by reference.SEQUENCE LISTING

[0002] The instant application contains a Sequence listing which has been submitted electronically in XML file format and is incorporated by reference in its entirety. Said XML copy, created on May 5, 2026, is named 212391-704601_SL.xml and is 98,723 bytes in size.BRIEF SUMMARY

[0003] Provided herein are genetically-modified bacterial cells of species Vibrio natriegens comprising a genetic modification to an mltG gene that results in reduced expression of mltG polypeptide encoded by the mltG gene, as compared to an amount of mltG polypeptide expressed from the mltG gene prior to the genetic modification. In some embodiments, the genetic modification results in increased transformation efficiency of a plasmid transformed into the genetically-modified bacterial cell after the genetically-modified bacterial cell is made chemically competent, as compared to transforming the plasmid into a comparable chemically competent wildtype bacterial cell. In some embodiments, the genetically-modified bacterial cells provided herein further comprising an additional modification to a gene selected from the group consisting of RecA, DAM, DNS, KDO, KdsD, gutQ, kdsA, kdsB, waaA, msbA, yhiD, IpxL, IpxM, (|)prol, (|)pro2, and any combination thereof.

[0004] Provided herein are genetically-modified bacterial cells comprising a genetic modification that results in reduced expression of a polypeptide encoded by a gene having a polynucleotide sequence of SEQ ID NO: 1, as compared to an amount of expression of the polypeptide encoded by the gene having the polynucleotide sequence of SEQ ID NO: 1 by a comparable chemically competent wildtype bacterial cell, wherein the genetic modification results in increased transformation efficiency of a plasmid transformed into the genetically-modified bacterial cell after theDocket No. 212391-704601genetically-modified bacterial cell is made chemically competent, as compared to transforming the plasmid into a comparable chemically competent wildtype bacterial cell. In some embodiments, the genetic modification that results in reduced expression of a polypeptide encoded by the gene having the polynucleotide sequence of SEQ ID NO: 1 comprises a deletion of the gene having the polynucleotide sequence of SEQ ID NO: 1. In some embodiments, the genetic modification results in at least a l.O-fold, a 1.1-fold, a 1.2-fold, a 1.3-fold, a 1.4-fold, a 1.5-fold, a 1.6-fold, a 1.7-fold, a 1.8-fold, a 1.9-fold, a 2.0-fold, a 2.1-fold, a 2.2-fold, a 2.3-fold, a 2.4-fold, a 2.5-fold, a 2.6-fold, a 2.7-fold, a 2.8-fold, a 2.9-fold, or a 3.0-fold increase in transformants, as compared to the comparable chemically competent wildtype bacterial cell. In some embodiments, the genetically-modified bacterial cell further comprises a second genetic modification. In some embodiments, the second genetic modification results in reduced expression of a polypeptide encoded by a gene having a polynucleotide sequence ofSEQ ID NO: 3 in the chemically competent genetically-modified bacterial cell, as compared to the comparable chemically competent wildtype bacterial cell. In some embodiments, the second genetic modification that results in the reduced expression of the polypeptide encoded by the gene having the polynucleotide sequence SEQ ID NO: 3 comprises a deletion of the gene having the polynucleotide sequence of SEQ ID NO: 3 In some embodiments, the genetically-modified bacterial cell further comprises a third genetic modification to one or more genes selected from the group consisting of DAM, DNS, KDO, KdsD, gutQ, kdsA, kdsB, waaA, msbA, yhiD, IpxL, IpxM, (|)prol , (|)pro2, and any combination thereof. In some embodiments, the genetically-modified bacterial cell comprises a genetic modification to a DNS gene. In some embodiments, upon transformation of the plasmid into the genetically-modified bacterial cell, the genetically-modified bacterial cell expresses the plasmid with a reduced amount of plasmid multimers or concatemers, relative to an amount of plasmid multimers or concatemers produced in the same amount of time upon transformation of the plasmid into the comparable chemically competent wildtype bacterial cell. In some embodiments, the genetically-modified bacterial cell comprises a genetic modification to a DAM gene. In some embodiments, the genetically-modified bacterial cell comprises a genetic modification to a KdsD gene. In some embodiments, the genetically-modified bacterial cell comprises a genetic modification to a IpxL gene. In some embodiments, the genetically-modified bacterial cell comprises a genetic modification to a IpxM gene. In some embodiments, uponDocket No. 212391-704601culturing the genetically-modified bacterial cell in a growth medium, the genetically-modified bacterial cell replicates with reduced secretion of endotoxin into the growth medium, as compared to an amount of endotoxin secreted by a comparable bacterial strain lacking the genetic modification that is replicated in the growth medium for the same amount of time. In some embodiments, the genetically-modified bacterial cell comprises an inactivation or a deletion of (|)pro 1 or (|)pro2. In some embodiments, the genetically-modified bacterial cell: transforms the plasmid at an increased level; replicates the plasmid at an increased level; reduces an amount of plasmid multimers or concatemers; expresses a transgene encoded by the plasmid at an increased level; or a combination thereof, relative to a level of plasmid transformation, plasmid replication, plasmid multimers or concatemers, or transgene expression, respectively, produced in the same amount of time upon transformation of the plasmid into a comparable wildtype bacterial cell. In some embodiments, upon transformation of the plasmid into the genetically-modified bacterial cell, the genetically-modified bacterial cell replicates the plasmid at an increased level, relative to the level of plasmid replication produced in the same amount of time upon transformation of the plasmid into the comparable wildtype bacterial cell. In some embodiments, upon transformation of the plasmid into the genetically-modified bacterial cell, the genetically-modified bacterial cell replicates the plasmid at a level that is at least 200% greater than the level of template plasmid replication produced in the same amount of time upon transformation of the plasmid into the bacterial cell of a comparable bacterial strain lacking the genetic modification. In some embodiments, upon culturing the genetically-modified bacterial cell in growth medium, the genetically-modified bacterial cell reaches a target density at least 150% faster than a replication rate of a bacterial cell of a comparable bacterial strain lacking the genetic modification that is replicated in the growth medium for the same amount of time, as measured by optical density at 600 nm. In some embodiments, upon culturing the genetically-modified bacterial cell in the growth medium, the genetically-modified bacterial cell replicates with a doubling time of about at least about 5 minutes, at least about 10 minutes, at least about 15 minutes, at least about 20 minutes, at least about 25 minutes or at least about 30 minutes, as measured by optical density at 600 nm. In some embodiments, upon culturing the genetically-modified bacterial cell in the growth medium, the genetically-modified bacterial cell replicates with a doubling time of less than 30 minutes, less than 29 minutes, less than 28 minutes, less than 27Docket No. 212391-704601minutes, less than 26 minutes, less than 25 minutes, less than 24 minutes, less than 23 minutes, less than 22 minutes, less than 21 minutes, less than 20 minutes, less than 19 minutes, less than 18 minutes, less than 17 minutes, less than 16 minutes, or less than 15 minutes, as measured by optical density at 600 nm. In some embodiments, upon transforming the plasmid into the genetically-modified bacterial cell, the genetically-modified bacterial cell in liquid media reaches a cell density for purification in less than 24 hours that is equivalent to a cell density for purification reached by E. coli DH5a n liquid media after 36 hours, as measured by optical density at 600 nm. In some embodiments, upon liquid culturing colonies of the genetically-modified bacterial cell comprising the plasmid, the genetically-modified bacterial cell reaches a cell density for purification in less than 4 hours that is equivalent to a cell density for purification reach by E. coli DH5a in liquid media after 12 hours, as measured by optical density at 600 nm. In some embodiments, the genetically-modified bacterial cell is Escherichia spp., Shigella spp., Salmonella spp., Campylobacter spp., Neisseria spp., Haemophilus spp., Aeromonas spp., Francisella spp., Yersinia spp., Klebsiella spp., Bordetella spp., Legionella spp., Citrobacter spp., Chlamydia spp., Brucella spp., Pseudomonas spp., Helicobacter spp., Moraxella spp., Stenotrophomonas spp., Bdellovibrio spp., Acinetobacter spp., Enterobacter spp., and Vibrio spp.

[0005] Further provided herein are genetically-modified bacterial cells comprising a genetic modification that results in increased and / or constitutive expression of one or more bacterial stress genes as compared to a comparable wildtype bacterial cell, wherein the genetic modification comprises an insertion of a modified oxyR gene into the genetically-modified bacterial cell, and wherein the modified oxyR gene is exogenous to the genetically-modified bacterial cell prior to the insertion, and wherein the increased and / or constitutive expression of the one or more bacterial stress genes results in an increase in plasmid yield after transformation, as compared to the comparable wildtype bacterial cell. In some embodiments, the modified oxyR gene has a polynucleotide sequence with at least 95% identity to the polynucleotide sequence of SEQ ID NO: 2 In some embodiments, the modified oxyR gene has the polynucleotide sequence of SEQ ID NO: 2. In some embodiments, the genetic modification results in the increased expression of OxyR polypeptide encoded by the modified oxyR gene. In some embodiments, the OxyR polypeptide encoded by the modified oxyR gene has at least 1 amino acid substitution with respect to a wildtype OxyR polypeptide encoded by an oxyR gene sequence of SEQ ID NO: 7. In someDocket No. 212391-704601embodiments, the genetic modification results in increased expression of the one or more bacterial stress genes, as compared to the comparable wildtype bacterial cell. In some embodiments, the genetically-modified bacterial cell further comprises a second genetic modification. In some embodiments, the second genetic modification results in reduced expression of a polypeptide encoded by a gene having a polynucleotide sequence ofSEQ ID NO: 3 in the genetically-modified bacterial cell, as compared to the comparable wildtype bacterial cell. In some embodiments, the second genetic modification that results in a reduced expression of a polypeptide encoded by the gene having a polynucleotide sequence set forth in SEQ ID NO: 3 comprises a deletion of the gene having the polynucleotide sequence of SEQ ID NO: 3. In some embodiments, the genetically-modified bacterial cell further comprises a third genetic modification to one or more genes selected from the group consisting of DAM, KDO, KdsD, gutQ, kdsA, kdsB, waaA, msbA, mltG, yhiD, IpxL, IpxM, (|)prol, (|)pro2, and any combination thereof. In some embodiments, the genetically-modified bacterial cell comprises a genetic modification to a DAM gene. In some embodiments, the genetically-modified bacterial cell comprises a genetic modification to a KdsD gene. In some embodiments, the genetically-modified bacterial cell comprises a genetic modification to a IpxL gene. In some embodiments, the genetically-modified bacterial cell comprises a genetic modification to a IpxM gene. In some embodiments, upon culturing the genetically-modified bacterial cell in a growth medium, the genetically-modified bacterial cell replicates with reduced secretion of endotoxin into the growth medium, as compared to an amount of endotoxin secreted by a comparable bacterial strain lacking the genetic modification that is replicated in the growth medium for the same amount of time. In some embodiments, the genetically-modified bacterial cell comprises an inactivation or a deletion of (|)pro 1 or (|)pro2. In some embodiments, the genetically-modified bacterial cell replicates the plasmid at an increased level or expresses a transgene encoded by the plasmid at an increased level relative to a level of plasmid replication or transgene expression, respectively, produced in the same amount of time upon transformation of the plasmid into the comparable wildtype bacterial cell. In some embodiments, upon transformation of the plasmid into the genetically-modified bacterial cell, the genetically-modified bacterial cell replicates the plasmid at the increased level, relative to the level of plasmid replication produced in the same amount of time upon transformation of the plasmid into the comparable wildtype bacterial cell. In someDocket No. 212391-704601embodiments, upon transformation of the plasmid into the genetically-modified bacterial cell, the genetically-modified bacterial cell replicates the plasmid at a level that is at least 200% greater than the level of template plasmid replication produced in the same amount of time upon transformation of the plasmid into the bacterial cell of a comparable bacterial strain lacking the genetic modification. In some embodiments, upon culturing the genetically-modified bacterial cell in growth medium, the genetically-modified bacterial reaches a target density 150% faster than a replication rate of a bacterial cell of a comparable bacterial strain lacking the genetic modification that is replicated in the growth medium for the same amount of time, as measured by optical density at 600 nm. In some embodiments, upon culturing the genetically-modified bacterial cell in the growth medium, the genetically-modified bacterial cell replicates with a doubling time of about at least about 5 minutes, at least about 10 minutes, at least about 15 minutes, at least about 20 minutes, at least about 25 minutes or at least about 30 minutes, as measured by optical density at 600 nm. In some embodiments, upon culturing the genetically-modified bacterial cell in the growth medium, the genetically-modified bacterial cell replicates with a doubling time of less than 30 minutes, less than 29 minutes, less than 28 minutes, less than 27 minutes, less than 26 minutes, less than 25 minutes, less than 24 minutes, less than 23 minutes, less than 22 minutes, less than 21 minutes, less than 20 minutes, less than 19 minutes, less than 18 minutes, less than 17 minutes, less than 16 minutes, or less than 15 minutes, as measured by optical density at 600 nm. In some embodiments, the genetically-modified bacterial cell is Escherichia spp., Shigella spp., Salmonella spp., Campylobacter spp., Neisseria spp., Haemophilus spp., Aeromonas spp., Francisella spp., Yersinia spp., Klebsiella spp., Bordetella spp., Legionella spp., Citrobacter spp., Chlamydia spp., Brucella spp., Pseudomonas spp., Helicobacter spp., Moraxella spp., Stenotrophomonas spp., Bdellovibrio spp., Acinetobacter spp., Enterobacter spp., and Vibrio spp. In some embodiments, the plasmid comprises an origin of replication selected from the group consisting of pUC19, pcDNA3.1, pET, PBR322, pACYC184, RK2, RSF1010, pl5A, pNG2, pSClOlts, pSa, pTHT15, pAL5000, pAMBl, pBBRl, pBBRl-UP, pBCl, pBPl, pCB102, pCD6,pIJ101, pIM13, pIP501, pMBl, pSG5, pUBl 10, and pWKSl. In some embodiments, the plasmid comprises an antibiotic selection marker selected from the group consisting of kanamycin (KAN), tetracycline (TET), chloramphenicol (CAM), gentamicin (GEN), spectinomycin (SPEC), erythromycin (ERM), and carbenicillin.Docket No. 212391-704601

[0006] Provided herein are genetically-modified bacterial cells of species Vibrio natriegens comprising a genetic modification to a gene selected from the group consisting of mltG, RecA, DAM, DNS, KDO, KdsD, gutQ, kdsA, kdsB, waaA, msbA, yhiD, IpxL, IpxM, (|)prol, (|)pro2, and any combination thereof.

[0007] Provided herein are also an expression product produced by the genetically-modified bacterial cell provided herein.

[0008] Provided herein are systems for replicating a genetically-modified bacterial cell, comprising the genetically-modified bacterial cell disclosed herein and growth medium. In some embodiments, the growth medium comprises yeast extract, vegetable tryptone, MgSC , NaCl, K2HPO4, and a buffering agent. In some embodiments, the buffering agent is Tris. In some embodiments, the growth medium is in a liquid or a solid agar format. In some embodiments, the growth medium increases growth kinetics of the genetically-modified bacterial cell, or plasmid yield or plasmid quality of a plasmid replicated using the genetically-modified bacterial cell, as compared to a LB or a TB media.

[0009] Provided herein are methods of making a genetically-modified bacterial cell, the method comprising obtaining a wildtype bacterial cell; and performing a modification that results in altered expression of a polypeptide encoded by at least one gene having a polynucleotide sequence of SEQ ID NO: 1 - SEQ ID NO: 2, wherein the altered expression of the polypeptide comprises an increase in expression of the polypeptide or a decrease in expression in the polypeptide as compared to the wildtype bacterial cell prior to the modification, thereby generating the genetically-modified bacterial cell.

[0010] Provided herein are methods of expressing a biomolecule encoded by a plasmid in a genetically-modified bacterial cell, the method comprising: transforming the plasmid into the genetically-modified bacterial cell disclosed herein; culturing the genetically-modified bacterial cell comprising the plasmid; expressing the biomolecule from the plasmid using the genetically-modified bacterial cell in culture medium; and purifying the biomolecule from the genetically-modified bacterial cells.

[0011] Provided herein are biomolecules produced by the method disclosed herein.

[0012] Provided herein are systems for transforming a genetically-modified bacterial cell, comprising the genetically-modified bacterial cells disclosed herein and a cloning plasmid. In some embodiments, the cloning plasmid comprises a backbone comprising a high-copy origin of replication, an antibiotic resistance marker, or aDocket No. 212391-704601restriction enzyme site. In some embodiments, the cloning plasmid comprises a backbone comprising a high-copy origin of replication selected from the group consisting of pUC19, pcDNA3.1, pET, PBR322, pACYC184, RK2, RSF1010, pl 5 A, pNG2, pSClOlts, pSa, pTHT15, pAL5000, pAMBl, pBBRl, pBBRl-UP, pBCl, pBPl, pCB102, pCD6,pIJ101, pIM13, pIP501, pMBl, pSG5, pUBUO, and pWKSl.In some embodiments, the cloning plasmid comprises a backbone comprising an antibiotic resistance marker selected from the group consisting of kanamycin (KAN), tetracycline (TET), chloramphenicol (CAM), gentamicin (GEN), spectinomycin (SPEC), erythromycin (ERM), and carbenicillin. In some embodiments, the cloning plasmid comprises a backbone comprising SEQ ID NO: 39. In some embodiments, the cloning plasmid comprises a backbone sequence set forth in any one of SEQ ID NOs 40-42.BRIEF DESCRIPTION OF THE DRAWINGS

[0013] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

[0014] FIGURES 1A-1B show transformation efficiency of genetically-modified bacterial cells. FIG. 1A is a graph depicting the number of high copy plasmid transformants for wildtype bacterial cells, and exemplary genetically-modified bacterial cells. FIG. IB is a graph depicting the number of medium copy plasmid transformants for wildtype bacterial cells, and exemplary genetically-modified bacterial cells. Y-axis shows transformation efficiency (CFU / ug), and X-axis shows the bacteria type.

[0015] FIGURES 2A-2B show representative images of liquid cultures for exemplary genetically-modified bacterial cells (FIG. 2A), and wildtype bacterial cells (FIG. 2B) treated with hydrogen peroxide as an assay for catalase activity.

[0016] FIGURES 3A-3C show increase in plasmid yield in genetically-modified bacterial cell cultures as compared to wildtype bacterial cells in three different growth media: Growth Media 1 (FIG. 3A), Growth Media 2 (FIG. 3B), and Growth Media 3 (FIG. 3C). Y-axis shows plasmid volumetric yield (mg / L), and X-axis shows the bacteria type.

[0017] FIGURES 4A-4C show plasmid yield and growth characteristics of strains with and without dns::oxyR2. FIG. 4A shows stains with oxyR had greater cell density than the stainsDocket No. 212391-704601without oxyR. X-axis treatment groups; Y-axis optical density at 600 nm OCeoo. FIG. 4B shows stains with oxyR had greater plasmid yield than the stains without oxyR. X-axis treatment groups; Y-axis plasmid yield in mg / L. FIG. 4C shows stains with oxyR had greater specific yield than the stains without oxyR. X-axis treatment groups; Y-axis specific yield in mg / L / OD.

[0018] FIGURE 5 shows transform efficiency of various engineered V. natriegens strains with pUC19, pACYC 184, and pCYC-3 plasmids. X-axis shows wild type stains, stains with dns deletion, stains with dns, RecA, (|)pro 1 and (|)pro2 deletions, stains with dns::oxyR2 duplication, RecA, (|)prol and (|)pro2 deletions, stains with dns::oxyR2 duplication, RecA, (|)prol and (|)pro2 deletion and SEQ ID NO: 1 modification; Y-axis: CFU / pg.

[0019] FIGURES 6A-6B show topology of plasmid DNA isolated from Vibrio natriegens strains with and without RecA. FIG. 6A shows topology of plasmid DNA isolated from genetically-modified Vibrio natriegens strains transformed with pUC19 plasmid. FIG. 6B shows topology of plasmid DNA isolated from genetically-modified Vibrio natriegens strains transformed with lentiviral transfer plasmid.

[0020] FIGURE 7 shows impact of different buffering agents in rich media on plasmid yield.

[0021] FIGURES 8A-8C show comparison of genetically-modified Vibrio natriegens strains to benchmark strains in accelerated plasmid production workflow. FIG. 8A shows growth curves measured directly in the 24-well plate via an Essitech mtpOD online biomass monitor.FIG.8B shows average volumetric yields (in mg / L) of pcDNA3.1 after 6 hours of cultivation isolated by Qiagen miniprep columns and measured by Qubit double-stranded DNA assay. Averages were calculated from yields from four independent colonies (n=4) from each strain.FIG. 8C shows plasmid quality assessed by a supercoiled agarose gel stained with SYBRsafe stain.

[0022] FIGURE 9 shows comparison of growth of the genetically-modified Vibrio natriegens strains and DH5a strains harboring various plasmids after 6 hours of growth.

[0023] FIGURE 10 shows plasmid volumetric yields from the genetically-modified Vibrio natriegens strains after 6 hours of growth.

[0024] FIGURES 11A-11C show growth and plasmid yield with the genetically-modified Vibrio natriegens cultivated for in different culture formats and different incubation times. FIG. 11A culture density (in OD600) of each culture at different timepoints. FIG. 11B volumetric yields determined by harvesting 200 pL aliquots of each culture and processing through a column. Plasmid concentrations were measured using a Qubit fluorometer. FIG.11C Total plasmid (in pg) that can be recovered from the respective culture volumes at 4, 6,Docket No. 212391-704601and 8 hours.

[0025] FIGURES 12A-12D show representative data from transformations of genetically-modified Vibrio natriegens with Gibson Assembly reactions. FIG. 12A shows the genetically-modified Vibrio natriegens transformed with pACYC184. FIG. 12B shows the genetically-modified Vibrio natriegens transformed with pcDNA3.1. FIG. 12C shows the genetically-modified Vibrio natriegens transformed with gWIZ-GFP. FIG. 12D shows the genetically-modified Vibrio natriegens transformed with saRNA plasmid.

[0026] FIGURE 13 shows a set of standardized high-copy cloning vectors (pCYC series cloning vectors).DETAILED DESCRIPTION OF THE INVENTION

[0027] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not to be construed as restrictive of the disclosure.

[0028] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including, but not limited to, patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference in their entirety for any purpose.Overview

[0029] Disclosed herein are genetically-modified bacterial cells, expression systems containing the same, and methods of making expression systems containing the same, which increase transformation efficiency, plasmid yield, the growth rate and production yields of biomolecules produced within the cells. A common requirement in biotechnology applications involves introducing engineered plasmids into bacterial production strains via a process known as transformation. The efficiency by which plasmids are introduced (routinely measured in the number of transformed colonies generated per microgram of plasmid DNA used) is a key limitation for molecular cloning and recombinant DNA workflows. Current disclosure provides genetically-modified bacterial cells and system with superior transformation efficiency and dramatically enhanced plasmid yield and quality. The genetically-modified bacterial cells and system offer a practical and immediately deployable route to accelerate design-build-test cycles across basic research and industrial biotechnology, an outcome that has broad implications for both laboratory productivity and commercialDocket No. 212391-704601DNA manufacturing.

[0030] As described herein, a genetically-modified organism can have a modification to any combination of gene targets described herein, including, but not limited to: gutQ, kdsD, kdsA, kdsB, kdsC, waaA, IpxL, IpxM, msbA, yhjD, yrbH, yhbV, yagG, hemB, secD, secF, ribD, ribE, thiL, dxs, ispA, dnaX, adk, hemH, IpxH, cysS, fold, rplT, infC, thrS, nadE, gapA, yeaZ, aspS, argS, pgsA, yefM, metG, folE, yejM, gyrA, nrdA, nrdB, folC, accD, fabB, gltX, ligA, zipA, dapE, dapA, der, hisS, ispG, suhB, tadA, acpS, era, me, ftsB, eno, pyrG, chpR, Igt, fbaA, pgk, yqgD, metK, yqgF, plsC, ygiT, pare, ribB, cca, ygjD, tdcF, yraL, yihA, ftsN, murl, murB, birA, secE, nusG, rplJ, rplL, rpoB, rpoC, ubiA, plsB, lexA, dnaB, ssb, alsK, groS, psd, om, yjeE, rpsR, chpS, ppa, valS, yjgP, yjgQ, dnaC, ribF, IspA, ispH, dapB, folA, imp, yabQ, ftsL, ftsl, murE, murF, mraY, murD, ftsW, murG, murC, ftsQ, ftsA, ftsZ, IpxC, secM, secA, can, folK, hemL, yadR, dapD, map, rpsB, infB ,nusA, ftsH, obgE, rpmA, rplU, ispB, murA, yrbB, yrbK, yhbN, rpsl, rplM, degS, mreD, mreC, mreB, accB, accC, yrdC, def, fmt, rplQ, rpoA, rpsD, rpsK, rpsM, entD, mrdB, mrdA, nadD, hlepB, rpoE, pssA, yfiO, rplS, trmD, rpsP, ffh, grpE, vfjB. csrA, ispF, ispD, rplW, rplD, rplC, rpsJ, fusA, rpsG, rpsL, trpS, yrfF, asd, rpoH, ftsX, ftsE, ftsY, frr, dxr, ispU, rfaK, kdtA, coaD, rpmB, dfp, dut, gmk, spot, gyrB, dnaN, dnaA, rpmH, mpA, yidC, tnaB, glmS, glmU, wzyE, hemD, hemC, yigP, ubiB, ubiD, hemG, secY, rplO, rpmD, rpsE, rplR, rplF, rpsH, rpsN, rplE, rplX, rplN, rpsQ, rpmC, rplP, rpsC, rplV, rpsS, rplB, cdsA, yaeL, yaeT, IpxD, fabZ, IpxA, IpxB, dnaE, accA, tilS, proS, yafF, tsf, pyrH, olA, ripB, leuS, Int, glnS, fldA, cydA, infA, cydC, ftsK, lolA, serS, rpsA, msbA, IpxK, kdsB, mukF, mukE, mukB, asnS, fab A, mviN, me, yceQ, fabD, fabG, acpP, tmk, holB, lolC, lolD, lolE, purB, ymffC, minE, mind, pth, rsA, RecA, ispE, lolB, hemA, prfA, prmC, kdsA, topA, ribA, fabl, racR, dicA, ydfB, tyrS, ribC, ydiL, pheT, pheS, yhhQ, bcsB, glyQ, yibJ, gpsA, mltG, nadA, nadB, nadC, nadD, nadEl, nadE2, DAM, (|)prol, (|)pro2, and DNS.Definitions

[0031] Unless otherwise indicated, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Unless otherwise indicated or obvious from context, the following terms have the following meanings:

[0032] As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a sample” includes a plurality of samples, including mixtures thereof.Docket No. 212391-704601

[0033] Any reference to “or” herein is intended to encompass “and / or” unless otherwise stated. As used herein, the term “and / or” includes any and all combinations of one or more of the associated listed items.

[0034] Use of the term “including” as well as other forms, such as “includes” and “included,” is not limiting.

[0035] As used herein, the term “comprise” and its grammatical equivalents specifies the presence of stated features, integers, steps, operations, elements, and / or components, but does not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof.

[0036] As used herein, the term “about” in reference to a number or range of numbers is understood to mean the stated number and numbers + / - 10% thereof, or 10% below the lower listed limit and 10% above the higher listed limit for the values listed for a range, as well as variations of ±5%, ±1%, ±0.5%, or even ±0.1%.

[0037] The terms “% identical,” “% identity,” and “percent identity,” or grammatical equivalents thereof, refer to the extent to which two sequences (nucleotide or amino acid) have the same residue at the same positions in an alignment. For example, “an amino acid sequence is X% identical to SEQ ID NO: Y” can refer to % identity of the amino acid sequence to SEQ ID NO: Y and is elaborated as X% of residues in the amino acid sequence are identical to the residues of sequence disclosed in SEQ ID NO: Y. Generally, computer programs can be employed for such calculations.

[0038] The terms "essential gene" and “auxotroph,” as used herein, refer to a gene that is necessary for cell growth and / or survival and the organism missing the necessary gene is referred to as an auxotroph. Bacterial essential genes can be identified by targeted gene deletion and / or random mutagenesis and screening (see, for example, Zhang and Lin, “DEG 5.0, a database of essential genes in both prokaryotes and eukaryotes,” Nucl Acids Res, 2009; 37: D455-D458 and Gerdes et al., “Essential Genes on metabolic maps,” Curr Opin Biotechnol, 2006; 17 (5): 448-456.

[0039] The term “enhance” or “increase” refers to an increase in the specified parameter of at least about 1.25-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 8-fold, 10-fold, twelvefold, fifteen-fold, etc.

[0040] The term “inhibit” or “reduce” or grammatical variations thereof as used herein refers to a decrease or diminishment in the specified level or activity of at least about 15%, 25%, 35%, 40%, 50%, 60%, 75%, 80%, 90%, 95% or more. In particular embodiments, the inhibition or reduction results in little or essentially no detectable activity (at most, anDocket No. 212391-704601insignificant amount, e.g., less than about 10%, 5%, 1%, 0.1% or even 0.005%).

[0041] As used herein, a “non-native” and “exogenous” nucleic acid sequence or polynucleotide refer to a nucleic acid sequence not normally present in a bacterium, e.g., an extra copy of an endogenous sequence, or a heterologous sequence such as a sequence from a different species, strain, or substrain of bacteria, or a sequence that is modified and / or mutated as compared to the unmodified sequence from bacteria of the same subtype. In some embodiments, the non-native nucleic acid sequence is a synthetic, non-naturally occurring sequence (see, e.g., Purcell et al., 2013). The non-native nucleic acid sequence or polynucleotide may be a regulatory region, a promoter, a gene, and / or one or more genes in a gene cassette. In some embodiments, “non-native” refers to two or more nucleic acid sequences that are not found in the same relationship to each other in nature. The non-native nucleic acid sequence may be present on a plasmid or chromosome. In addition, multiple copies of any regulatory region, promoter, gene, and / or gene cassette may be present in the bacterium, wherein one or more copies of the regulatory region, promoter, gene, and / or gene cassette may be mutated or otherwise altered as described herein. In some embodiments, the genetically-modified bacteria are engineered to comprise multiple copies of the same regulatory region, promoter, gene, and / or gene cassette in order to enhance copy number or to comprise multiple different components of a gene cassette performing multiple different functions.

[0042] The term “protein”, “peptide” and “polypeptide” are used interchangeably to refer to an oligomer of two or more linked amino acids or derivatives of the same. The term “exogenously introduced polypeptide” refers to a polypeptide encoded by an exogenous polynucleotide.

[0043] As used herein, the term “transform” or “transformation” refers to the transfer of a nucleic acid fragment into a host bacterial cell, resulting in genetically-stable inheritance. Host bacterial cells comprising the transformed nucleic acid fragment are referred to as “recombinant” or “transgenic” or “transformed” organisms.

[0044] The terms “complementary” and “complementarity,” as used herein, with reference to a nucleic acid molecule or nucleotide sequence, refer to the characteristic of a polynucleotide having nucleotides that base pair with their Watson-Crick counterparts (C with G; or A with T) in a reference nucleic acid. For example, when every nucleotide in a polynucleotide forms a base pair with a reference nucleic acid, that polynucleotide is said to be 100% complementary to the reference nucleic acid. In a double stranded DNA or RNA sequence, the upper (sense) strand sequence is in general, understood as going in the direction from itsDocket No. 212391-7046015'- to 3 '-end, and the complementary sequence is thus understood as the sequence of the lower (antisense) strand in the same direction as the upper strand. Following the same logic, the reverse sequence is understood as the sequence of the upper strand in the direction from its 3'- to its 5 '-end, while the ‘ reverse complement" sequence or the ‘ reverse complementary" sequence is understood as the sequence of the lower strand in the direction of its 5'- to its 3'-end. Each nucleotide in a double stranded DNA or RNA molecule that is paired with its Watson-Crick counterpart called its complementary nucleotide.

[0045] The term “length” as it applies to a nucleic acid (polynucleotide) or polypeptide may be expressed as “kilobases” (kb) or “base pairs (bp),” and may be used interchangeably with the term, “linked nucleosides.” Thus, a length of 1 kb refers to a length of 1000 linked nucleosides, and a length of 500 bp refers to a length of 500 linked nucleosides. Similarly, a protein having a length of 500 linked amino acids may also be simply described as having a length of 500 amino acids.

[0046] The term “guide nucleic acid,” as used herein, refers to a nucleic acid that includes a nucleotide sequence that hybridizes to a target nucleic acid and that is capable of hybridizing to a portion of an additional nucleic acid that is bound by a nuclease.

[0047] The term “genetic modification,” as used herein, refers to any genetic change.Exemplary genetic modifications include those that increase, decrease, or abolish the expression of a gene, including, for example, modifications of native chromosomal or extrachromosomal genetic material. Exemplary genetic modifications also include the introduction of at least one plasmid, modification, mutation, base deletion, base addition, base substitution, and / or codon modification of chromosomal or extrachromosomal genetic sequence(s), gene over-expression, gene amplification, gene suppression, promoter modification or substitution, gene addition (either single or multi-copy), antisense expression or suppression, or any other change to the genetic elements of a host cell, whether the change produces a change in phenotype or not.

[0048] The terms “non-naturally occurring,” “engineered,” “genetically-modified,” “genetic modification,” and grammatical equivalents as used herein, are used interchangeably and indicate the involvement of the hand of man. The terms, when referring to a cell or expression system, refer to a cell or expression system that is substantially free from at least one other feature with which it is naturally associated in nature, and / or contains a modification (e.g., gene edit, chemical modification, nucleotide sequence, or amino acid sequence) that is not present in the naturally occurring cell or expression system.

[0049] The term “biomolecule” as used herein, refers to a polypeptide or polynucleotide thatDocket No. 212391-704601is expressed by a cell or expression system of the invention as described herein. The biomolecule, for example, can be a therapeutic polypeptide or polynucleotide used to alleviate or lessen a symptom of a disease or condition or used for a health, nutritional, or cosmetic benefit in a subject. Examples are, but not limited to, antibodies, messenger RNAs, antisense oligonucleotides, and short interfering RNAs.Genetically-modified bacterial cells

[0050] Disclosed herein are genetically-modified cells having one or more genetic modifications. Such cells can be modified to impart or disable specific cellular traits. In some embodiments, the cells are bacterial cells. In some embodiments, the cells can be a gramnegative bacterium. For example, a non-limiting list of bacteria that may be useful to modify specific cellular traits include Escherichia spp., Shigella spp., Salmonella spp., Campylobacter spp., Neisseria spp., Haemophilus spp., Aeromonas spp., Francisella spp., Yersinia spp., Klebsiella spp., Bordetella spp., Legionella spp., Citrobacter spp., Chlamydia spp., Brucella spp., Pseudomonas spp., Helicobacter spp., Moraxella spp., Stenotrophomonas spp., Bdellovibrio Acinelobacler spp., Enterobacter spp. and Vibrio spp.

[0051] In some embodiments, the genetically-modified bacteria are any organism of the genus Escherichia. Some examples of organisms in the Escherichia genus include, but are not limited to, Escherichia alberti, Escherichia coli, Escherichia fergusonii, Escherichia hermannii, Escherichia marmotae, and Escherichia vulneris, but the expression system can be applied to any Escherichia sp. organism, or to any combination or sub-combination of the Escherichia spp. In some embodiments, the genetically-modified bacterial cells are Escherichia coli. Examples of Escherichia coli include, but are not limited to, Escherichia coli K-12 strains such as W3110 strain (ATCC 27325) and MG1655 strain (ATCC 47076), Escherichia coli K5 strain (ATCC 23506) and Escherichia coli B. In some embodiments, the genetically-modified bacteria can be any organism of the genus Vibrio. Some examples of organisms in the Vibrio genus include, but are not limited to, Vibrio cholerae, Vibrio cholerae non 01 non 0139, Vibrio mimicus, Vibrio par ahaemolyticus, Vibrio vulnificus, Vibrio alginolyticus, and Vibrio fluvialis,

[0052] In some embodiments, the wildtype bacterial cell is a bacterial cell derived from any organism of the Family Escherichia. In some embodiments, the wildtype bacterial cell is a bacterial cell is derived from any organism of the Family Vibrionaceae. The Vibrio sp. organisms can be any species of the genus Vibrio. Some examples of organisms in the VibrioDocket No. 212391-704601genus include, but are not limited to, Vibrio natriegens, Vibrio cholerae, Vibrio fischeri, Vibrio parahaemolyticus, Vibrio campbellii, and Vibrio vulnificus, but the expression system can be applied to any Vibrio sp. organism, or to any combination or sub-combination of the Vibrio sp. organisms listed herein. In one embodiment the genetically-modified organisms are Vibrio natriegens. In another embodiment the genetically-modified organisms are Vibrio cholerae. In another embodiment the genetically-modified organisms described herein are Vibrio fischeri. In another embodiment the genetically-modified organisms are Vibrio parahaemolyticus. In another embodiment the genetically-modified organisms described herein are Vibrio vulnificus. In some embodiments, the genetically-modified bacteria described herein are Vibrio natriegens deposited under accession number NCIMB 857.

[0053] Vibrio spp. have several advantages as host cells over other bacteria for many molecular biology applications. One advantage is their rapid growth rate. One of the most time intensive steps in modem biotech workflows is waiting for the host cell to grow to a sufficient density before DNA / protein / product can be recovered or the phenotype can be assessed. E. coli is considered to have one of the quickest growth rates relative to other organisms used in the biotech sector, and this has been one of its strengths. Because Vibrio spp. have a growth rate 2-3 x faster than commonly used E. coli strains, it is able to achieve a dramatic reduction in the time necessary for the host to grow, and will accelerate research efforts.

[0054] An additional advantage is the compatibility of Vibrio spp. with standard lab protocols. Unlike organisms that require specialized techniques or methods, Vibrio spp. is compatible with many standard cloning vectors, growth media, workflows and commercially available kits developed for E. coli or recovering DNA.

[0055] A further advantage is the nutritional versatility of Vibrio spp. allowing it to grow on a range of different growth media, including inexpensive, minimal media. Coupled with its rapid growth rate, this feature allows for industrial scale production in less time and at lower cost.

[0056] In some embodiments, an altered Chromosome II can serve as a vector or plasmid or artificial chromosome having the exogenous or heterologous DNA and for the construction, cloning, maintenance, and / or recovery of large DNAs and for the expression, production, and secretion of proteins or peptides or other biomolecules. In some embodiments, a polynucleotide, a plasmid, vector, or artificial chromosome described herein comprising the DNA insert or essential genetic elements can be replicated and maintained in the host organism, which can be a Vibrio spp., an E. coli, or other gram-negative bacteria.Docket No. 212391-704601

[0057] Provided herein are genetically-modified bacterial cells of species Vibrio natriegens comprising a genetic modification to an mltG gene that results in reduced expression of mltG polypeptide encoded by the mltG gene, as compared to an amount of mltG polypeptide expressed from the mltG gene prior to the genetic modification.

[0058] In some embodiments, provided herein are also genetically-modified bacterial cells comprising a genetic modification that results in reduced expression of a polypeptide encoded by a gene having a polynucleotide sequence of SEQ ID NO: 1, as compared to an amount of expression of the polypeptide encoded by the genehaving the polynucleotide sequence of SEQ ID NO: 1 by a comparable chemically competent wildtype bacterial cell, wherein the genetic modification results inincreased transformation efficiency of a plasmid transformed into the genetically-modified bacterial cell after the genetically-modified bacterial cell is made chemically competent, as compared to transforming the plasmid into a comparable chemically competent wildtype bacterial cell.

[0059] Further provided herein are genetically-modified bacterial cells of species Vibrio natriegens comprising a genetic modification to a gene selected from the group consisting of mltG, RecA, DAM, DNS, KDO, KdsD, gutQ, kdsA, kdsB, waaA, msbA, yhiD, IpxL, IpxM, (|)prol, <])pro2, and any combination thereof.

[0060] Thus, in some embodiments, the genetically-modified bacteria comprise one or more genetic modifications where the genetic modifications as described herein are with respect to a specific Vibrio bacteria strain. In some embodiments, the genetic modifications as described herein are with respect to the bacteria strain deposited under accession number NCIMB 857. In some embodiments, the genetic modifications as described herein are with respect to the bacteria strain deposited under accession number ATCC 14048. In some embodiments, the genetic modifications as described herein are with respect to the bacteria strain deposited under accession number NBRC 15636. In some embodiments, the genetic modifications as described herein are with respect to the bacteria strain deposited under accession number DSM 759. In some embodiments, the genetic modifications as described herein are with respect to the bacteria strain deposited under accession number CIP 75.07. In some embodiments, the genetic modifications as described herein are with respect to the bacteria strain deposited under accession number LMD 73.19. In some embodiments, the genetic modifications as described herein are with respect to the bacteria strain deposited under accession number LMG 10935. In some embodiments, the genetic modifications as described herein are with respect to the bacteria strain deposited under accession number CAIM 12. InDocket No. 212391-704601some embodiments, the genetic modifications as described herein are with respect to the bacteria strain deposited under accession number CCUG 16371. In some embodiments, the genetic modifications as described herein are with respect to the bacteria strain deposited under accession number IFO 15636. In some embodiments, the genetic modifications as described herein are with respect to the bacteria strain deposited under accession number NCCB 73019. In some embodiments, the genetic modifications as described herein are with respect to the bacteria strain designated P. Baumann 111. In some embodiments, the bacterial strain is NCIMB 857.

[0061] In some embodiments, the genetically-modified bacteria comprise inactivating or eliminating the restriction-modification (R-M) system of the bacteria, thereby, increasing uptake and maintenance of recombinant plasmids. In some embodiments, the genetically-modified bacteria comprise inactivating or eliminating one or more recombination-related genes to increases stress-resistance and enhance plasmid recommendation events. In some embodiments, the genetically-modified bacteria comprise inactivating or eliminating prophages-integrated viral genomes to maximize stability and eliminate the risk of phage-related contamination. In some embodiments, the genetically-modified bacteria comprise increasing expression of stress responsive genes. In some embodiments, the genetically-modified bacteria comprise one or more modifications to reduce natural resistance to antibiotics, thereby, reducing the risk of background colony growth. In some embodiments, the modifications to natural resistance to antibiotics comprise modifications to genes or clusters related to efflux pumps, cell envelope, capsular, biofilm, peptidoglycan or exopolysaccharides production. While specific classes of exemplary modifications are provided below, the present disclosure encompasses bacterial cells having one or more of the classes of modifications described below (including any combination of the modifications provided below).

[0062] In some embodiments, the genetically modified bacterial cell is compatible for use with a cloning vector that comprises an origin of replication selected from the group consisting of pUC19, pcDNA3.1, pET, PBR322, pACYC184, RK2, RSF1010, pl 5 A, pNG2, pSClOlts, pSa, pTHT15, pAL5000, pAMBl, pBBRl, pBBRl-UP, pBCl, pBPl, pCB102, pCD6, pIJlOl, pIM13, pIP501, pMBl, pSG5, pUBUO, and pWKSl.

[0063] In some embodiments, the genetically-modified bacterial cell provided herein is compatible with a cloning vector that comprises an antibiotic selection marker selected from the group consisting of kanamycin (KAN), tetracycline (TET), chloramphenicol (CAM), gentamicin (GEN), spectinomycin (SPEC), andDocket No. 212391-704601erythromycin (ERM), and carbenicillin. In some embodiments, the antibiotic selection is agar based-based selection or liquid-based selection.

[0064] In some embodiments, the genetically-modified bacterial cell provided herein is compatible with a DNA assembly technique that comprises Gibson Assembly, Golden Gate, Traditional restriction or ligation, e.g. restriction enzyme-mediated ligation, or a combination thereof.Transformation efficiency

[0065] Disclosed herein are genetically-modified bacterial cells comprise a genetic modification that when made chemically competent have an increase in transformation efficiency of a plasmid transformed into the genetically-modified bacterial cells, as compared to a chemically competent wildtype bacterial cell. In some embodiments, the genetic modification results in reduced expression of a polypeptide encoded by a gene having a polynucleotide sequence of SEQ ID NO: 1 in the chemically competent genetically-modified bacterial cell, as compared to the comparable chemically competent wildtype bacterial cell. In some embodiments, the genetically-modified bacterial cells having a genetic modification that results in reduced expression of a polypeptide encoded by a gene having a polynucleotide sequence of SEQ ID NO: 1. In some embodiments, polynucleotide sequence of SEQ ID NO: 1 is:GTGATTAAAAAACTATTGGCTGTTGTTGTACTGATTGCTTTGATTGGTGCA GCAGGTGTTTTTTACGTTGTTTCACAGGCGAAGCAATACGTAAATAAGCC AGTTCTACTTGAGCAACCACAGCTATTTACGGTAGAAAACGGTACAAGCT TTAACCAAATAATACGTAACTTGGTGAAAGCAGAAGTTATCGAGTCTTCT GAATATACTCGTTTTATTCCGCGTCTTTATCCGGAACTGTTACAAGTTAGG GCAGGGACGTATCAACTCGAGCCTAACATGTCGCTTTATCAAGCGTTAGA GCACCTCAACACAGGCAAAGAATATCAGTTCGCGATTACTTTTGTAGAAG GCAGCCGTTTTTCTGAATGGTTGGCCTTGCTAAAAGAAGCACCTTACGTAG AGCATGATTTGACTGCACTCTCCGAAAAGGAGATGGCGGCTAAGCTGGGT ATTGAACGTGAAAAGCTAGAAGGGCTATTCCTGGCAGAAACATACCATTA CACTGCTGGTACCACAGAAAGCCAGCTACTAAAGCGTGCGCATCAGAAAT TAAATAGCATACTTGATGCTCAATGGGCGTCACGTCAGGAAAAACTGCCT CTTGAAGATAAATACCAAGCTTTGATTTTGGCTTCAATTATCGAAAAAGA GACCGCGATTGATTCAGAGCGTGAGCGTGTTGCATCGGTGTTTGTTAACC GTTTGAACAAGCGTATGCGTTTGCAAACGGATCCGACAGTGATTTACGGA ATGGGCGATGAGTATGACGGCAATATTCGTAAAAAAGATCTGCGCACGCC AACTCCATACAATACGTATGTCATTAGTGGGTTGCCGCCAACGCCAATTG CCATGGCGGGAGAAGCGTCAATCGTTGCGGCGTTGAACCCTGAAGAGAGC GCCTACTTATACTTTGTCGCAAGCGGAAAGGGCGGACATGTGTTCAGCAA ATCCCTTGCTGAGCATAATCGTGCCGTAAGAGCCTATTTAAGAGAACTAADocket No. 212391-704601GAAAGAATAAATGA(SEQ ID NO: 1)

[0066] In some embodiments, the genetic modification to SEQ ID NO: 1 results in at least a 1.0-fold, a 1.1-fold, a 1.2-fold, a 1.3-fold, a 1.4-fold, a 1.5-fold, a 1.6-fold, a 1.7-fold, a 1.8-fold, a 1.9-fold, a 2.0-fold, a 2.1-fold, a 2.2-fold, a 2.3-fold, a 2.4-fold, a 2.5-fold, a 2.6-fold, a 2.7-fold, a 2.8-fold, a 2.9-fold, or a 3.0-fold increase in transformants, as compared to the comparable wildtype bacterial cell. In some embodiments, the genetic modification to SEQ ID NO: 1 results in an increase in transformation efficiency is greater than 50%%, as measured by the CFU / pg DNA as compared to a comparable wildtype bacterial cell. In some embodiments, the efficiency is 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%%, as measured by the CFU / pg DNA as compared to a comparable wildtype bacterial cell. In some embodiments, the genetically-modified bacterial cells have an increase in transformation efficiencies that is at least about 0.001%, at least about 0.01%, at least about 0.1%, at least about 1.0%, at least about 10%, at least about 20%, at least about 30%, at least about 50%, or at least about 90%, as measured by the CFU / pg DNA as compared to a comparable wildtype bacterial cell.

[0067] In some embodiments, the genetic modification comprises a deletion of a gene or a gene cluster, wherein the gene or the gene cluster has a polynucleotide sequence of any one of SEQ ID NOs: 4 - 6. In some embodiments, a polypeptide encoded by the polynucleotide of any one of SEQ ID NOs: 4 - 6 modulates the cell wall of a bacterial cell. In some embodiments, the polynucleotide of SEQ ID NO: 4 encodes a cps gene cluster that is involved in the synthesis of capsular polysaccharides. In some embodiments, the polynucleotide sequence of SEQ ID NO: 4 is:ATGAAATACAAAGGACTTATTCGTTCTCATGAAGCAGAGTTCGCTTTTTTA TATCGCATCGCCGATCTTACCGTCATTGTCTTCTTTATGCTGTTTCTGGTAT TCAGAGGAACGCATACCACAATGGACAAGGACTACGTCATACTCTCATTT GTCGCTGGTATCTCATTTTTGTTGATGGCTGAGAGCGGCAACCTTTATCGC TCGTGGCGTACCAGCTCCTTTAAAGCACAAGCACTCATCACCTGTATGTCG TGGCTGATAACCGTCGCATTGCTGTTTGCGGTTATTTATTTTTCTGAAGTGT ATCCATTGTTTGATCGCAGCATTTTAGGATTTTGGGTGATCATTACACCGC TTTTGCTTTTAACGTGGAGACTGGCCTTCCGCACGGGCTTAGCGTATTTGC GAACAATGGGTTTAAACACTCGTACAGCCATCATTATCGGCCAAACCCCA CACGGTATTACCCTAGCGAACGAAATACAATCTCATACCGAGCACGGTGT CTTGTTTGATGGTTTCTACGACGAACGTTCCATAGACAGACTCCCTCACTC CCAATACCCAATAAAAGGCCCTGTTGACCAAGCACTAGAACGCGCTAAAA AGGGCGACGTTGATTATGTTTATATCGCGATGCCAATGCATGCGAATGAG CGTATCGCATCGCTTCTTAATCAGTTCTCTGACACCACCGCGAACACATAC CTCATACCAGATTTCTTTACCTATAACTTGTTGCATTCTCGCTGGGATCAA ATCGGACAGGTTCAGACTCTCAGCGTTTTCGACACGCCTTTCGCTGGTGTTDocket No. 212391-704601TCATCCTGGATAAAACGTCTTGAAGATATCATTTTCTCAAGTCTGATCTTG CTCTTAATCTCGCCAATACTCATTGCGATAGCTATCGGCATCAAAGCAACG TCCAAAGGACCAGTCATCTTTAAGCAGCACCGCTATGGTTTGGATGGTCG CAAAATTGCCGTTTGGAAATTCCGTTCCATGACCACCATGGATCAAGGTA GCCACATTAAACAGGCAACAAAAAACGACCCTCGAATTACCCCGTTTGGT GGGTTTCTACGCCGCACATCACTCGACGAGTTGCCGCAGTTTTTTAACGTA TTGCAAGGCACCATGTCCATCGTAGGACCGCGTCCTCACGCCGTTGCCCA CAACGAAGAGTATCGTCAAATTGTCGACCGTTACATGCTGCGACATAAAG TAAAACCCGGCATTACTGGCTGGGCTCAAATTAACGGTTACCGAGGCGAA ACCGATACTCTCGATAAAATGGAAAAACGCGTCGAGTTTGATTTGGAATA CATCCACCAATGGTCGGTATGGATGGATATAAAAATCATATTCCTGACCG TATTTAAAGGATTCACCGGCGCTAACGCTTACTAAGGTAGAGACGATGAA GACGGCAACTCCAATCTTTTCGCTACTCTTTTTGCCAATGTTCACTTTGGC AGAACCAATGGCGTATACAACTGGCTCAGGTATTGAATTTATTCCGCAAG TGAAAGCCTTTTATGAAGGCGACGACAACGTGAATAAAGACGAAGAGAA CGCGAAGTCCATTAATACTTGGGGAGTAGAGCCAAGCCTGCTGGCCCGAA TAGAGCGAAATCAATATCGCGCTAACCTTATGTACAAATTGAAATCGGGC TTCTCATCGGATGACAGCAATGATTACGATGATCATACGTTTCAATTCACC AATTTCTTTGAGTTTAACCACCGGAATCGTCTGGTCGTCGATTATCAATTC CGTGCCCAACATGAATTGAGAGGTGAAAACATCACAGAAGGCAACGGTG ACGCGGTTGACTCGCCGATTCGATTCCATCGTAACGATCTAAAAACCAAT TACATTTTTGGTTCCGAGGGGGCCAAAGGACGTTTCGAGTTCGGTATTAAC TATAGCGACAAAACCTACCAAAACTATCGCGACGGCTTAACGTTCGCACC AAATGCGAAAACAAAATACAACGACTTTAGAGCATCCAGTGCTCACGCTG AGTTTTATTTGCGAGCAACTCCAAGAACCTATTGGCTGATAGGTAGCCGA CAAATTCAAACCGATTATCAGCACAGAAACCCAGCCATGGCATCCAGAGA CAATACGGCGGGCTTTTACTATACCGGAGCACAATGGGAAGTAACCGGAA AAACACAGGGTATTGCTCGACTTGGCTACCAAATAAAAGATTTTGATAGC AATGAGCGAGAGACTTTTAAAGGCTTCAGTTGGGATATCGGCTTTGAGTG GTCACCTCAAGAGCAAACACTGATTACGGTAAAAACAACTCAAGCTGCGG TGAATCCAGATCAAGATGGCGACTACAACCTGCAAACTCGCTATCGAATT GATTTTAAGCATGACTGGAATAGCTACCTCGCCACAGAGTTAGGATTCCT ATACCAAGAAGATGACTACACCGGGGAGCTTCCGGGAATGGCTTCAAGA GATAGCGAACGTTACTCGCTGTCTGCCGGTATCGACTATCAAATCAAACG TTGGATTCTACTGCAGGCCAACTGGCAATACCAAGATAAAACGTCAGACC GAACAGGCTATAGCTTCCAACAGAATGTTTGGACACTAAGCACTCAATTT TCGCTGTAAAAAGGATTTTTAATGAACCCATTAACGACGCTTATTAGCCTG GTTTTATTGCTATTTAGCACGTTCGCCACGGCTACGACGAATGAACAAGA CTACCTACTTGATACCGGGGATACCATTTCGATACAAGTTTATGGTGAAG AAGATTTGTCGATTTTGAACATACAGATCACGTCTGACGGCTACTTTGATT ACCCTTATCTCGGCAGAATTAAAGCTATCCAGAAAACGCCCAAACAGATT AAAGATGAAATTGAAACCGGGCTGAAAGGCGATTACCTGATAGATCCAA AAGTCATGGTTACGATCAATAACTTCCGCCTTTTCTACGTCAATGGCGAAG TACGTAAACCCGGTGGTTTTGAGTATCGTCCGGGGCTGACGATAGAAAAA GCGATCGCTCTCGCGGGTGGGCTCACTGACAGAGCATCACGCAAGGGAAT CAACCTCACCAAACACAAAACCGGTAAAACGGTAGAAAATGTCGATATG CACCTGAATGTTGAGCCTGGTGACATTGTATTTATTGATCAAAGCTTCTTT TAAGTGACAGGTAATCAAATGAACGGAACTCACCCAAGCACCTTCCCGAT GAACAAAGTAGAACTGATTCGTTTTGGTCATCACTATAATACGCTCAAAA AGAACTGGTTGAGTATTGCTGCTTTTACCTTAATTTTCTCTTTGGCCTGCAC CTGGTATATCTACTCGAAAACATCGATTTACCAAGCAACAGCGACACTTTTDocket No. 212391-704601GATTCAAGAAGAGCAAAAAAGCGCTTTGTCCATAGAAGAAGTCTATGGA GTGGATACGACCAAGAAAGAGTACTTCCAGACTCAAGTGGCGATTTTACA GTCGAACCACATCGCGGATAAGGTTATCCAAGGCCTTAACTTGACTCAGT ATCCCGAGTTCACGAGTACAGGTGGGCTAAAACAAACCATTGATAACATA AAATCAATTCCACTGGTTCAAGACTTACTCAACGTTACGCCAAACCCAAC AGAAACAGCGCAGTATTCCGATACCTATTATCGAGCACTGCAAACGTTTA AAGACAAGCTAGAAATAGAACCTGTCCGCAATACGCAAATGGTTAAAATC CGTTTTCGATCGGTGGATCCTAAACTAGCAACACAAGTCGCCAATGCGGT GGGTCAAGCCTACATCGACACAAACTTTGAAGCGAAATTAGTCGTCACAC AAAATGCCGCAACCTGGCTGACCAACAACTCACAAAAGTTAGAAGAGCG TTTGAGAGACTCAGAACAGGCTCTGCAAGACTTCTTATTGCAAGAGGGGC TGATTGATATCAACGGTATCGATGAAATCTACGCCAATGAGCTGGAAGAG CTCAACCGAAAACTCAACACCGCTGTTAACAACCGTATTGAAGCGCAGTC TTTGATTCAGCTTCTCAGACGCAAATCATCGCAAAGCTTAGATAGCCTGCT GTCGATAGATGAGTTCGCCAACCAAGTGCAGATCCGTGATCTAAAACTCT CGGAGGCTCAGGCGGAGAAGAACTTGTCCGAACTGGCACAGCGTTACGG ACCTAAGCACGATCGTATGATTCAGGCGAAGGCTCAATTAGATTCGATCC AAACCAGAACCCAACAGCTAATTCGCGAAATTTCGTTCAGTAAACAGCAA GACTTACTGTCAGCAAAATCTCAGGAAGACATGCTGCGTGCTGAGTTGAA TCGCAAGAAAACAGAGTTCCAATCATTGGGTTCACAAAAAGCGCGCTATG AACAACTCAAGCGAGAAGTTGAATCCAACAAAGCGCTTTACGAAGCGTTC TTAAACCGAGAGAAGGAAACCAGTGCGACCAGCGACTACAAAAATGTCA CTGCTCGTTTCACAGATAAAGCCATTATTCCTCTGTTTCCCGTTGCGCCAC AGAGAATGAAGCTGGTTTTTATTGCAACAGTATTCGGATTTGCAATTGCCT GTGCGCTCGTCATCATTTTAGAAACATTGCGTGAGGTGATAAGAACTGCA TCGGATGTTGAAGAAAAACTAGGCGTGACCTGCTTGGGCACTATCCCACT CGTCAAAAGTCGTCGCTTGCGTAAAAGTGGGCTCAGCTACACAGCTTACT TAGACAAGAATGAAAAACTGTTTAGTGAAGCGTGTCGCTCCGTCAGAACC TCTCTGTTACTCAGACTGACCAACGCAAAACAGAAAGTTCTGCCCTTTACT TCTGCTATCCCGGAAGAAGGGAAAACGTCCACCAGCATTAATATGGCCGT GTCTTTTTCTACCATGGAAAAGGTATTGATCATTGACTGCGACCTTCGCCA ACCTTCATTGGCCAAAAGGTTCGACATTGCCGAATCTCAACCGGGATTAA CCAACATACTTACGATGGATACGTCCATTAAAGACTGCATTGTGAGAGTG GAAGAAGCAAAGCTGGATGTTTTGCCAGCAGGATTAATTCCGCCAAATCC GCAGGAACTGTTAGCCTCGGCACGCTTTAAAAAGCTATTGGATTACCTTC AGGAAAAATACGACCGCATCATTATTGACACTCCACCATTACTGTCAGTG AGCGATGCTCTGATTTTGGGTCAGTATGCGAATGGTCTGATTACCGTTATT CGTGCAGAGTCGACCAAAGCACAACTGGTTAACGTTGCGTTATCCAAACA ATTACAACATTCCGTACCATCTCTTGGCGTGCTTATTACACAGGCAAAATC TAAGGAAGGGGAAGCGTTATATGTCCACAAATACGCCTACTAAACAAGTG TCTTGGTACCAAACGCTGAAGCGTCAGGAACAGCCCGTATTGATATACCA AATGGGAAAAGTGGGTTCGAGTGCACTCGAAAAGTCGATTGAGGGATCG ATCCATCTGCATGACCTGATGTCCATTTCGGCGTCAAAACAGATCTCCCCT GTGCGAGCACAGTTATACAAACCAAAAACCAACTACGTCAAGCGACTACT GAAACGGGCCATTATGATCAACATGCTAAAACGTAAACAGCATGTGCGTA TTATCTCGCTGGTCAGAGAGCCTATTGGCAGAAACATATCCATGCTCTTTC AATCACTCCCTTTTTGGGTCGCTGATAAATACCTCAAAGATGACAGTGCCG TACGTTCAGAGCGTCCTCAACTGCTTCATGAAGCGTTTGAGGAGCATGTG AATCATCACTATCCGCTTGAGTGGTTTGACAACGAAATCAAAGCACTCAC AGGAATAGATGTTTTTATTCATCCGTTTGATCATGAGCTTGGTTATCAAAC CTATCAAAAGGGCAATTTCTCTTTGATGGTGATTAGAACCGACAAACTGGDocket No. 212391-704601ACCAGTCACAGCAGGCGATCAGTGAATTTTTGCAGCAAGACATCCAAGTG ACTCATGACAACCAATCGGAAAACAAGTGGTACTCGCCACTTGCCACTGA GTTCAAGAGCTCTTACCAACTCAAACCAGAGTTTGTTGAGGACATGCTTTC TTCAAAGCTTGCTATGCATTTCTTTACGAGCTCAGAAATTGACAACATCAA GAACAAATACACACAAAAACAGCTTGGTAGATAAATGAAGATACTGCAT ATAATTAATGACTTATCTAACAACGGGGGAGCACAGCGCTTTCTGGTTGA CCTTGTTGTTAAGCATAAGCCCCACTACGAAGTAAAGATACTGGTTCTGA ATAAAGACAATGACTTCGAGACCCAGCTAAATGAAAACGGGGTCAGTTTC TATTACTGGCCTTCCCTGTCGATAAAAGAAAAGTGGGGGCTGTTGCGCTG GCCAAACCTGATCCACAGCCATTTATTTCCTTCGATATACGTCGCTTTACT GGCGATTGGTAAGAAACGGGTACAAACCGAACACAATACGACGAACAGA CGCAGAGATTACCCTGCCTTGAAGTTTATGGAGTATCTGATGTACCAAAA ACATCAGAAAACGATTTGTATCACCAATAAAGTAAGAGAAGAGTTAGTCA GGTTCTTGCCGAGATACAAGGATCGCTACGACGTTATTTACAATGGCGTC GACTTAAACCGTTTCTCCAGAAAAGCCAAATCGTATAGCAGAATTCAACC AGACAGCCCAATCAATATCGGGATGGCAGGCAGACTTCATGGCTATAAAG ATCACCCGACGCTCATAAAGGCCATCGCTAAATTACCGGAACACTACCAC CTTCATTTAGCGGGTGACGGTGATAAAAAACAACAGCTGCAAGATTTAGC GCAACAATTAAATTGCGCTCACCGTGTGCACTGGCATGGTGTCATCTCAG ATGTGCCGACTTTTTTATCCAATCTTGATGTGTATGTTCAATCTTCAATTAT TGAGGGATTTGGGCTGGCCGCCGTGGAAGCGATGGCTGAAGGGTTGCCCG TTTTAGGCTCGAATGTTCCGGGATTAGATGAAGTGATTGGTAACGACTCCT ACTTATTTGAACTAGGAAACGAACAGGAATTAGCCGATAAGATTGAGATA ATTTGCAGTAGCCAAGCCCATTATGAAATGGCTACCCAATTTTTTGTCGAA CGTTGTAAATCTTTCACTCTGGAACAATTCAGAGAGAGCTATTACAAGGC TTATGATGAACTCTATGCCAGTAAGTAATCACATTCCTCTGCTGGCTGCGT TCACCCTAGCGCTCTTTTTTGTGCCAGTGAAAATTCAAGCGGGAGGTATTG CGCTAGCGCCGAGTGATATCGCAAGTCTTCTCTCTCTGGGATTAAGTGCGC TTGTTGTTATGGAAAGCAAAACACGCAAGCTCCTGCATCCGTGCATCGGA TTTGTATTGCTGTTCACCGGTTATGTGTTTATTAACGGCCTACTTAATCGTG TGCCCTTGATGCCTCTCATTACCGAAACCGTTCAGTGGGTAGCGATTCTTA GTCTGCTCGGATTACTGTTCGCTTATGGAGCTTTCGAAGATGAACGAGTCA TGGTGTACTTTTCTTATATTCTCTTCGTTATTTGCTGTCTGGTTGCCGCTTG GCATTTTGCCCAAGGTTATCAAAGTGGATTCAAGCTTCTTGGGGTCAGTAA GTATGGTTTTGGCCTGCTCTGCTCGTTGCTCTATTTATATCGAGACAAAAT TCGCGCCTTCCATATTTTAATGCTGATAGCACTGGTCTTACTGGTTTTATCG CAAGAGCGCAAAGCCTTGCTTGGCTTTTGTTTATTGTTTCTTTTGGATCAG CTTTTCATTAAGAGTTTGATGAGAAAAACCGTCAGTGAAACATATACCTG GACCATATTACTAACCCTGAGTTTCGCGGTGTTGGCTGCGGTGTCCATCAC TTCATATGTGGGCTTCGACACGTTAGCCGATCAGCTAGAGTTCACCCAAG AAGACATCTTGTTTGCCAATCAGAGTGAAGCGAGGTGGGTATCCAATTTG CACCGAAAACTTTTACTCGCCAATGGTTTCGACATTCTCCAACAGCATCCC ATCTTAGGTGTGGGAGCCAAAATGTTGCCTAGCTTCATGGTCAATTACTTT AACTATCAAGAGCTGGCGATTTACACCCATAACTTTGTTCTAGATACCGCC ATCGAGTATGGGTTACTGGGTATTGCGCTGTTGTTCGGTGGATACTTTTTT TTCATCAAATTTTGCTTCTATAGCTTAAATGAGAACCGCAAAAGCCTGCTA CTCGCAGCGTACGCGCTCATTATGGTCTGCTTCGTTGCGGTAAATACCACG ATTATTTTAATCCTGTTACTACCGGTAATGCTCAGCATAAAACGCACGGAT GAATCCAGCCGCATGCCTTCATGTTCGGGAATTAAAGCCACCAATTTTAAT AATCAAGGACTTGATCAATGAAATATTCAATCGCTCGACAATTTGAAAAG AACCGAGAGCTTCGAGCTGACAACTTTGTCTTGGTTTACCAGATGGGAAADocket No. 212391-704601AGTCGGCTCATCTTCCATTGAACACACGTTGGGGGAGCGTAATATTCCCA GTTACCACATCCATACCTTTGATGATCATGAGGAGTTCCACATGTATCACA ACAAACGCGATGTGAAGAAATTCTTCGATTTCAAAAACCGTGCAATTTAC CGTTTGGTCCTTAACCAAAGAAAACGAATTCTGCAAAAACGCGAACAGAT AAAAATCGTCACTTTAGTGCGTGACCCTATCGCTACTGTATTGTCTCGCTT TTTCCAGGACCTTCATTTTCAGTTTATCGAAGGTAAAAAAAACGAAGCGA TCCACAACGACATGGACGTGACCTACCAGCATTTGGAGCACTGCTTCGAC AACTACATTAACCTCAACTATTTTGCCGACTGGTTCGACAACGAACTGAA ACGTAACTTCAACATCGACGTATTGGACCAGAAGGTTGATAACACCCAAC CTTTCTTTACCTTTAGCAACAGTCAGGCAGAAGTACTGTTAATTAAGTGCG AAAAACTCAGCTCGCTAGACCGAGAGATTGGCCAGTTCTTGAATGTCGAC GATTTTGAGTTGAAGAATAGCAACGAAGCGAAAAACAAATGGTATTCAAA CATCTATCAGTACTTTAAGCAGCAATACGATTTTTCTAAGTTGTTCTACAT GTACGACTTGCCGCTTTATCAACATGTTTACTCAGTTCAAGAGCGAGACGC ATTTAAGTCCAAATGGCAGCAAACTCCGGGAACCAAGTCATCATGAAAAG AGTACTGCATATAACCGAATCTTTTGGTGGTGGTGTTCAAACGGCACTTTA CAGTTACACGCACTCTTCCCGCCATGAACCTTATCAGCATTTTCTGGTTGC CAGAGCTCGCGAAAATGATTTAACCAATGACAGCGGCCACAATGTATTTT CACGTGTTCAATGGGTAAAGGGTGGACTGCTGCAATTCATCAAAGATGCG AATAAAACAATCGATGAAGTCAAACCAGATATTGTCCACCTACACTCGAG CAAAGCAGGCTTTTTGGGGCGTTTTTTGCGACTCAACAACGCACGATTAGT TTACACGCCCCACTGCTACGCATTTGAGCGGGAGGATATTTCAGGCTTTGC TCGACAACTCTATAAAACGTTAGAGCGCTTGCGATTAGATAGAATCGATA TCGTAGCGGGATGCAGCCAACGTGAATGTGACTTAGCCATCAGCATCGGC GCCAAGCAGGCTGAGTTACTTAATAACTACGTATCTTATCAAAGTGAAGA GCGCGAAAGCCGAGATAAAGCCGCCGCATTAAAACTGGTGGTACTTGGCC GGGTCGCACCTCAGAAAGACCCTCAGTTTCTGATTGATACTCTTTCCCACC TTGATGTTGCGACACTCAATCGTCAGTTTGAGATCACCTGGATTGGTGGTG GCGACCAAGAGCTTGAACAGCGTTTAAAAGACCAAGGCGTACACGTGACT GGCATGCTTCCTCGTAGTGAAGTTATGAAGAAATTAAAAGCGTCGGATAT TTATCTGCACACTGCCGCTTGGGAAGGCATGCCACTAACGATTCTCGAGG CCGCTAAGCTGCATCTCCCAATGGTTATTCGCAAGATTGGCGCGACAGAA GCTCTGAACTATCCATTTTTGGCGCAAACGCCGCAAGAAATGGCAAAACA GCTGACCCACTGTATCAACCACTATCACGATATTGATTTTGGCCAATACAC GACTGAATTGAACGACACATTCAGTGAAGAAAAGCAGCGTCTCGCTTTAA ATAGCATCTACCGTTAGAGATATTACATGTTTCACGCCTTTCAACAAAAAA GACTGTCTGCGCCCAGCGAACAAAAAAGCTTGTTCTCACTTGGCTTAAAA ACCGCGCTTACCCGAGTGTTCAGCGCATTGTTTGCATTTTTGCTTGCAGTC ATGGTGTCCCGAACCACAGATGCCTCGATAGCGGGTCAGTTTTTCTTCTTA TTTAATCTGGTATCACTGACCGCGATTATTTCTCAGTTGGGCTTTGACGTG GCTTTGGTGAGATACAACGCCATAGCCTTTAACAGTCACAATGCTCAGCA ACAAAGCGATAATTACAAAACAGCGTTATCCCGAAGCTTCGCATTTTGCG TCCCGGCCGGACTGGCCATTTTTGCCGGATTCTATCTATTCCCCGAGACAG TCAATCAGACCAATGCCCCACTACCAGCCGTTGCACTCGCGTTACTCTGTG TTCCTTTCTTAGTACTTGGACAAACCAATAGCCGAGTCTTGCAAGCGAGCA AAAAAGTGGTCTCTTCGCTATTCGCTTTGCAATTGGGTGTGAGTATGCTGA TGGTGTTTGCCATTGCTGCTTTAGCCATGTTTGGCTTGCAAAGTCTTAACT ATCTCATGGCCGCTCTACTGCTAACATGCGTGATTGTTGCCACGACATCGA CAACAAACTGGGTGAGATCGGGGCAATTTCGCAAACCAACGTCAACGCCT AATCTCCAACTGACGGCTTCAGCCAAACAAGTCTGGATTGGGAGCATATT TAACAACGTTCTTCAGTGGGGAAGCCTCGTCATCGCAGGGTTCTTCATTTCDocket No. 212391-704601AGCTTCAGAGATTGGCTTGTTAGCCGCAGCCCAACGGACCTCACTATTGA TCGGCTTTGTGTTAATCACTATTAACTTTGTCGTCGCTCCAATGTTTGCGTC ACTTTACAAAGAAGGTGAGATGGACAAATTACGCAATTTGAGCCGGATGG CCTGTCGAATGAACATTGCAGCCGCATTAATTCCAGTGTTGATTTGTACAC TGTACCCTGTATTTGTACTGAATTTTTTTGGCGAAGAGTTTGTCGCTGCCG CGCCTCTTCTTGTGGTGCTGTCCCTCGGTCAATTGGTCAACGTTGCCACTG GCTCGGTCGGGTTTCTGCTTTTAATGAGCGGACATGAAAAAACAATGAAA TACATCACCATTGGCTCTGGAACCATCTCGATTTTGCTGCTGCTCGTCTTG TGCCACATTCACGGTGTTATTGGCGCAGCTTGGGCTATGGCAATCGGAAT GGCGATACAGAACCTTGCCGCACTGTACTTTGTTAAACGATATTTGGGATT CTTTCCGGTAGGCTAATTATGTCTTCTATGATTGCGCGCATCAGTTTTGGCT TCGTATCACTACTCACCGTCATCCTTTCCTTATGGAAAAGTTCTGATTTGA GTCATGCGACCTATCTCAATATGGAGCACTATGTCGGCGGTTCAACGACG CTCCACTTTACCTTCAGTCTGCTGATTGGCCTCTGTGCCGTATTTGCATTTC CCCGCCATGCCAGACCAAACAAAGCAGATACTTTTGGAATTCGCCTTTTG CTGTGTCTGCTGTTAATAATTTCACTCGAGGAGTTTAGTCAGCTTTTTATCC CCAACCGCACATTTAGCGTTGCGGATCTCAGTACCAACTGGAGCGGCATG TTACTTGGTTACTTTGCCGCTAAGGTATGGCTTAGCATACGAAATCACTAA GCTGTCGGTTTTAGCCAACTGAGGATTAATAAGCGACGTGCACTGAAATA AGCACCTCGAGGTTATTCAGGTATCGCTATATAATGCATTTACATAACCTT GAGAAGCGAGTGCTGCATGTCATCTCATCCAACAACCATCACCTTTTTTGA ATTTCTGACCCCTTTGATCACATCGGGCAAAAAAACCATCACGATACGAG ATGAGTCAGAAAGTCACTACATCCCAAATACCGAAGTGGAAGTCTTTACT TTAGAGACTAACCGCAAGGTCTGTGACATCAAGATCCTATCGGTAAATCC GCTTAACTTTGATGAAATCAACGAGTTCCACGCAGAACAAGAAGCCATGG AGTTACCAAAGTTGAAGCAGTTGATTAGGGAGATTTACCCTGATACTGAC ACACTTTTCGTTATTGAATACGAGTTGCTCAAAACAAACTAGACGACTGG TCTAATTTTAACTATAGTACGTCCCATGAACGCAAAGACTAACGACACAC GCCAACATATTCTCGAGGTCGGATACGAGTTAATCGTAACTCGAGGCTTT ACGAGCGTTGGACTTTCCGAGCTTCTAAAAACGGCAGAAGTACCAAAGGG CTCGTTTTATCATTACTTTAAATCCAAAGAGCAGTTTGGTGAGGCTTTGAT TGAGGCTTACTTCGATCGCTATTTCCACAAGTTAGATGAGATCTTTACCAA TACTGATCGCAACGGATACCAACGTCTGATGAGCTACTTTGAGGAGTTGG CAAAAATTGAAGATCACGTATGTAATGCAAATAGATGTCTGTTAGTCAAA CTTAGCGCGGAAGTTTCTGACCTTTCCGAACCAATGCGACTTGCACTACGT CGTGGAGCCGACAAATCAATTCAAGCCATCGCGGACTGTATTGATGTTGG CATTCAAGACGGATCGATTGCAAATGGTGATAGCGCTTTATTAGCAAGAC AACTTTACTACCTTTGGAATGGTGCAAGCTTACTCAACAAGCTGTATCAAG ATCAGACGGCACTGACGCAGAGTCTGACCTATACTCAAGATCTATTGCAG AATACACGCACTTTATCGTAAGTGGCTTCAACGCAGTAAGAGAACAACCC TATAAGTGTCTGTTTAAGGCTAGCCTTAAACAGACACAAAATACTTTCCCG CTCTCAGAGCGGGATATTTTGCAACAAAAACTAGACGACCGGTCTAGTCT AAGGTGAAAATAACATGACAGACGCACTTAACCGCAGAATCGTACTTGCA TCACGCCCACACGGCGCACCAACAACTGAAAACTTTAGACTGGAAGAAGT GGCAAAGCCAGTACCAAAAGATGGTGAAATGTTGTTAAGAGCCGTTTACT TATCACTAGACCCATATATGCGTGGTCGCATGAGTGATGCAAAATCTTAC GCAGAACCAGTTGCAATTGATGACGTAATGGTTGCAGGAACCGTGTGTCA GGTTGAAGTATCAAACCACCCAGATTACGAGGCGGGTGAATGGGTACTCG CTTACACTGTGGGTTGGCAAGACTACGCGATTTCAACCGGTGAAATGGTC ATCAAGCTGGGTAAAAATCCACAAAACCCTTCGTATGCACTAGGCGTAGC AGGCATGCCTGGCTTTACGGCATACATGGGATTGCTTGATATCGGCCAGCDocket No. 212391-704601CAAAACCAGGGGAGACTATCGTCGTTGCTTCGGCAACCGGCCCCGTTGGC TCAACGGTCGGTCAAATTGCAAAACTTAAAGGCTGTCGCGTAGTCGGTAT TGCCGGTGGTGAAGAGAAATGTCGCTATGCAAAAGAAGAGTTGGGCTTCG ATGAGTGTATTGATCATAAAGCCGACGATTTCGCGCAACAATTGAAAAAT GCATGTGACAATGGCATCGATGTCTACTTCGAAAACGTAGGCGGCAAGGT ATTCGATGCGGTACTTCCGCTGCTTAATACAAACGCCCGTATTCCTGTATG TGGTTTGATTTCTCAATACAATGCGACCGAGCTTCCACAAGGCACAGACC ACCTGCCACTACTGATGGTTAACATTCTGACAAAGAGAATCAAAGTTCAA GGATTCATCATTTTTGATGACTACGGACACCGTTACGATGAATTTGCGCAA GACATGAACCAATGGTTGGCAGAAGGAAAGATCCAATACCGTGAACAAC TCGTACAAGGCCTGGAAAATGCACCTGATGCGTTCATCGGTCTGCTCGAA GGAAAAAACTTCGGCAAAGTTGTTGTTCAGGTAAACAACCCTCTGTAAAT ATAGGATAAAGAATGATTAAACTTCACCATCTCAATCAGTCTCGCTCGAA ACGCATTATCTGGTTACTTGAAGAGCTCAATGTGAGCTATGAAGTCGTAC CGTATATACGTGACAAAGTGACTTTTTTGGCTCCTCCAGAGCTTAAAAGTG TACATCCACTAGGCAAGTCACCAGTTCTGGAAGATGACGGTGAAATCATC ATTGAGTCAGGCGCAATTACAGAGTATCTGATCGAAAAATACGGCGATGG TCAACTTGCTCCAGAACGCGGAACGAAAGCTCATACGCAGTACTTGCAGT GGATGCACTTTGCTGAAAGCTCGGCGATTTTACCAATATTGCTGAAAGTCT TTGTAAGCAAAGAACCAACTCAAACAGAGTTCTTATCAGGCTACGCAGAT AAAGAAACCATGAGTGTTTTGAATTACTTCGAGCAAGCTTTGGAAGAGAA AACCTATCTGGTAGAGGAGCGCTTAACCGGAGCAGACATCATGATGTCTT TCATCGTGGAATTGGTACATAAGTTTGGCATGAGCAAACATTTCCCTAATA TTGAAAGTTATGGAAACCAACTTGCCACTCACGAGGGGTTCTCAAAAGCA GAACAGCTCGAAGTCAAATACGCTTAA (SEQ ID NO: 4)

[0068] In some embodiments, the polynucleotide of SEQ ID NO: 5 encodes a syp gene cluster that is involved in the polysaccharide production for biofilms. In some embodiments, the polynucleotide sequence of SEQ ID NO: 5 is:CTATTGCCCCCGACCATCAAACATCACCACAATGGTTTTGGTAATGATGCT CATATCCATACTGAGCCAAGACTTCATCGAGCATAGAGAAAGCGCGTAAC TGTGGTCATAGCCGACTTTTCTTCGCACGTCATCAATGCAGGTATCGTAAC CCTGATTGACTTGCGCTAATCCGGTAATACCCGGCATCACACCATAGGTTC TATCAGCGAAATAAGGGATCGCACTCTCCAGTTTGCTATAGAAACTAGGG CGTTCAGGTCGTGGACCTATCAGTGACATGTCACCTTTAACTACGTTAAAA AGTTGTGGGATTTCATCCAAACGAGTCTTACGTAAAAATCGTCCAACTGG CGTGATTCTTGGGTCATTTTCCGTCGCCCAGACTGCCCCTGTATGTTGTTCT GCGTCTTGGTACATGGTGCGAAATTTAATGATTTCGAAAAACATCATTTTC TCTGGTGTAGATTTACCGACTCGAAGCTGTTTATAAAACACAGGGCCCGA AGAGGAGAGTTTGATTGCTATCGCGATAAAAGGCATTACTGGTGACAGAA GCAGTAAACCAAATAGCGCGCCGAACAAATCAAAGAGACGTTTTGCAAA CCAAATTGAAATATGTGCGGATACGTTACTCATAGTGCATCTCCTTTTTGG CCCACACGAGACCACTTTCCTGATTCAAGACCAAATAGGTATCGCATACC ACCGATGAAATTTGCGCAATGACCAGCAACGATGTAAAGCAGTAGCTTGC AGGCTTTGTGACAAAATATATGTGGTAGGTGATAAATTACAATCGCCAGT GAATAGATCGTGATTTGAGTGACCAGTGCAGCCATGAAAAGTGGGTTGTC CATCATGGCGATAGAACTAACAAAACAAAATAGAAGTAGGTAAGGGGTC ATGAGCCGTAGCCCTTTGCCGGAAAAGAATGCAAATGCGACACCTCTGTADocket No. 212391-704601CTTCGGTAAGAACATCTCACAAAGCTGGATTGCCTGCTGCATGTTGCCAG CAGAGATACGCAGTCTTCGGCTAAAGTCATCTTTCTCGTTGGTGGCTTCCA TCTCCAGAGCAACCATATCAGGCTCATATTCAGCAATATAACCCTGACGT ACGATCGACATAGGAATTATAAAGTCATCATTGATTGTATTGGCACTCATA GATTCAAACAGGTGCGTGCGGAATAGATAAAATGCGCCATGCGCCCCAAG CGTTGAGCCAAGTGAGGCTTCACGCATCTTAAGCTGACTTTGGTATTTCCA GTAACTGGCTTCCCCTGCATTACCCGGCTTAAACAATTGATAGTGACCATT GACGACGCCGACTTTACTGTCTTGAAAATGTGTATTTGCAATCCATAGCGC ATCAATGGAAATAAGGGCGGACACGTCGCTCAATGCCGTAATATCACTGG TGATGGTTTTCATCTGTTCATTTATCAGGGCAACTTTGCCACGATTGGTTTT AAATGCCCGGATTTCAAAATGTGTATCGGAACAAATTGCTTCTTGAATGGT TTGTTCTGCAATACTCACTGTCTTATCGGTACAGCCATCACATGCGATGAT GACTTTGTACTTATTTTTTGGGTAATCAAGCGCAGATAGGTTGCGAATTTT GTCCGCTATCCACTGCTCTTCGTTGTAGGCAGGTACCAAGATAGTGATGGT TGAACATCCCCGATCGCTTTTGATACTTCTGTATCCACGCGTTCTATGGCT GCGGGCTTTGTAAGGGTGATTTTTAGAATACCAAGACAGTAAAACAGGGT AGCCAACGTGGTGATAGATAACCAACACGCAACTGATAATAAACAGTGTG GTAAGTAGTAAATCAATCATGCGCTTTTCTCCTCAGCTAATATTTCGTATG CACGCATCATGTCCCTGATGTCGTTATGCTTTAAGACAAACTGTCTTGGGG ATGCTTTTACTGGTTTGTTTAAGGCGGTTTTTACACTGGCGGCCAACTGCT GTGAGTTTTCACTTTCAAACAACACTCCGGTGCTTGGGCAAAGGGTTTCTT TTGTTGCACCTACGTCGCTTGCTAAAGTGACAATGTCACATGCTTGGGCCT CTAAAGTAGAGAGCGGGAAACCTTCACGACGTGAGGGCAAACAGAATAA GTCCAGCGTTTGATAAAATCGCGTCATGTCATCAACAAGACCAAGAAAGG TTACTCGACTTCTTAACCCAAGTTGCTGCACTTGCTGTTCTAATTTGATAC GTTGGCTACCATCCCCAGCGATAACTAGCTGTATATGGTTCGGCAGTAAT GCCATCGCGTTGATCAAAATGTCGTGACCTTTGACTTGTTCTAATCGACCT GCCGTACCAATAATGGTGCTTTGCACAGGCAGTCCAAAAAGCTGACGGGC AAGGTGCTTGGAGCCAGTGGTGAATTTCTCGCAGTCGATACCGTTTTTGAT CACCCTGACATCCTGATAATCAAAATGTTGATGAATTCGTTGTTTTACCAG AAGTGCATCGGCAACAACGCAGGGTTTAGCGATTTTTAGTGCCAGGTTTT GTAAAGCGCGGTGCTTTTGGTCTGATAGATGCCATGCATCATGTTCGGTAT GAATTCGAGCTTTTACCCCGGCCAAGCGAGCAGCAACGGAGCCGTATAGA ATCGGACCAATATGATGGGTATGAACAACGCTTGGCTTTAACGTGAGAAA CAGTTTAACAAGTTGTATCAGCGTCTTAACGCTATAGCCTGACGGCTTGTT AAGAAAGATTAATTGGTTTTCAACCGACTTCAGTTTTGACCATTTCAATAC TGCTTCTTGTTTTTTACCTTCCAAACTAACAATGAGTACTTTCTGGTGTGGG GACGAAAACGCCAGCATGTTGAGTGCGAGCGCCTCTAATCCACCAGGGGA AAGGTGCTGAACCACGTGAATAATCGTTTTGGACTTTATGCTCATACTCGC TCCTAACGGATGTTTAGCTCTGAACTAGTATTAGCATTATGTGTGCCAGAT TTATTATTTAATCAATACAATGGTTTACGAGCTTTTTGTCGTATTTCTCAAC CTGAAAGTCAATTTGAAAATCGTTATGATTAATACGGCTTTATTCTTGGAA TGTGCGTGAGTACAGGCGCATGTGTAATGGCTTCGATCTCTTCTTTGCGTC TTATCGATGAATCAAACAGCTCGATCAATAACGCAACACCAGCACCTAAA CCAATTCCCGCCACCAATCCCGCAATGACAAATACAATCGCCGGAAGATT CGCCGGGCGACTAGGGGTATAGGGAAGGTCAATAATTTTGACGCGTTTGT TTTGCTCGAAAACCCCTAAAGAACCAGTGAGCTGAGCCATTTCGTAACGT TGAATTAATTCATCATAGAGTTGACGCTTAATTTCAGCATTGCGAACTAAA CGATGCATGGTTTTCGCGTTGTCACCGAATCGATTGGCTTCTTGCTCCAGG CTGGAAATCATTTCTTTTAAACTCTTTGTTTCTTCTGTGAGGGATTCATAAC GACCTCGCACGAGTTGCAAGCTTTGTAGCTGGGTGACGAGTAAAGGTTGADocket No. 212391-704601ATCTCTCCAAGATCTTTTAATTTATTACTGCTGGCTATATCCCAAAGCTGA TCGCTACTGATATTAGGTTGCTCCATTTTCAATAATAAGGCGCGTTCATTT TCTAAACGGCGTAACTCGCGTTCTTTGCCTTGAACAGCACTATGACTCTCT GTGTACTTCGCTTTGAGAAGAGTCAGTTCGCTACGAATCTCGATGATCTGA TCTTCAATTTTTCCGACCACGGGGTTGGTTGTTGATAGTTGTTGATCGAGA GAACCCAGGCTCTTTTCAACCCCAGCGAGTTCGGCTTTTTTCTCTGCGTAG CTTTGTTTCAGAGAGGCAAGGCGACCTAGCGACTGACTTTGCATTTCCGGC GTTACCGATGCAAAGCGATTTTTAAAATCAGCCAGTTCGTTTTCCGCAATG TCGAGTTCCTGTCTGCGTTTCTCAATATGAATAGCGAGAAATTCTGACGAG TCCTGAATCGATGAACGCTCTGGTGCGAGAAGCTGTTCAATAAAATGCTC ACTGATAGACTCTAATAACTCTTTCATACCGTCCGGACGGGGAGCGGTCA GTGAGATTTTAAGAAAGTCTTTGCCCGGTTGAGTGATCGTTAAACTGTTTG AAAGCTGATTGATGATGTAATCACGCTTGGCTGGTGGCATTGAGTCGTTA ATCAGCTGATGCTCATTCGCCACCGCAGTGAGTACATGGCGACTTTTCAGT AGCGTACTCAAGGCATTTAGACGTTCTTTTAGCATGGTTGAGACCGCGAT ATCTTCCAGAAACGGATTCATCTTCGCGGTTTCCTGAATCAGCATTGACGT ATGCGACACGTAGTTAGTCGGTGCAATTTTACCAATAAAGTATCCAACGA ATGGAAGGATAAGAATCGGTACGACAATCACATACCGTTGTCGCCATGCT GAATTGAGTATGACGATAAATCTCCGTTTTAACTCGTTCATAGTGACTCCA ACATACAGTTCAATTTAAGCGTACGTGCATCCCAACTTTCGTCGATAACTG ACTTTTGTCGCTCATCGGTTGATTGACGATCTAACTGATTTAATGCCTCTGT GAATTGCTCGCAATCAGTGACGGTTGAAACCAAGGCTTTGTAAGGCGATA ACGCGGGAAAAGGCGTAGTGATGACGGGACAGCCTGCCGCAAAGTATTC CAGTAATTTTAAAGGGCTGCATGAAGCAATTTGTCCATTGGATTTAAACG GAAGTAAACTCACATCCCAATGTTGACTGTAACCGGGTAAGTCGCGATGT GGCTTAGGGCCAAGGTAGTGCACATTTGCCAGTTTCGGTAGCGGATAGTT TGGGAGTTCAATTGGGCCGATAAACACAAATTGCCAGCTAGGGTTCGCGA GGCAAACTTGCTCGATGAGTTCGTAATCTAGCCAGTTAGACAGGCTGCCA TAAAACCCAGCAATCTTGTGATTTGGAGAGGGTAAATCCGTGGCACGCTG GCTTGGCCGACTAAAAAGTGAGGTATCTACGCCATGAGGCAAGTAGTGAG TTTTGGACTGCGGAAATTTTGCTAGCAAGGGTGCACTGGCTGCGAGTATC AGGTCCGCGTGCTCCACGAGTTTGTCTTCGTGCTGTTTGACCACCTTATGA TCGACACCGGCAAGCGATGAGAAATCGTCTCCGCAATAGTAAACCACCGA TGACTCACCGAGAGTTCCACATAAATCGGCTGCAGTCGGAAGTGAAGTCC ATAAAATTGGTTTGTGCAGCTGAAGCCTCTCGATAACGGGTTTCAGCTGC AGACGCATCAAGGTTTTGGCGATATAACGCGCGAATGCTGACTTAGGAGC AGGAAGTGTTTTAAGGTTGATCACCGTAATATTTACGTGATGCTCTCGCTG GTCGGTGTAACCACCTTTACTTTTACCCACAAGCTTACCGCAAGCACGTTT AACATCGTGCATATTTAACTTGGGTTGACGGAGTCCTATCGAGTTAACCCA AAGTACCTTGCGTTGTTTTGCTAACCGGGTAACCAGATGTTGTGTACTCGA TGGTAAGCCACCAAAATCTTCACCAAAAACAATAAGATCTCGCATAGTGA ACTCCTTAGTGATTAAGTGAACGTATCACTCTGGCAGGATTACCTGCAGC AACAACAAAAGCAGGCAGGTCTTTAGTGACCACACTACCAGCACCCACGA TGGTCCCTTCGCCAATCGTGACATTGGGGCAAACCGTGACGTTTGTTCCTA GCCATACGTCCTTTGCAAGTACGATATCTCCAACATCGCAATCGAGATCG CCAAAGCCTTTCGCTCTTAAATCAGCGTCAAGTGAGTGACCAGAATACCC AAACAGAAAGGCGCGACCGGCAATTCGAACATTGTCACCAATTTCAATTC GGCTCCCAATCGCAAAAGTACTCTGCCAACCGATATCGACGTTACTGCCA ACAATCAGTTGTGGATCACTGGATTGGGGTCTGGCGCTAAACGTTGTTTGA CCAGAGATGCGGCAATCGTCTCCAAGAGTGATGGAAAGTGGCCCGGAAA CAAAAGGCACACCACCAAAGAGATAAAGCCCTCGACCATACTGAGAAAGDocket No. 212391-704601TCGACCTTTAAAGGCGGGGGTATGGATAAATACCCGAACCAAGTTGTTCC AAATGGAGGTACTCGCTGAATAAACAGTGCGAACCGTCTTGTTCATCCAC ATCGGTGTAGGAAGATCACATGCACGAATCGATTTCAAAATGAGAAACAA TTTGCGATATGAAGGGTTTTCGTGGTGTTGTAACCACACTTTGAAGTCATT TAACTGCTGAGCCAACATGATACTGTCCCTTATATTGAGGTGATAAAGAG ACTATTTCACGTTGCGTGCCAAAAAATTAATTGTTTAAAAACAGTAATATA AGAATTATTTGTTGAGTGTTTCTTTGGTTTTCTCAATTTGAGAACGGATTTG AGTAATGCGGGAGATAGCGATACAAAGCGCTGCGAGGATATAAATCGGC CACGTGAAGCCTTGGGTTAGGAAAGTACCGGAAACCACAGTGCCTATTAC ACCTGCATACACCGCAAGCGCTGTTGCTGTGAGATAAGGGGAAACCAAGC CTTTTCGCTGATTTAAGATAGAAAGCGTTTGTCGGCTCGTTTTGATAAGCG AAATGATCATACCAATAAACACAGCCAGGCCAAGAAACCCGGTCTCAGCC AACACGCCGAACCAAGTACTGTGAACCGCGTGGTTGAGCCCGTCCCAATG TGGGCTGTAATAGTAGTAATTCGAATAGAAATTGTTTAAACCCACGCCAC TAAACGGGTTCACCACCGCCATCTTAAACGCCGCTTCCCATGCATATAAG CGTCCCATGGCTGATGCGTCGATGCCGTCTTCTGCTGCGCCGCCCGACTGA CGGTCGGAAATTCCGGCTACGGCAAACAGTCCCAGCAACCCAATTACAGC GATGAAGATCAATAGTGATTTTGAGCGAATCAAGCGCAGACCAAAAATAC CAAATACAGCAACTGATCCCAAAAGCCCACCACGGCTTTGTGTCGCGATA ACGGCTGCCATTGCCAGTACTAGCCCGGTAATACCAAGAATACGTGAGAA GCCTATACCTTTTGTGGTGGCAAAGCTGATCGCAAACGCCAGAGGGAACA TTAATACCAGCGACAAATCATTCGGATCACCAAGCACAGAGCCCAACTGA CGACCGATGGTGACTCTCGTCCCCTCAACTAAACCAATCCCTGAAGCCGA GTTATACAAAGCAACTACGGCGATTAATCCACCCGCTAAGATAATCAAGG TTGCGATTTTTCGCACTGCATCTTCCGTATTCACCAACCAAGCGATGGCTA GAGTCATGATGATGATTTTCCAATAGATATTTTTAAAATAGGTTATCGCAA CGCCCGGGTTAGAGGACAAGACAATGCCTATGACAACAAGCCCCCAAAA TAGGACGAGCCACGTCATACTCGGGTGCCAGAAAGTTTGTAGCTGGCGAC TGATCAAGGTGTGCCAAATCAAAGCGCCAAGTGCTCCTAAAGAGAGGAGT AAAGGGATTTTTAATGAATAAAGTGCGGGTAAGGCTTCGTGAATTCGAAA GAAGGAAAACAGTACAAATAGACTCACCAACCAGAATGTCTGATGGAGC ACAAACAATGCCGCAAGCGGTAAAAAGCAGAGCACAACGACAATGGCTG GATGAGGTATAACATACCAAACCATGGCTAGCGTAAACGTAACCAGCGTC ATTATCATTATTGGCCTGGCGTGTTTGACACTATTCATAGTGAGCGACCCA CGTAACGAGTTAACGTAATTGAAAGACGTTTGAGTGAAGCACCTGAAATC AACTGGAACCGAATGGCAAAAGCGATAATGCCTAACGGTTGAAGCAGCA GCATTAACGCGGACACCTCGATACTTTGATGATACCGACTGGTTAATAGA AACAGCACCGTTAACGCTGTCAGCGCACAAATAGGGCTGGTTTGATAATC CAGATAATGCGCACGTTGGCTAAACCAGATTGTGAATATGAATCGACTTA ATTGCCCCGCGATCAACCCGTAAAGCATTGCTTCAATGCCGAGGTCAGCA GAAAGGATACAAATCACCATCGCCAATGCGGTGGAGGCGAGGTTAATGT ACAAAAGCTGAGAGGTGTGCTTTTGGTAGAGAATGCCGAAGTTGGTCAAC TCGACCAGCTCTTTGAATAGCATCATTGTTATGGTCATTCCAACCAAATTG ATAGCAGGCTGGTAAGAGTCCGGTAAAGAGAACGAAATAAAAAGTTGAC TAAGCCATGCCACAGCGACAGAAATAACGCACAACAGCAGTATCCCTTGA GTCGTCACGCTAGCGACATGTTCTCCTCCATTTTTGTCCATGGTTTCGAAA CGTTTTGGCATCCACCACATATGAAAAGGTTGGATAAGAATACCGACGCC AAGCGCGAATTTAGCCGCAATCGCATACATGCCTAAGGTTTCTAAATCGG TTGCTCCAGCGATCAGCCACCTTTCTGCACCACTTAAACCAAAAGCCACA ACACCGGATAGCATAAGCGGCGCAGAGTAGCGGATATAACGAATAAAGC GTTGTTTGTTAGGTAGGGAAAATGGAAAGTTGATGAAAACGTGCAAAAACDocket No. 212391-704601AAAAACTGTATGAAGGTACACACGATATTGAGGGCAAAAACGAGTGTCA CGTCCGGTTTGTATGTCAGGACGACAACAAGTAAAGAAACCTGAGCTAAT ACGGTCACGACACATATCTTAAAGAACAAGCTTGCTTGATTATGCAATCTT AACCAGGCAAGGCTGATAGCAAGGGGCGCTTCGTAACACCAAACCAAAG CCATAAATAGGATTTGCTCACTGGTGAACGTCGAAAGCTTAAAAGGGACC AGGTAATAAATGAACAAGATAAACAAACTCAGACTGAAAGAAGCAACGA GCGATGCACTGTACAGTTGAGAAGCTTTTCTTTTTCGCACCGTGAAGCGAC TGATTGTGCCTATAAATCGATAAAGATTTTCGTGCATTGCAATGCCCACAA TCAGACTAAAGAATACCGTTGTGATACCGAGCAACTCGAGATGGCCGATT TCTTGCGGTGACAAGTATTGGGCCATAAGAGGTAAAGTGAATAGGGACAC ACCTTTAATGAGAAACAGGCTGACTGCATATAAACTGATGTTTTTCAGATG GCTAACATTCATTGCAATATTTCCTATTCAAACTGAATTAGTTGCATGCGT GAAGGGCGGATGTAACCACGTCACCATTAATGTGTTGTGCAAACTTTTGG TAGCAATGTTCAGCTTTATAGCGGGCCGCTATTTCTAACGCACGCTGGCTG CAACGATGAAATGCTTGCTGGTCGTTACTGGCGTAGAGCAGAGCATCACA CAAAGAATCAGGGTTTCCCGGTTGATACTTAATGCAGTTTTCATTGTGGGT CAGTGTCTTGTCCCAATATGCGCCATCTCGAGGAATGACAACGCACATAC CCGCAGCCAGAGCCTCTAGAATTGATAAACCGAATGGCTCATTACCGCTG GTTGAAACAAAGATGTTGGATTGACTCCGGATATCATCCAAGTTTTCAGG GTCTTCATACCATATGGTGTGGGAGAGCAAAACCGGAGCGTTGGAGATTG GTAAACACGTATCGACGGGGCGAATGTAGCAAACATTGAGTACGACAGA CTGACTAATAGCGGCACGTTTGGATGCTTTTATTAACGTTTCCAGACCTTT CCATTTCAGCAGCGATGCAGCCCAAAAGTAAACTGGCGTGTTTTTTTGAC ATTCCTGTGGCCAACGAGATGCCGGAATGCCATTCACAAATGACTGATAT TGAGATGAGTTTAAGTAACTTTCAGCCATTGCCGAGGCGTCTTTTATTTTG GTCACGGCTTTAAGGTAAGTTTCTAGTGCCGCTTTGAGGCTACAACGGGT AGAGGGTAAGTAAAACACGGCGTTCGCTCGGGTAAGACAGAAGCCAATA GAGCGTGACAGCCCGACGTTGCCGTGGATAAACTGAACGACTTCAATATT AAGAACCATCTGTAACAAATAGACTGGCATATCCATACCTGGCCCTGAAG CGCCGATGAACGTAGTAATGCCGCGATGCCCAATCAAAGTCTTTAGCAAT ACCAATAGAAGATACAGTTGGTTTAGCCAGTAGAGAATCCCATTGTGCTG ACTCATTAACCAAGGAACTGGGGAAATGGAAATCAAAGTAACATTGTGTT TGGCGTAGAACTCTGTTTGCTTCCAGAATTCCGTGTCTACTGTTGCGACAA TGAAATCATTGGACTCAACACGGCATACATTGAGCGCATCACTGGTGGCA ATCTTAGAGCCGCCTTTAAATGCGATAGGGTCAAAAATAAGCGTTTTCTTG TTTTGACTAGTCATGCTGGCCTCCAAACGACAAACGATTTACCACATAGGT TTTGAGGGGGGATAAAGTGCTTATTAGAGACCGATTGGCTACAAATGGCT GTTCCAATAAGTCTCTATAAAGAAGTTCTATTTTTCGGCAACTGACAGATA GATCATGATTTTGGGTAATGTGAACAAAACCGCTCATTCCATACTGTTCAC ATAGTTCAGGATTATTGATTAGCACGCGCATCGCTTTTGCTATTGGGCCAA TGCCCTGATTCGGATACAGAACTCCAGTTTCGCCATGGGTAATGAATTCA GGAATGCCACCTTCAAGCGGCGCGATAACCGGGATCTTAGCAAGAGCAGC TTCTGCAACAGCCAGCCCAAAGGCTTCACTGCGAGCACAACTGATAAAGG CATCACATCCCTTGAGCCATCCAACGACATTGGATTGTTCGCCAACAAAG TGAATATGATTGCTTAGGTGCAGACGACTGGCTTGCTGAACAAGCTTGCC CATTAAATCGCCATCGCCAATGACAACGAGACTGACGTTAGGATACTCAA AAGCCACGTGACGCATTGCGGTTATGATCCGGTCTACACCTTTACGGTGA ATCAGAGAGCCAACCGTCGCAAAAACAAAATCCTGCTCCGGAATGGATA ACGCTTGCCTAACATCGACTTTTTGCTGCGCGGAGAGGGAGACGGTATCA ATACCATTGTGAATAACCGATATTTTTTCGTTAGGGTAACCATCTTTAGTC ATGAATTCAGCGACGTACTGACTGACTGAAATAATGTGCGGAGAAAGGTGDocket No. 212391-704601CAGGCCAAGCGTTAGGCGGTCGCGTGCTGGGTAAGGGCAGTGGAGCTGG GTAACGACGGGCACTTTCTTCATTTGTGCAGCGGCCAACATCCACTGGCA GGGCGCACCACTATTAATGTGTACAAGGTCTATTTTTTCGCGTTCGATGAT CTCGCAACCATGCTTAATCAGACCAAGCCAACCTGATACGTTGTATTTAG GTGGTTTCCAGCCAAGCAGCAGTGGAAAATGATTAAGCTGAGTTGGAACA TTCATCAGTTCTAACTGTTTTGAGAGTTCGCAATTATTGGTCCAAACGTAA CAAGCGTAGTGATGATGTTCCATGTACTTAATGAGATCGAGCAAACATTT CTCACTTCCTCGGATCCAGTCATCGCCGTAATGTACAAATAGAATCTTTCT CTTCATGCCAACCCCTCACATCGCATTTGCATAAAACCGTTAATTGCACTT TTCGATAGGACTAACGCAAATGTGATGCCAAGAAGGCGGTGGTTCTATGT GATTGTTTTTAAGGTTCTTTATAGGAGGCTTGAGGTGGGGCTTTATTGTTT CTCAATTTGACAATCAGATTGAGAGCTATTGGGGAAGTAGAGTTTCATCA TTTTTGGGATGACGGCAGATTGAGAATAGTGCTGTTCAACGCTATCAATCG CCTGCTTTTTTATCGCTAATTGCTGGTGGGGGGCGAGGGACAGATAGGTGT TTAAAGCCTCATTCAATTGATTGACGTTGTCGACTAAGTACCCGTTGGTTT CGTGTTGAATAAGCTTCGACATATTGCCAACATTAAGTGAGACAACAGGG ATACCTCTCGCCATCGCTTCGAGCGCTGTCATGGGTAAGCCTTCATAACGA GAGCAAATGATTAAAATGCCAATATGTTGCCAAATGGAGTCCATGTTGTT TTGGTGACCATGAAACCTGACGTTTGCCGGAGCGCCTTGTGTTAGCTCCGA TTGCATGGCCCCTGAGCCATAAAGATCAAACCGCTGTGTTTGATTTAGGC GCGCCAAGTCAATAAATCGGTCGGGACCTTTCTCATGGCTTAGCCTGCCA ACAAACGCGATTTGGTTTCCTGTTGAGGTAGACAGCGTCTTGGTATCAATA AAATTATTGAAACTTTCTGATTTGGTTATCAGCTTTTGGGTGATTCTTTCAC TCACGGCGATTGAGTGATTTGACACAAACGTGGTGAACCGGTCGGCACAG TCATATAACCACACCTTACCCGTTGGAGTTTCTCCTGCGTGATACGTAGAT ATTTGGCGAACTCCGGTCATTATTCTTGCTAGCTTGCAAACTAAGCTTGCT TTATAGCCATGAGCGTGGAGAAGAGCGGGTTTTTGCTTTCGTACCTGGCTA ATTAAGTCGCTAAAGTAATTCGTGCCTGTAGAGCTCAAAAACTGGAAAGC AATGCCGCTTGATTCCAGCTTGTCTTTGAGCAATTGCGGTTTGGAATAAGA GCGCAGAAACATGACTTTGACAGGAATTTCAAAATGCTTGAGCCCATTTG CGAGCTCAAGCACATGTGTTTCAATGCCACCGAAAGTCAGGCTGTCGATG ACTAGCCAGACTTCGTTACACGAGTTGTTGCTCATCTTCAGCTTCCCAGGC TTGCTTCTTACGGTATACCGTAGAAGGGCTAAGCTCTAAAAGTACCGCCG CGTTCAGCACGTTTCCGTCGCAGTAATCAATGGCTTGCTGTATTGCCTCAC GTTCAATTTGCCACATTGGCCTTATCGCTACAGGTCTTTCAATTTGCGGCT CAGTAACCGCGTCGTGACTATTTTCAGGAGCCTCATTGATCACGACGGGTT GTGGAGTGATGACTGGTTCAGGTTTAGCTACGCTGTTTTGCTTTGGCGCAC GGCTTGATGTGACCTGAGATGGCAAATGCTCAAGGCGCAAATGACTATCG TCATTAAGGACCACGATATTGCGAATAATGTTTTGAAGCTGACGGACGTT ACCCGGCCACGCATAGCGTTTTAGCGTTGGCTCTGCATCTCGGTGGATTGC GTTAAACTTTTTGCCATCTTCTTTAGCGTACAGCTTAAGAAAGTGAGTCGC TAATGTCGTAATATCATTGCCGCGCTCGCGTAATGGTGGCATATCAATAG GCACTACATGCACGCGGTAGTAGAGATCTTCTCTGAAACGGCCTTCTTCTA CTTCAACAAGAGGATCTCGGTTCGTCGCGCAGATGATACGAATATCGACT TTCATTTCTTTATTTGCGCCTAGTGGGGTAAAGGTACCTGTCTGCAAAAAT CTGAGTAATTTCTTTTGCATCTCAAGTTCCATCTCACACAGCTCATCAAGA AAAAGCGTACCACCGTTGGCCATTGAGGCCGCACCTTTGCGATCGGCAGT AGCGCCTGTAAATGCGCCCCTGACGTGACCAAAGATTTCACTCTCCATGA GATCTTTTGGAATCGCACCACAGTTAATGGCGATAAACGGTTTATCTTTAC GCTTACTCTCACGGTGGATGGCTTCGGCGCACACTTCCTTACCTGTGCCAC TTTCACCGACAATAAAAACACTTGCTGTCGTTGGTGCCACTGAATCGATGDocket No. 212391-704601ATCTTGTACACACCTTGCATTGGAAGGCTAGATCCGATGAAGCCGTGGAA TCGGTTTCGATCGAATTTGTTTTCTATGTCTTCGACAAGGTTCTCCAGTTTA ACTTGTTGCAAGTGCAGAGCGATGGAGGTTTTAAGACGATCAGCATTAAT TGGTTTTTCCAGAAAGTCTTTCGCTCCTTTTTGCACAAGGCTAACCGCCAA ATCTACTGAGCCATGCGCCGTGGCAATGACGACGGATGTCGGGACTTGGT TCTCGTTAATCCAATCCAGAATTTGCTCACCATCCATGTCGGGCAGTCTAA AGTCCAGAATAACTAATTGGGGAACATTTCTTTCAATAAAGGCGATGGCT TCTTTACCTGTCTCTACATGAAACAGGTCATAGGGCTCGTGCTGTACATAC TGTTTGTACAAAATAGCAAGAGAAGTTGAGTCTTCGATAAGTAGTACTTTT GGTTTCATTGGAGCTTTCCTCTCTTAAGCCTTTATAGTTGTGTTGGTTCAAT AAACCCTTGCTGTTTCCTTTCCTCTAATGCTTTTAGTGACTCTGAGGCAAC AACTTCAAGTTTTTGTTTGTAGCTGAAAGCCTGCTCTTGTTTGCCGTCTAA GCAAAGATGCTCGATTTTTCGCGCGAAATTGGACAAAGTTCTATTACCGA GTGCCAGAGCTGAACTACCTAGGGTATGCGCTTCAAACTCTAATGTTTCTT TGTCTTGAGACTCCATAGCCAGATATATTTTTGCTAAACGCTGCTGAGATT CTTCAAGATAATGCTCTATGAGCAATGGAATGACATCGGCACTCGTGTCT GCGATCATTTGCTGCAAAATCTGTTCGTCGACTAAATCCAAATTTACTGCT TCCTCACGTTGGTTCGATTGACCTACGCTTGTATTTGTATATGAATTCTGAT GCTTAATCAAATGACAGGGGCCTGATTTTAGATCTTGGTTTTCCTCTTGGT CATCATTTAAGAATAGGTTAATTTTTTCAATTAGTTGTGACAGCCTTAGGG GTTTTGACAAGTAGTCGTTCATGCCCGATGCAAGAAACTTTTCTTTATCAC CAGCCAGTGAGTGTGCAGTTAGGGCGATAATTGGGATATCACACGCCTTA CTGTCATCAAGGCTCCGAATCGCTTTGCAGGCTTGCATGCCATCCATTTCA GGCATGGAGATATCCATAAAAATCAGGTCATATTGATATTCCTGAACCAT GGAAACCGCTTGTTTGCCATTTTCGGCAATATCGATAGATAGACCAACCC GCTTGAACATTTCTCGTATGACGAGCTGATTTGCTTTGTTATCTTCTGCAAC AAGAATACGAGCGTTCGAACGAATCAATTCCTGACGGAGTGAATCAATAT TTGGAGAGGTCAATAACTCATCGGCTACCGAGAGCGTGATGTCAAATGTG AATGTACTGCCTACGCCGGGTGTGCTCTCGACCGTGACGTCACCATCCATA AGGGTACAGAGTCGGCGACAGATAGCGAGGCCAAGCCCCGAACCTTCTTT GCTGCGTGAATAGGTTTGGTCCGCCATCGTAAACTCATCAAACAAGTAAT CAATCGAGCTATTTTTGATGCCAATTCCTGTGTCTTGAATTTGGCAGGTGA TTTTTACTCGCCCTTGTTCCAATGCCTCCGACCCAACTTTAACCGTGACGC TGCCTTCATGAGTAAACTTGATGGCATTGCCTATCAGGTTGAGCAGTATCT GTTTGACGCGGTTTTTGTCTCCGCTGACTTTGCTTGGAACAGTGCCCTCAA TGTAGCAATGTAAAATCAGGTTTTGACTCTTGGCTGCGGGCAAAAATGAA TTCACCACGCTTTCGACACACTGTCTGAAGTCGAAAGGTTTATCTTCCAGA ATGAGCGTATTGGACTCCATACGAGTGAAATCAAGAATGTCATTAATGAC GGAAAGTAGGAAGTTGCCCGATTCAGTAGCGGTTGCGACCAGCTTTCTTT GCTCGTTGGTGAGTTTGGTCTCTTCGAGGATATTTAATATGCCCAATACGC CATTCATTGGAGTGCGTATCTCATGAGACATGGAGGCGAGAAAGCGGCTT TTAGAGTCGTTTGCCAGTTCGGCACCTTCCCGTGCCGCAGTGAGGTTTTGA TAGTCTTGTTCTAACTTAGCCGACATCTCATCGAATGCTTTGGTGACTTCA CCAAGCTCATCTTTGGAATAGTGGTTAAGTTGGAACCCCGGGCCTTTTTCC CGAAGTGTTTGGGCGGCAGAGGCTAAACGGGTGAGATTCTTAGTCAGATA GGTTCCAAGGATAAAGGAGAAAAACGCCACCAATACGACTTCGATGGTTG CGATACTGATGATAGCTTGCTGCGCGTCAATGAGCATATTGCTGATAGGG TGCGTTTCGAACCCCATATCTACATACCCATAGATATTACCGTTACTTTCA ATGGGTGTACGCAGATCAAAGATACCGTCTTTCACGTCTTTTAAAGTTTCG TCACTGACCATTGAGCGTGCGAGTAGCGCTGGGTCTCCTGCAGTGGCCAT TTGGTTGCCACCGCGTAACACACGAACGTAAGCGACATCTTCTAACTTGADocket No. 212391-704601TGAACTCTTGAGCTAAGTCGTCCAACGTCGCTAAATCAGTAGAAAGTAGC GCGTCTTTCGCAGCATGAGTAAACATAACTGCACTTGAATGAGCTCTTTGG AGTAACTGCTTCTCGTTGGAATCTGAGAGAAAACTCATCGCATTAGCCAC GAGAATGATGAGTGCCGTAATTTCGATGAGAGCTATGCCAAGAATTGTTT TAGAACGCAACGTCATTAAAGCCTCCGGTTAGTCCAGTACTTTGATATTGA GTGCTCTTACATCGTCCCAATCGGTGTCGATAGCTGATTCAAATCCGTTGA TATTTAATAATTTTAGGGACGTTCTCCCTTCGAGTGTTTGATCTATAGACTT GAGCGCTTGTTGGATCGATTTGACTTGTTCGTGAGTCATTCTCGGGTGATG GGCTATGGCATGCGGTGTGTACGGTTTTGTTGTCCAAATCGGTTCTAGCTG AGATTTAACCTCGTCAGGTAATGAGTTAAAGGTTCTCATCACACCGCCGC CTGCTGGGTAAAAACCTCTCGCCACAGACAAATACACCGAGTCATGTGAT GTAACGTAGTCAGACTCAAACTCGACGTTAGCCTCTCTCAAGTCACTTTGC GTTAATACCGTTGCAGCAAAGGCAGCAGGAGAAGGGAAGGCGAGCCGTT GTCCTTGTAGCGCTTGTAAAGACTCAATATTGTTGGTTTTCCTTGCTACCA GAATTCCGCTTATTTTTTTATCCTTGGCTTTGGCGAAGGCCCGATAGCCCG GCTGTTTGCTGTAGACGGTGTAATGATATGGGTTCATGTAAGCGATATCGT ATTCGCCCGCCGACAAACGCTTTTCATACTCCGGAATGTTAGGAGCCGTG CTAAAGGCAATGTCGTAACCGGTTTCTCTGCTTATTTCAGCAACGAGAGG CTCCCACTGCTCGGCAAGTCGGCTGGCAGATTGCTGAGGGACAACGCCAA ATGTAAGAGTTTCAGCAACGGTTACTGCCGAAAGTAACAGAGTCGAAAGC GCGATAAAGGTTTTTCTCATGGCAACTCCTAAGCAGACTGAGCAAGGAAC TCGTTGGTAAGAATATTCTGCGACCACTTTTCTCGCCAACTTTTGGGGATA AAGCGAAGCCGATTCAGCTCGCGCACCATCTCCTGAGCCAGTGATGCCTG GTCTTTTAAATTGAGTATCGAGCCTAACAAGGTGATTGAAGGCGAATCAA TCAATTGCATGGCTTTTTCAAGTTGGCTGGAAGACGTTTTACCACCCATCA CCACGAGTGCTGTCTGGTCACAAGCGCTCGCAACGACTTGTGCAGGAATA TTTCCTCTATTGACTTGAAGCAGCGGTGACGTGTCGCAAATAACGCGGTC GTATTGGCAAAGCCATTGTTTGACCGCGGCTCTCAGATGTGTGGGATCTTT GTACGCCAGAACTGCTGATTGGTTGTTCGGCACGGTTAACCCGGTAAACA TTTGTCGCGTTGAAGCGTGCGCGACCAAAGAACCAATCTGATTGTCGATA TCTGGTGTGATATCAATGCATTCGAAAGCTGGGTGGAAGGTATTAAGATC CACCACCAAGGTTCGGTGACCCGCGAGCAGATAACGCTCAGCCAGTGCAG CGACAACGGAAGTCACGCCATCGCCAGATTGACATGCGGTAATGCATAGT GAGCGACTGTCACGCATTTCTGCTGCAAGATAGATTTGCTCTATTTCTGTA TGAGTTGCAGGAATAATCATTACAGAGCTCCTATTAACACGATGGTTGTC GTTAGGCGCAGAATGTCTTCAAGACCCACGCGTGCTTTTTCGATGATACTT TCGTTTCGATCGGGCACATAGATGGTATCGCCAGCTCGTAGTACCGGAAG TTTGTAAATGTTGGCAGTTTTACTAAAGTCTACCAGGTCAAAGGTTCTTGC TTGTCCTTGGCAACAAGACATATTGACGATCGAGATCTTCTCTAAGTAGGC TCGATCAGACGGACCGCCCGCTTCGGCAAGTAAGTCCAGCAAGGTCATGT TGTCGTCAAATACATATCGACCTGGATTATTGACTGCTCCTAGTACGCGTA CTGTTGACTCCTTAGAACGATCCAACCAAATCTTATCTTTTTCAGGGATGT AAATGGTGTCGCCCATGGTGACATTTGGAAGTAAGCTTTCATCCCCAGTCT CAAAGTATAACGATAGGTTAAGCTTACTTACTTTGGAATAGCTTTTGTCGC GATGTGTGATACGAATGTTGTGGATATCCGCGTCTTTTGTTGGGCCATCAG CCGCAGACAAAATATCGAGGAAATGCATATCCTTAGTGAAACGGTAGCGG CCAGGGGCATTGACTTGTCCAAAGACATAAATGGATGCATCTGAGCTTTG GCGAACCCATTGCGATTTGTTGTCGGAAGGATCTTGCGGTAGATCGTGTA CACGTACAATCGCACCAGCACTGATGTTAGGTAATTCGCTGTTCGGCGCG CCTTTTAGAATGAAATCATCGAGATCGAATATGTGTAGCTGATTATCAGCG GCGACCACTTCAATTTTCGAGGTGTCCGCGCGAAGGGTTGGGCCGCCAACDocket No. 212391-704601ATGAGATAGCAAGTCCATAAGATCCATTTCATCTGACCACTCAACACGTC CGGGGCGAACTACTTCTCCAATCACACTGACGGCGCGATTGGGCGCAATT TTCAGCCAAGACTTTTCATTCATGTCTGTCTTCTCAGGAACGAAGATCGCA TCTCCCGGGCCAATCTTAGGCGGGCTTTTACGGGTCAGGCCTTCAGTGAAC GCGGTTAAATCAAATTTGATCACCTGACCGTTGGATTTAATGACTCGAATC TGGCGTGATTCTGCGTAACGAGTAGGACCGCCTGCATTAGCCAGAATATC CATAAACGACGCATTCTTCTTACCTTCATAGGCACCTGGGCTTGCCACTTC ACCCATAATGTAAACCACGTTCGCGCCTGCCTTGATCTCTTCTTCTTGTTTA GGAACGAAGATGGTGGTTCCCGGTGTTAGTGGCGGTAGCAATGAGATATC ACCGCTATCGAGATAGGTTTTAAGGTTAAACAGCTTAGGGGTATTGTCTG AAATGACACGTATTTGTTCGACAGAGGCATAGCGAGTAACGCCGCCAGCT CGCATAATGATGTCAACCAGATCGCTATTGGCTTTAAAGCTGAATGAACC CGGCGCGTTTACTTCTCCAAACACTTTAATTGCTGTTCGGCCGTCGGCGCT GTCACCTGCGTTAGCGAGTTTGTTCGCATCGAACTCTTGCTCGATGTTACC GACCAGTGGAGAAGCAGGAACAAATATCGTATCAAGTGAAACCAGCTCA GGTAGCAGTGATTCATCACCTGTATCGAGAAACGTTTTGTAGTTAAAGGT GATCTTATCTTTGCCACGTTTGATAAACAGACTGTTGAGCTGCGCGCCGGA GCGTAATCCGCCCGCTGCGTGAATGGCCATTTGGACATCAGAAGACTTAG ATAAAGTGTATTCGCCCGGAGAGGTCACATACCCTTGTACCGAGACTAAA ATTTGTTGCTCAGCGATATAGACAGATGCAGAGGATAGGTCTCGATACAC TTTCTCCAGAGATTCTTTAACGACTTGTTCAAGCTGAGCTTCACTGTAACC CGCGACGTATAGCGCGCCAACTTCAGGCAGAGTGATGCGGCCACGCTTGT CGACTTGAAAGCCTTTATTTAACGATGACTCACCGGGTAAGTTGACCTGA ATGAGATCGCCAATTTGTACTCGTTCTTCATTCGCGTGCGCCACAGAGAAA ATTGAAGTAAGAAGAAATAGGGCAATTAGGTTAATCCATTTCATTGTAAG CCTCCCTGCAAACGCTGCTTGGTTTGTTCTTGAGTATCCACCACTTCGATG CTTACGCGGCGGTTGGTAAGACGAACACCTTCCGATTCACCCTCATAGAG AGGAAGCGTGTCGCCGACCGATTGTGTTTCTATACGTTTTGGATTGAGACC AAAAATGGTCAGGTAGCGCTTGACTTGATTCGCACGTCCCATGGCAAGTT CCTGGTTGTACTGACCATCACCTACAGAATCAGCGTGACCAGTAACTTTG AGGTTTAAACTTTGGTGCTCATTTAAGATGTTCGCGGATTGGGCTAGATGG CCCATGTACTTTGGATTTACTTCTGTGGAATTAAATGCAAACTGATTATCG ACGTTAAGCAAGCTATAAAGTTGATCAATCATAGCTAAGCGCTTCTGAAA TGCGTTTTCATCCATAGGAGGTACACACTTGGTCTGTGAGGTCGCATAGTC CAGTTGAAGTTCTAGCTCATTAAGACGCTTGCGCTGAATAACAATGTCGTT GGCAGCATCAAGCAGTAAACCACCTTCAAGCTCTCTAGCGATTCGGTTTT GTTTCTCCAACGCTTGTACAACTGCAGCTGGGAAACACCAACGCGCGCCT TCTCTGATCAAAGAGTCTAATTGCAGCTTAGTCAGTTGCCAGTCAAAACG AAGTCCGTGCTCAGGGCCGAGGGGCTCATCTGGCATTACGGGTGTAAAGT TTGATTGGATGTAGTTTTCCCCAAGACCACCACGGCCTTCCTCTGGGTAAC TACTGCATCCAACCACGGCAGTCATAGATACAGCTAGGGCTATGTGTTTG AAAGAAAAGTTCATGCCAACGTCCTTTGTCAGTGATCGTTATTTAGTAAGT TCGAGAGTTAACTGGTATCGCTTGGTTAATGCGCAGTAGATTCATTATTTC GAGAGGTTGGCCTGACGCGTTTTCAATACGCATGCTTCTCTGGTTCTCGAT AAGCCGTTTATACAGGTACACGATCGCACCTACGCCTGATGAATCAAGAA ACTGGACTCGGCTGAAGTCAATTTCTATTTCTCGAGTTGAGGGCTCAGCCA AAATTTCATCAATGTGTGGCTGTGCCTGGCGGCTACCGTCTGCGTCAAGGT TCCCGTTGATCACCCATGTCACGATAGTGTCGTTTGTTTCAATTTTACGAA GTTCCAT (SEQ ID NO: 5)

[0069] In some embodiments, the polynucleotide of SEQ ID NO: 6 encodes a wbfF geneDocket No. 212391-704601cluster that is involved in the synthesis of capsular polysaccharides. In some embodiments, the polynucleotide sequence of SEQ ID NO: 6 is:ATGATGATAAAAGAATTCAACAAGTGGCTAGGTACAGCGACCCTCTCTTT GGTATCTCTATCAGTCTACTCTAATGACCTTAGTAGCCTCACTTTAAACCA AACTTCTTCAGCTCTAGCGGGAACGAATGTAATTCCAGCAACGCCCAATG AAGAGCTTGAGAATGGAAGCTTTACGAAAAATAACCGCAATAACTTACTA TTGCCCGGTGAGACTGATGTAAGACTATTATTACCCTCATCAGGCGAAGC CCTCCCTCCTCCATACGGCGCTAACTTATTTGCTGGCGGATATGAAACCGA ACGAACCGATGGTCTGAATGACAACTACCTCGTTGCTCCAGGTGATAAAA TTAATATATGGCTTTGGGGAGCAGTAAGTTACTCAGATGTAGTCACGGTA GATAACCAAGGCAATATTTTTGTACCCGAGATTGGCCCAATAAAAGTCGA AAATGTTAAAGCCAGTGAAGTAAATAGCTATGTAGCGAGCCAAATTAAGA AAGTCTACACTAATAACGTCAGTGTATACGTAAACTTACTGACCGCGACT CCAGTGAGTATTTTTCTTTCAGGCCCAGTGATTCGCCCTGGTCAATACGCG GGAATGGCTTCAGATAGCTTGCTCTACTTCCTCAAACGAGCTGGGGGGAT CGACCCTGAACGCGGTAGCTATCGCTCCATTCAAATTAAGCGCAATAGTA GTATCATTGCTGACGTAGACTTGTACGATTTTATCCGTACTGGCCAATTGC CTAATGTTAGCTTTAAAGATGGAGATATCATTTTAGTTACTCCTCAAAAGC CAGCCATCACCGTTTCAGGCGGAGTAAGAAACCCATTCCGCTTCGAATTA AAAGAAGCGAAATCATCGGGCTCTAAACTGATTGACTTCTCTAGACCTTT AGCCAAGATCAGTCACGTAGGTGTGATTGGTAATCGTGACAGCGGGCCAT TTTCTTTATACATGCCTTACAAAGACTTCCAATCTTTCGAACTTGAAGATG GCGACAAAGTCATTTTCAACGATGACCTTCATGCTCAAGTGATGGATATC CAAGTATCAGGGAGTTATTTAGGTCCATCTTATTTTGCAGTTCAAAAAAGA ACCAAATTACATGATCTGCTGAATTATATTCCAGTCGATCCTGTACTCGCT AATACAGATTCCATTTACATTCTTCGCCAAAGTGTTGCTGAGCGTCAGAAA CAAATGATCGAGGAATCTCTAGACCGACTGGAACGCAGTGTTTTTACTTCT CCAGCCTCTTCAGATGGTGAAGCGACAATACGAGCAAAAGAAGCAGAAA TGGTCTTGCAATTTACCGAGCGTGCCAGAAAAGTAGAGCCTCTTGGCAAA GTTGTAGTATCAGACAAGGGTCATGTAGCGAATATCCTTCTCGAACAAGG GGATGTTATCGTCATACCGAACAAAACCGACCTAATACAAATTGGCGGTG AAGTATTAATGCCTCAAGCCGTTGTCTACAATAAAGATGCCACGATTGAT GACTACATTGCGTGGGCTGGTGGTTTTACCGAACGCGCAGAGGATGCACG CATCGCAATCGTACGCGCTAATGGTCTGGTTGAATTTGACAGCGAAGATC CTATTGAAAAAGGGGATCAAGTCTTGGTTCTACCAAAAGTGGACACCAAA ACCATGCAGGCAGTTAAAGACATCACGCAAATTATTTATCAAATTGCGAT TGCAGCTAACGTTGCGGTCAATTGA (SEQ ID NO: 6)

[0070] In some embodiments, the genetically-modified bacterial cells comprise a genetic modification to stress-regulatory genes to enhance resistance of thegenetically-modified bacterial cells to environmental stressors as compared to a comparable wildtype bacterial cells. In some embodiments, the stress-regulatorygenes comprise (|)prol , (|)pro2, oxyR, or any combinations thereof. In some embodiments, the deletion of the (|)pro 1 or (])pro2 gene increases the transformation efficiency by at least 10 fold, 20-fold, at least 50-fold, at least 100-fold, at least 200-Docket No. 212391-704601fold, at least 500-fold, at least 1000-fold, at least 2000-fold, at least lx 104-fold, lx104-fold. In some embodiments, duplication of oxyR or insertion of an exogenous mutant oxyR gene increases the transformation efficiency by at least 10 fold, 20-fold, at least 50-fold, at least 100-fold, at least 200-fold, at least 500-fold, at least 1000-fold, at least 2000-fold, at least lx 104-fold, lx 104-fold. In some embodiments, the genetically-modified bacterial cells comprising modifications to oxyR and at least one of (|)pro 1 or (|)pro2 produce a synergistic effects on increased transformation efficiency as compared to a comparable wildtype bacterial cells by at least 10 fold, 20-fold, at least 50-fold, at least 100-fold, at least 200-fold, at least 500-fold, at least 1000-fold, at least 2000-fold, at least lx 104fold, lx 104fold.

[0071] In some embodiments, the genetically-modified bacterial cells comprising at least one of modifications to (|)pro 1 , (|)pro2, oxyR, RecA, SEQ ID NO: 1 haveincreased transformation efficiency as compared to a comparable wildtype bacterial cells by at least 10 fold, 20-fold, at least 50-fold, at least 100-fold, at least 200-fold, at least 500-fold, at least 1000-fold, at least 2000-fold, at least lx 104fold, lx 104fold.Plasmid yield

[0072] Disclosed herein are genetically-modified bacterial cells comprise a genetic modification that results in an increased in plasmid yield, as compared to a comparable wildtype bacterial cell. In some embodiments, the genetic modification that results in increased and constitutive expression of one or more bacterial stress genes as compared to a comparable wildtype bacterial cell.

[0073] In some embodiments, a genetically-modified bacteria cell can comprise a genetic modification in a gene encoding a polypeptide involved in regulation of transcription, relative to an otherwise comparable cell that does not comprise said genetic modification. In some embodiments, the genetic modification is an insertion of a modified / mutant oxyR gene. The oxyR gene in Escherichia coli and other bacteria encodes a protein called OxyR, which acts as a transcriptional regulator in response to oxidative stress, specifically hydrogen peroxide. OxyR senses hydrogen peroxide and activates genes involved in peroxide metabolism, redox balance, and peroxide protection.

[0074] In some embodiments, the genetic modification results in an insertion of an exogenous mutant oxyR gene having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to a polynucleotide sequence of SEQ IDDocket No. 212391-704601NO: 2:ATGAATATTAGGGACTTTGAGTACCTCGTCGCGCTTGCGGAACATAAACA CTTCCGTAAGGCGGCAGAAGCATGTTTTGTCAGCCAGCCGACCCTTAGCG GACAAATTCGTAAGTTAGAAGACGAGCTTGGAACAACGCTTTTGGAGCGT AGCAGCCGCCGAGTGCTGTTTACTGACTCTGGTTTACAACTGGTGGATCA AGCAAAACGTATTTTAAGTGAAGTGAAAATGTTTAAGGACATGGCGAGCG GCCAAAATGGCGCGATGACCGGTCCATTGCATATTGGCTTTATACCTACA GTCGGTCCTTACTTATTACCTAAAATCCTGCCAGATCTAAAAGTTGAATTT CCGGATCTGGAGTTATTCCTACATGAAGCGCAAACCCAGCAACTGGTGCA TCAGTTGGAAGATGGTAAGTTGGATTGTCTGGTACTGGCGTCCGTGGCAG AAACCGAACCATTCAAAGAGATCGAGGTGTATAACGAGCCGTTAAGTGTG GCAGTACCTTGCGATCATGAATGGGCATCGTTAGATAAAATTGACATGAT GTCCCTTAAGGGGAAGACGGTACTGGCTCTCGGAGATGGCCATTGCTTAC GTGATCAGGCGCTCGGCTTTGGCTTTGCGGCAGGTGCAAAAGATGATGAG CGATTCAAAGCCACGAGTTTAGAGACGCTGCGTAATATGGTGGCTGCAGG CGCTGGGATTACTTTGTTACCTCAGCTATCACTGCCACATGAAAAGCAAA AAGATGGCGTTAGTTACATTCCAGCGGTAAATCCGACGCCCACTCGTAAA ATTGTGCTGGTGTACCGTCCTGGCTCACCACTGCGTGCACGCTTTGAAGCA CTTGCGGCGAAGATCAAAGATATTCTGGCGAGTTACCCATCTTCTATTGCC GCTTAA (SEQ ID NO: 2)

[0075] In some embodiments, the genetic modification results in the increased expression of an OxyR polypeptide encoded by the exogenous oxyR mutant gene having the polynucleotide sequence of SEQ ID NO: 2 In some embodiments, the genetically-modified bacterial cells expresses both the exogenous oxyR mutant gene having the polynucleotide sequence of SEQ ID NO: 2, and an endogenous wildtype oxyR gene (e.g., a wildtype oxyR gene having the polynucleotide sequence of SEQ ID NO: 7).ATGAATATTAGGGACTTTGAGTACCTCGTCGCGCTTGCGGAACATAAACA CTTCCGTAAGGCGGCAGAAGCATGTTTTGTCAGCCAGCCGACCCTTAGCG GACAAATTCGTAAGTTAGAAGACGAGCTTGGAACAACGCTTTTGGAGCGT AGCAGCCGCCGAGTGCTGTTTACTGACTCTGGTTTACAACTGGTGGATCA AGCAAAACGTATTTTAAGTGAAGTGAAAATGTTTAAGGACATGGCGAGCG GCCAAAATGGCGCGATGACCGGTCCATTGCATATTGGCTTTATACCTACA GTCGGTCCTTACTTATTACCTAAAATCCTGCCAGATCTAAAAGTTGAATTT CCGGATCTGGAGTTATTCCTACATGAAGCGCAAACCCAGCAACTGGTGCA TCAGTTGGAAGATGGTAAGTTGGATTGTCTGGTACTGGCGTCCGTGGCAG AAACCGAACCATTCAAAGAGATCGAGGTGTATAACGAGCCGTTAAGTGTG GCAGTACCTTGCGATCATGAATGGGCATCGTTAGATAAAATTGACATGAT GTCCCTTAAGGGGAAGACGGTACTGGCTCTCGGAGATGGCCATTGCTTAC GTGATCAGGCGCTCGGCTTTTGTTTTGCGGCAGGTGCAAAAGATGATGAG CGATTCAAAGCCACGAGTTTAGAGACGCTGCGTAATATGGTGGCTGCAGG CGCTGGGATTACTTTGTTACCTCAGCTATCACTGCCACATGAAAAGCAAA AAGATGGCGTTAGTTACATTCCAGCGGTAAATCCGACGCCCACTCGTAAA ATTGTGCTGGTGTACCGTCCTGGCTCACCACTGCGTGCACGCTTTGAAGCA CTTGCGGCGAAGATCAAAGATATTCTGGCGAGTTACCCATCTTCTATTGCC GCTTAA (SEQ ID NO: 7)Docket No. 212391-704601

[0076] In some embodiments, the genetically-modified bacterial cell comprises an exogenous mutant oxyR gene that encodes an OxyR polypeptide having at least 1 (e.g., at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or more than 10 amino acid substitutions, insertions, or deletions with respect to an OxyR polypeptide encoded by the oxyR gene sequence of SEQ ID NO: 7. In some embodiments, the expression of a polypeptide encoded by the modified oxyR gene (e.g., having a polynucleotide of SEQ ID NO: 2) and a polypeptide encoded by the polynucleotide of SEQ ID NO: 7 results in an increase in expression of one or more bacterial stress genes. In some embodiments, the expression of a polypeptide encoded by the modified oxyR gene (e.g., having a polynucleotide of SEQ ID NO: 2) and a polypeptide encoded by the polynucleotide of SEQ ID NO: 7 results in constitutive expression of one or more bacterial stress genes. In some embodiments, the increase and constitutive expression of the one or more bacterial stress genes results in an increase in plasmid yield after transformation, as compared to the comparable wildtype bacterial cell. In some embodiments, the genetic modification that introduces the exogenous mutant gene results in at least a 1.0-fold, a 1.1-fold, a 1.2-fold, a 1.3-fold, a 1.4-fold, a 1.5-fold, a 1.6-fold, a 1.7-fold, a 1.8-fold, a 1.9-fold, a 2.0-fold, a 2.1-fold, a 2.2-fold, a 2.3-fold, a 2.4-fold, a 2.5-fold, a 2.6-fold, a 2.7-fold, a 2.8-fold, a 2.9-fold, or a 3.0-fold increase in plasmid yield, as compared to the comparable wildtype bacterial cell. In some embodiments, the genetic modification that introduces the exogenous mutant gene results in more than 3-fold, e.g., 3.5-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, increase in plasmid yield, as compared to the comparable wildtype bacterial cell. In some embodiments, the genetic modification that introduces the exogenous mutant gene to the bacterial cell results in an increase in plasmid yield is greater than 50%, as measured by the plasmid volumetric yield (mg / L) as compared to a comparable wildtype bacterial cell. In some embodiments, the genetic modification that introduces the exogenous mutant gene to the bacterial cell results in an increase in plasmid yield that is greater than 10%, 20%, 30%, 40%, 55%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%, as measured by the plasmid volumetric yield (mg / L) as compared to a comparable wildtype bacterial cell. In some embodiments, the genetically-modified bacterial cells have an increase in plasmid yield that is at least about 0.001%, at least about 0.01%, at least about 0.1%, at least about 1.0%, at least about 10%, at least about 20%, at least about 30%, at least about 50%, or at least about 90%, as measured by the plasmid volumetric yield (mg / L) as compared to a comparable wildtype bacterial cell.Docket No. 212391-704601Endotoxin-Free (or Reduced endotoxin levels)

[0077] Disclosed herein are genetically-modified bacterial cells that replicate with reduced secretion of endotoxins. Also provided herein are non-toxic or reduced toxin (e.g., endotoxin free) cells (e.g. gram-negative bacterial cells such as E. coli). The present disclosure is not limited to a particular method of providing non-toxic cells. Lipopolysaccharides (LPS) are large molecules consisting of a lipid and a polysaccharide that are bacterial toxins. They are composed of an O-antigen, an outer core, and an inner core all joined by a covalent bond, and are found in the outer membrane of gram-negative bacteria. Lipopolysaccharides can have substantial impacts on human health, primarily through interactions with the immune system. LPS is a potent activator of the immune system and pyrogen (agent that causes fever). In severe embodiments, LPS can play a role in causing septic shock. In lower levels and over a longer time period, there is evidence LPS may play an important and harmful role in autoimmunity, obesity, depression, and cellular senescence. The term endotoxin is often used interchangeably with LPS. The LPS layer is essential to both the form and function of the OM of gram-negative bacteria, providing gram-negative pathogenesis and survival of the bacterium. LPS of various gram-negative bacteria is built generally to a common structural architecture including among others: the outer membrane embedded lipid A. Lipid A is the most conserved LPS domain amongst gram-negative bacterial, and is the structural component responsible for the biological activities within the host. Lipid A in LPS can be referred to as the endotoxin moiety. The majority of gram-negative bacteria has an inner core having at least one 2-keto 3-deoxy-D-manno-octulosonate (KDO) molecule. KDO is an essential component of LPS that is a conserved residue found in nearly all LPS structures. For example, the minimal LPS structure required for growth of E. coli is made of two KDO residues attached to lipid A (KDCh-lipidA), indicating the importance of KDO in maintaining the integrity and viability of the bacterial cell. The biosynthesis pathway of LPS structures is initiated by the enzyme d-arabinose 5-phosphate (A5P) isomerase (API / KdsD / yrbH), which converts the pentose pathway intermediate D-ribulose 5-phosphate into A5P. Subsequently, A5P is condensed with phosphoenolpyruvate to form KDO 8-phosphate (KD08P) by KDO 8-phosphate synthase, hydrolysed to KDO by KDO 8-phosphate phosphatase, activated as the sugar nucleotide CMP -KDO by a CMP -KDO synthase, before finally being transferred from CMP -KDO to the acceptor lipid IVA by a KDO synthase. The lauroyl and myristoyl -acyl carrier protein dependent acyltransferases transfer the fatty acids laurate and myristate,Docket No. 212391-704601respectively, to KD02- lipid IVA to form the characteristic acyloxyacyl units of hexaacylated KDO-lipid A.

[0078] The disruption in a gene of the LPS biosynthetic pathway is performed by at least one genetic modification in a gene encoding a protein selected from the group consisting of D-arabinose 5-phosphate isomerase, KD08P synthase, CMP-KDO synthetase, KD08P phosphatase and KDO transferase. Such a modification can be a modification in the expression or the coding sequence of the genes encoding the listed proteins. Such modifications can provide a reduced expression or an abolished expression of one or more genes encoding such D-arabinose 5-phosphate isomerase, KD08P synthase, CMP-KDO synthetase, KD08P phosphatase and / or KDO transferase.

[0079] The disruption in the outer membrane biosynthetic pathway can be due to at least one modification in a gene or expression of a gene encoding for the protein selected from the group consisting of gutQ, kdsD, kdsA, kdsB, kdsC and waaA, wherein gutQ and kdsD encode a D- arabinose 5-phosphate isomerase, kdsA encodes a KD08P synthase, kdsB encodes a CMP- KDO synthetase, kdsC encodes a KD08P phosphatase and waaA encodes a KDO transferase. . In some embodiments, the at least one genetic modification reduces or inhibits the expression of the genes. In some embodiments, the viable host cell with modified outer membrane biosynthetic pathway leading to disruption of said pathway, comprises a mutation in the expression or the coding sequence of any one or more of the genes encoding for the proteins selected from the group of poly-P-1 ,6-N-acetyl-D-glucosamine outer membrane porin, poly-P-1, 6-N-acetyl-D-glucosamine N-deacetylase, and / or poly-N-acetyl-D-glucosamine synthase and displays Lipid IVA in the outer membrane. Such a cell is additionally modified in at least one gene or the expression of at least one gene encoding for a protein selected from the group consisting of lauroyl acyltransferase and myristoyl-acyl carrier protein-dependent acyltransferase. The modification can be a modification in the expression or the coding sequence of the genes encoding the listed proteins. Such a modification provides a reduced expression or an abolished expression of one or more genes encoding such lauroyl acyltransferase and myristoyl-acyl carrier protein-dependent acyltransferase. IpxL and IpxM genes encode fatty acid transferases involved in membrane formation. In some embodiments, the host cell can be modified in at least one gene or the expression of at least one gene selected from the group consisting of IpxL and / or IpxM.

[0080] Provided herein are non-toxic or reduced toxin (e.g., endotoxin free) cells (e.g. gramnegative bacterial cells such as E. coli). The present disclosure is not limited to a particular method of providing non-toxic cells. In some embodiments, non-toxic cells are providedDocket No. 212391-704601through suppression of LPS expression. The present disclosure is not limited to a particular method of suppressing LPS expression. In some embodiments, LPS expression is suppressed through suppression of API / KdsD / yrbH protein expression. In some embodiments, API / KdsD / yrbH expression is suppressed through suppression of KDO protein expression. In some embodiments, KDO protein expression is suppressed through, for example, modification of the gutQ gene and the kdsD gene. In some embodiments, KDO protein expression at the outer membrane does not occur due to the KDO protein not associating with Lipid IVA, such that only Lipid IVA is transported to the outer membrane. For example, modifications in gutQ, kdsD, kdsA, kdsB, waaA msbA, and / or yhjD genes or mutations of any other biosynthetic, processing, or trafficking genes eliminate the formation of or membrane presentation of the (KDO)2-Lipid IVA complex, resulting in, for example, only the Lipid IVA molecule being transported to the outer membrane and no subsequent LPS formation.

[0081] In some embodiments, non-toxic gram-negative bacteria are used as hosts for the production of endotoxin free biomolecules. The present disclosure is not limited to particular biomolecules. Traditionally, the production of biomolecules in Gram negative bacteria, whether it be outer membrane vesicles for vaccines, LPS type molecules (such as monophosphoryl lipid A (MPLA)) to be used as adjuvants, recombinant pharmaceutical proteins, macromolecules, or DNA for mammalian cell transfection / gene therapy, is plagued by the presence of endotoxin from the bacterial host. Contamination of the therapeutic molecule with endotoxin is a concern, as the immunogenic potential of LPS is well documented. Current production strategies to alleviate endotoxin contamination include various purification techniques, such as the kits marketed for endotoxin free DNA plasmid purification, followed by assays to measure endotoxin levels. As such, the non-toxic gramnegative bacterial cells of the present disclosure (e.g., the endotoxin-free cells) provide improved methods of isolating endotoxin free biomolecules. Accordingly, as some cells of the present disclosure do not produce endotoxin, such purification steps are not required. For example, the endotoxin-free cell of the present disclosure can be a host for the production of commercially important biomolecules in an endotoxin-free environment using Gram-negative bacteria. Additionally, cells comprising a modification in a gene encoding any one or more of a D-arabinose 5-phosphate isomerase, a KD08P synthase, a CMP- KDO synthetase, a KD08P phosphatase and / or a KDO transferase, an ATP-dependent translocator, an inner membrane protein (e.g., gutQ, kdsD, kdsA, kdsB, waaA msbA, yhjD genes), or modifications in any other biosynthetic, processing (e.g., IpxL or IpxM), or trafficking bacterial genes can be hostsDocket No. 212391-704601for the production of commercially important biomolecules in an endotoxin- free environment using Gram-negative bacteria.

[0082] In some embodiments, a gene implicated in endotoxin production as described herein is itself modified to eliminate or reduce endotoxin production. In some embodiments, a noncoding portion of a gene implicated in endotoxin production as described herein is modified to eliminate or reduce the endotoxin production, such as a promotor, a polyadenylation site, a 5’ untranslated region, or a 3’ untranslated region. In some embodiments, an upstream or downstream gene that affects endotoxin production as described herein is modified to eliminate or reduce endotoxin production.

[0083] In some embodiments, a lauroyl and / or myristoyl acyltransferase polypeptide to be modified has at least 85% amino acid sequence identity to GenBank Accession No.ANQ15862 or a fragment thereof having lauroyl and / or myristoyl transferase activity. An exemplary lauroyl and / or myristoyl acyltransferase amino acid sequence follows:1 mskdkqmqpe fslsllhpm wgvwigfgll aiivnilpyr lllslgqsvg klgmrygkkr61 vhvakrnlel afpdksqedi ehivtenfkn tgmalietgi twfwptwrfk tllvekdvga121 Ikekaqegkg vllccvhaln leitarafav mglagygafr phdnpaynfi qywgrthngn181 klidrkdvkk mirvlrsger Ifylpdhdyg rnksvyvpff avedactttg tsilaytskc241 aivpgsgfm eqgkyeiiad kcieadypqk devaaaaymn kyveevilra peqwmwlhkr301 yktmqdenvp kgiryr (SEQ ID NO: 9)

[0084] In some embodiments, a lauroyl and / or myristoyl transferase polynucleotide encodes a lauroyl and / or myristoyl transferase polypeptide. An exemplary lauroyl and / or myristoyl transferase polynucleotide sequence to be modified is provided at GenBank Accession No. CP016347 (REGION: 198524..199474), which is reproduced below:1 ttatctgtag cgaatgcctt ttggcacgtt ttcatcctgc atggttttgt agcgcttatg61 cagccacatc cattgttcag gagcgcgtaa gatgacttct tccacgtatt tgttcatgta121 cgctgcggcg gcaacttcgt ctttttgcgg ataatcggct tcaatgcatt tatctgcaat181 gatttcatac ttgccctgct cattacggaa gcctgaaccc ggaacaatgg cacacttcga241 tgtataagcc agaatgcttg tacctgtggt ggtacacgca tcttctactg cgaagaatgg301 tacatacacc gatttgttgc gtccgtaatc gtggtcaggt aggtagaaca gacgttcacc361 actacgcagc acgcgaatca tctttttcac gtctttacgg tcaatcagtt tgttgccgtt421 atgggtgcgg ccccagtact gaataaaatt gtaagctggg ttgtcatgtg gacgaaacgc481 gccgtaaccc gcaagtccca tgactgcaaa agcacgtgcg gtaatttcaa ggttcaatgc541 atgcacacag cagagtagga cgccttttcc ttcttgcgcc ttttctttca gagcaccaac601 atctttttcc actagcagcg ttttaaagcg ccaagttggc cagaaccagg taatgccggt661 ttcgatcagt gccatgccgg tgtttttgaa gttttcggta acgatatgtt cgatgtcttc721 ttgagacttg tccggaaaag ccaactcaag gttacgcttt gcgacgtgta ctcgtttttt781 accataacgc atgccgagct tacccaccga ttggcccaac gacagaagca agcggtaagg841 aagaatatta acgatgatcg ccagtagacc aaaccctatc catacccccc agttacgtgg901 atggagaagg gaaagagaaa actctggctg catttgtttg tctttactca t (SEQ ID NO: 10)Docket No. 212391-704601

[0085] In some embodiments, a lauroyl and / or myristoyl acyltransferase polypeptide to be modified has at least 85% amino acid sequence identity to GenBank Accession No.ANQ 17067 or a fragment thereof having lauroyl and / or myristoyl transferase activity. An exemplary lauroyl and / or myristoyl acyltransferase amino acid sequence follows:1 mnkqkepvfe arflmprywg tlliigvmyl Isllpfkfql flgmigrla mrlmkkrqvt61 irmlelcfp kmdeskreai Ikanidnsgi alfetamawf wsdrrvnkhv tikgmehlea121 lerdgkgvlm lavhsmnlel garafgiqks gmgvyrpnnn pcfdyfqykg rsrsnrtlid181 rknvrgmlda Insgnrvwya pdhdygtrrs tfaplfavkn actttgtsll vdatdcaivp241 ftmvrgddgh ytltirkpvd gfpkgdtma aifinkivee simaspsqym wlhrrfktrp301 qgedclynpq lipams (SEQ ID NO: 11)

[0086] In some embodiments, a lauroyl and / or myristoyl transferase polynucleotide encodes a lauroyl and / or myristoyl transferase polypeptide. An exemplary lauroyl and / or myristoyl transferase polynucleotide sequence to be modified is provided at GenBank Accession No. CP016347 (REGION: 1624028..1624978), which is reproduced below:1 atgaacaaac aaaaagagcc tgttttcgag gctcggttcc taatgcctcg gtactgggga61 actctactca tcatcggggt gatgtattta cttagtcttc ttcctttcaa atttcagtta121 ttcctgggac gtaacattgg ccgtttggcc atgcgattaa tgaaaaagcg tcaggtcacc181 attcgtcgca atttagagct ctgtttcccg aagatggacg agagcaaacg agaagcgata241 ctgaaggcca acatcgataa ttctggcatt gcactgtttg agacagcgat ggcttggttc301 tggtcggatc gcagggttaa taaacacgta acgataaaag ggatggaaca cctagaagcg361 ttagaaaggg acggtaaagg ggtgctgatg cttgccgttc attccatgaa cttagagctg421 ggtgcacgtg catttggcat tcaaaaatct ggaatgggtg tttatcgacc gaataacaac481 ccttgttttg actattttca gtacaagggt cgttcgcgtt ccaatcgtac tttgatcgat541 cgtaaaaatg ttagaggaat gctggatgct ttgaattcag gcaatcgcgt ttggtatgcg601 cctgaccatg attatggaac cagaagatcg acctttgcgc ctttgtttgc tgtcaaaaac661 gcctgtacca caacaggcac cagtttactt gtcgatgcta cagattgtgc cattgtgccg721 tttaccatgg taagagggga tgatggccat tacacattaa cgatcaggaa gccagttgat781 ggatttccta aaggtgatac ccgaaacgcg gcgattttta tcaataaaat tgttgaagag841 tcgattatgg ccagccctag tcaatacatg tggttacacc gccggtttaa aaccagaccg901 caaggtgaag attgtttgta caatcctcag ttaatcccag cgatgagtta g(SEQ ID NO: 12)

[0087] In some embodiments, a D-arabinose 5-phosphate isomerase (KdsD / yrbH) polypeptide to be modified has at least 85% amino acid sequence identity to GenBank Accession No. ANQ 18079 or a fragment thereof having isomerase activity. An exemplary KdsD amino acid sequence follows:1 msrqfdfraa akqvldieva alqeldkyfd dqfeqacemi Isnsgkvvim gmgksghign61 kiaatlastg tsaffvhpge ashgdlgmis agdiviaisn sgesheilsl fpvlkrlnik121 iismtgkpes nmaqlsdlhl qitvpqeacp Iglaptsstt atlvmgdala vallqargfs181 aedfalshpg galgrklllk Isdimhfgna Ipkvspdsli rdalleisek glgmtaivde241 hdamlgiftd gdlrrtldkr idihttaige vmtqspttah pdmlavegln Imqskninal301 ilcnngkvvg alnmhdllka gvm(SEQ ID NO: 13)

[0088] In some embodiments, a D-arabinose 5-phosphate isomerase (KdsD / yrbH)Docket No. 212391-704601polynucleotide encodes a KdsD polypeptide. An exemplary KdsD polynucleotide sequence to be modified is provided at GenBank Accession No. CPO 16347 (REGION: 2865123..2866094), which is reproduced below:1 atgtcccgtc aatttgattt tcgcgctgct gcaaagcaag ttcttgatat tgaagttgcc61 gctctgcaag agctggataa atactttgat gaccaatttg aacaagcttg cgaaatgata121 ctttccaata gcggaaaagt ggtcatcatg ggcatgggca aatcaggcca cattggaaat181 aaaattgcgg cgacgcttgc aagtacaggg acttcggcgt tttttgttca tccgggtgaa241 gcttcacatg gtgacttagg tatgatcagc gccggagaca ttgtgattgc catttcaaac301 tctggcgaat cccatgagat cctgtcgctg ttcccggtat tgaaacgctt aaacatcaag361 atcatcagca tgacgggcaa gccagaatcg aacatggcgc aactgtcaga tttgcactta421 cagatcacgg taccacaaga agcctgccct cttggtttgg caccaaccag cagtacaaca481 gcaacgttag tcatgggcga tgccttggcg gttgcgctgc ttcaggctcg tggattctcc541 gctgaagatt tcgcgctgtc acaccccggt ggtgcactag gaagaaaact gctgcttaag601 ttgtctgata ttatgcattt tggaaatgct ctgccgaaag tctctcctga ttcgctgatt661 cgcgacgcac ttctggagat ttctgaaaaa ggactgggga tgaccgccat tgtcgatgag721 cacgatgcta tgcttggtat attcactgat ggcgacttac gcagaacttt agacaagcgt781 attgatattc atacaaccgc cattggcgaa gtgatgacgc aaagcccaac aactgcgcat841 ccagacatgc ttgcagttga aggtctcaac ctaatgcaaa gcaaaaatat caatgcgctg901 attttatgta ataacggtaa agtggtcggt gcacttaata tgcatgattt actaaaagcg961 ggtgtgatgt aa(SEQ ID NO: 14)

[0089] Endotoxin refers to complex lipopolysaccharide (LPS) substances present in the outer membranes of gram-negative organisms such as E. coli, Vibrio spp., and others. These substances are collectively called “endotoxin” and are toxic to mammals and other vertebrates. Endotoxin can be released when cells are disrupted or otherwise disintegrate. Thus, when these organisms are used to clone nucleic acids, vectors, plasmids or produce proteins, polypeptides, or peptides or other biomolecules the products can be contaminated with unacceptable levels of endotoxin. The genetically-modified cells (e.g., bacterial cells such as Escherichia spp., Vibrio spp. organisms) described herein are substantially lower in an in vitro endotoxin assay compared to a natural, unmodified, or wild type organism under the same conditions, i.e. the recombinant organisms produce or contain substantially less endotoxin or LPS substances, or are substantially less endotoxic to humans and other mammals (e.g., canines, felines, equines, bovines, or porcines). By substantially less endotoxin or less endotoxic is meant that the organism can have less than 50% or less than 40% or less than 30% or less than 20% or less than 10% or less than 5% or less than 3% or less than 2% or less than 1% or less than 0.90% or less than 0.50% or less than 0.10% of the endotoxin content compared to a corresponding unmodified or wild type bacterial cells (e.g., Escherichia spp., Vibrio spp. organisms) (or one that does not have the genetic modification to API, IpxL, and / or IpxM) cultivated and measured under theDocket No. 212391-704601same conditions. The endotoxin content or concentration, or the endotoxicity of the compared organisms can be measured using any generally accepted in vitro endotoxin assay, such as any of those accepted in the field as being a valid endotoxin assay, e.g., the HEKTm-Blue LPS assay, which can measure the activation of the TLR4 receptor to an endotoxin sample from an organism.

[0090] The genetically-modified cells described herein can also produce an endotoxin concentration of less than 50% or less than 40% or less than 30% or less than 20% or less than 10% or less than 5% or less than 1% or less than 0.50% or less than 0.10% of the endotoxin concentration produced by an unmodified or wild type E. coli organism (or one that does not have a genetic modification to an LPS biosynthesis gene such as API, IpxL, and / or IpxM) cultivated under corresponding conditions. In some embodiments BL21(DE3) can be used as the unmodified or wild type E. coli. The endotoxin concentration or level can be determined using any generally accepted LPS or endotoxin assay, such as an in vitro LPS or endotoxin assay accepted in the field.

[0091] The genetically-modified cells described herein can also produce an endotoxin-induced immune response of less than 50%, or less than 40%, or less than 30%, or less than 20%, or less than 10%, or less than 5%, or less than 1%, or less than 0.50%, or less than 0.10% of the response of an / ■ / coli organism comprising a deletion of gutQ, kdsD, IpxL, IpxM, pagP, IpxP, and eptA, or any sub-combination of them produced under the same or corresponding conditions. The compared E. coli organism can also comprise a compensating mutation in the msbA gene (e.g., msbA148) (E coli cells having all of the above deletions and the msbA mutation are commercially available under the trademark name ClearColi®). The endotoxin-induced immune response (or endotoxicity) can be determined or measured using an in vitro LPS or endotoxin assay. The immune response or endotoxicity can be relative to, or with respect to, the immune response in a human or other mammalian cell, and can measure activation of the TLR4 receptor. [The genetically-modified cells described herein can also have or produce less endotoxin (in the lower amounts stated herein and above) than the aforementioned E. coli organisms (e.g., the “ClearColi®” organism), which endotoxin amount can be measured using an endotoxin-induced immune response.]

[0092] The genetically-modified cells described herein can have an average endotoxin level for purified LPS molecules of less than 50 EU / ml, or less than 25 EU / ml, or less than 15 EU / ml, or less than 10 EU / ml, or less than 5 EU / ml, or less than 5 EU / ml, or less than 4 EU / ml, or less than 3 EU / ml, or less than 2 EU / ml, or less than 1 EU / ml, or less than 0.80 EU / ml, or less than 0.70 EU / ml, or less than 0.50 EU / ml, or less than 0.30 EU / ml, or lessDocket No. 212391-704601than 0.20 EU / ml, or less than 0.10 EU / ml, as measured in an in vitro endotoxin assay. The endotoxin level can be measured according to any generally accepted method. Any of the cells described herein can also have the stated endotoxin levels disclosed herein within plus or minus 10% of the stated value.Essential Genes

[0093] Disclosed herein are cells comprising a genetic modification that results in elimination or reduced expression of a polypeptide encoded by an essential gene, the absence of which is detrimental to the growth of the cell, as compared to an otherwise comparable cell lacking the genetic modification that results in elimination or reduced expression of the polypeptide encoded by said essential gene. In some embodiments, the genetic modification comprises disabling, reducing, or knocking out one or more essential genes required for cell growth and / or survival. Any essential gene can be disabled, reduced, or knocked out. For example, enzymes that are required for metabolizing specific nutrients or synthesizing specific nutrients (e.g., an amino acid, sugar, or other nutrient) can be disabled and the resulting cells will only grow and / or survive if that nutrient is provided. Other essential genes include, but are not limited to, DNA synthesis genes (such as thy A), cell wall synthesis genes (such as dapA ), and amino acid genes (such as serA and metA). In some embodiments, a reduction or elimination of polypeptide encoded by the essential gene can be cured by introduction of the polypeptide delivered exogenously, either directly or indirectly in order to reestablish cell survival in the presence of the polypeptide. For example, a plasmid encoding a copy of the essential gene or functional equivalent or functional variant thereof can be introduced in order to facilitate cell survival. The exogenous copy of the essential gene or functional equivalent or functional variant thereof can then be used as a marker for cell transformation.

[0094] Examples of other essential genes that can be disabled, reduced, knocked out in a genetically-modified bacteria of the present disclosure include, but are not limited to yhbV, yagG, hemB, secD, secF, ribD, ribE, thiL, dxs, ispA, dnaX, adk, hemH,IpxH, cysS, fold, rplT, infC, thrS, nadE, gapA, yeaZ, aspS, argS, pgsA, yefM, metG, folE, yejM, gyrA, nrdA, nrdB, folC, accD, fabB, gltX, ligA, zipA, dapE, dapA, der, hisS, ispG, suhB, tadA, acpS, era, me, ftsB, eno, pyrG, chpR, Igt, fbaA, pgk, yqgD, metK, yqgF, plsC, ygiT, pare, ribB, cca, ygjD, tdcF, yraL, yihA, ftsN, murl, murB, birA, secE, nusG, rplJ, rplL, rpoB, rpoC, ubiA, plsB, lexA, dnaB, ssb, alsK, groS, psd, om, yjeE, rpsR, chpS, ppa, valS, yjgP, yjgQ, dnaC, ribF, IspA, ispH, dapB, folA, imp,Docket No. 212391-704601yabQ, ftsL, ftsl, murE, murF, mraY, murD, ftsW, murG, murC, ftsQ, ftsA, ftsZ, IpxC, secM, secA, can, folK, hemL, yadR, dapD, map, rpsB, infB ,nusA, ftsH, obgE, rpmA, rplU, ispB, murA, yrbB, yrbK, yhbN, rpsl, rplM, degS, mreD, mreC, mreB, accB, accC, yrdC, def, fmt, rplQ, rpoA, rpsD, rpsK, rpsM, entD, mrdB, mrdA, nadD, hlepB, rpoE, pssA, yfiO, rplS, trmD, rpsP, ffh, grpE, vfjB. csrA, ispF, ispD, rplW, rplD,rplC, rpsJ, fusA, rpsG, rpsL, trpS, yrfF, asd, rpoH, ftsX, ftsE, ftsY, frr, dxr, ispU,rfaK, kdtA, coaD, rpmB, dfp, dut, gmk, spot, gyrB, dnaN, dnaA, rpmH, mpA, yidC, tnaB, glmS, glmU, wzyE, hemD, hemC, yigP, ubiB, ubiD, hemG, secY, rplO, rpmD, rpsE, rplR, rplF, rpsH, rpsN, rplE, rplX, rplN, rpsQ, rpmC, rplP, rpsC, rplV, rpsS, rplB, cdsA, yaeL, yaeT, IpxD, fabZ, IpxA, IpxB, dnaE, accA, tilS, proS, yafF, tsf, pyrH, olA, rlpB, leuS, Int, glnS, fldA, cydA, infA, cydC, ftsK, lolA, serS, rpsA,msbA, IpxK, kdsB, mukF, mukE, mukB, asnS, fab A, mviN, rne, yceQ, fabD, fabG, acpP, tmk, holB, lolC, lolD, lolE, purB, ymffC, minE, mind, pth, rsA, ispE, lolB, hemA, prfA, prmC, kdsA, topA, ribA, fabl, racR, dicA, ydfB, tyrS, ribC, ydiL, pheT, pheS, yhhQ, bcsB, glyQ, yibJ, and gpsA.

[0095] In some embodiments, an essential gene as described herein is itself modified to eliminate or reduce the expression of the polypeptide encoded by an essential gene.In some embodiments, a non-coding portion of essential gene as described herein is modified to eliminate or reduce the expression of the polypeptide encoded by an essential gene, such as a promotor, a polyadenylation site, a 5’ untranslated region, or a 3’ untranslated region. In some embodiments, an upstream or downstream gene that affects expression of the polypeptide encoded by an essential gene as described herein is modified to eliminate or reduce the expression of the polypeptide encoded by an essential gene.

[0096] In some embodiments, the genetically-modified bacterial cells having agenetic modification to an essential gene where the essential gene is an endogenous DNA strand exchange gene. In some embodiments, the endogenous DNA strand exchange gene has a polynucleotide sequence of:atgaataaatcggagaaagtaatggacgagaacaaacagaaagcgctcgccgctgcgctaggtcaaattgaaaaacaatt cggtaaaggctcaatcatgcgccttggcgataaccgcgcaatggacgtagaaaccatctcaacgggttctctttctcttgata tcgctttgggtgctggtggcttaccgatgggccgtattgttgaagtatacggtccggaatcttcgggtaaaacgacactaact cttgaacttattgcagcagcacagcgtgaaggcaaaacttgtgcgtttatcgatgcggagcacgctctggatcctgtatacgc gaagaagcttggcgtagatatcgatgcacttttggtttctcagcctgatacgggtgagcaagcgctagaaatctgtgacgcat tagcgcgctctggtgctatcgacgtaatggttgtcgactctgtggcagcactgactccaaaagcagaaatcgaaggcgaaa tgggcgacagccacatgggtctccaagctcgtatgctttctcaagcgatgcgtaagctaacaggtaacctgaagcagtctaa ctgtatgtgtatcttcatcaaccaaatccgtatgaagattggtgtgatgttcggtaacccagaaacaacaactggcggtaacg cacttaaattctacgcatcggttcgtcttgatatccgtcgtactggcgcaatcaaagaaggcgacgaagttgtaggtaacgaaDocket No. 212391-704601actcgcatcaaagtcgttaagaacaagattgcagcaccatttaaagaagcaaacacgcagatcatgtatggtcaaggcttta accgcgaaggtgagctggtagacttaggcgtgaagcacaaactggttgaaaaagcaggtgcttggtacagctacaatggc gacaagatcggtcagggcaaagcaaatgcttgtaattacctgcgtgaacatacagaagttgctcagactatcgacaagaaa cttcgtgagatgcttttgtctccagctgtagctgagggacctgaagccggtgaaatgccagagaagaaagaagaagagtttt aa (SEQ ID NO: 3)

[0097] In some embodiments, the genetically-modified bacterial cells having agenetic modification to an essential gene where the essential gene is an endogenous DNA strand exchange gene. In some embodiments, the endogenous DNA strand exchange gene has a polynucleotide sequence of atgaaatacctgttctctttattcattcttgcactatccagtgccgccgtggccgcgccaccaagttcattttcagccgctaagc gcgaagcggtaaaaatctatcaagatcatcccaccagcttttattgcggctgtgatattcaatggcaaggcaagaaaggctta cctgatctttcctcttgtggttaccaggttcgcaaacaagaaaagcgtgcttcacgcatcgagtgggaacatgtcgttccagct tggcaatttgggcaccagctgcaatgctggcaaagcggtggtcgtaaaaactgctcgcgtaatgacaaaacattccgctca atggaagccgatctgcacaacctgactcctgcgattggtgaggtaaatggtgatcgctctaactacaatttcagtcagtggaa tgggatcgatggcgcaacctatggtcgttgtgaagtccaggtaaacttcaagcaacgcaaagtcatgccacccgatcgagc acgcggctccatcgctcgtacctatctttatatgagcaaggagtacggcttcaaactgtccaagcaacaaactcagttaatga gtgcatggaacaaaacctacccagccgataaatgggaatgcgaacgcgataagcgcattgccaaagtacaaggcaacca taatccattcgttcaagaggcctgtcgcgcactgtaa (SEQ ID NO: 8)

[0098] One central biosynthesis pathway relates to nicotinamide adenine dinucleotide (NAD) biosynthesis. NAD is a coenzyme central to metabolism. Found in all living cells, NAD is called a dinucleotide because it consists of two nucleotides joined through their phosphate groups. One nucleotide contains an adenine nucleobase and the other nicotinamide. NAD exists in two forms: an oxidized and reduced form, abbreviated as NAD+ and NADH (H for hydrogen), respectively.

[0099] In metabolism, nicotinamide adenine dinucleotide is involved in redox reactions, carrying electrons from one reaction to another. The cofactor is, therefore, found in two forms in cells: NAD+ is an oxidizing agent - it accepts electrons from other molecules and becomes reduced. This reaction, also with H+, forms NADH, which can then be used as a reducing agent to donate electrons. These electron transfer reactions are the main function of NAD. However, it is also used in other cellular processes, most notably as a substrate of enzymes in adding or removing chemical groups to or from, respectively, proteins, in posttranslational modifications.

[0100] In organisms, NAD can be synthesized from simple building-blocks (de novo) from either tryptophan or aspartic acid. As a general rule, most prokaryotes utilize the aspartate de novo pathway, in which the nicotinate moiety of NAD is synthesized from aspartate. Briefly, aspartic acid is converted to iminoaspartic acid by nadB, which is then converted to Quinolinic acid by nadA. Quinolinic acid is then converted to nicotinic acid mononucleotideDocket No. 212391-704601by nadC, which is then converted to nicotinic acid adenine dinucleotide by nadD. Lastly, nicotinic acid adenine dinucleotide is converted to nicotinamide adenine dinucleotide (NAD) by either nadEl or nadE2 through either an amine dependent or glutamine dependent pathway.

[0101] In some embodiments, a genetically-modified cell of the present disclosure can comprise a genetic modification that results elimination or reduction in expression of a polypeptide encoded by any one or more of the genes associated with the NAD biosynthesis pathway, including nadA, nadB, nadC, nadD, nadEl, and nadE2.

[0102] In some embodiments, a nicotinamide adenine dinucleotide synthetase (NadE) polypeptide to be modified has at least 85% amino acid sequence identity to GenBank Accession No. UUI14161.1 or a fragment thereof having synthetase activity. An exemplary NadE amino acid sequence follows:1 mkklhisscs Inqtpmdwsg nlhniqkaik iahqagaell itpelcisgy gcedffhsph61 vseralksvs dltqsipnsm avsvglpvmi nnrvyngval vthegiqgis Ikrnlaangl121 hyeqrwftpw trdknatvvl kegtppvrvg nlvysvngvk vgf eicedaw vadrtserff181 nqgvevianp sashfsigks Itrkrlvees srvysacyvy snlsgcesgr aiydagvmia241 vdgslvakge rfhmsdvevv tadidlsrsr igqinssqry yeehdfdtea vvkvtlsksl301 sspklhvppl nqpwedseyl eheealraia iglrdwlrkt htggyalsls ggadsalvas361 avytsvilel welvtktekd decslpdhls qflsedqrsk fkqagssnkl eqfvrdtasa421 imanmlttay qasansgsvt rtaaqkvaes fgakflnlsv aevvknyesm iskatnleln481 wndhdialqn iqarvrspsi wfianlenkl llttsnmseg avgyctmdgd ssgvlapisg541 vtksrilkll vwleqkgfyc tgnhimklea Isyinnqrpt aelrpeeqsd eedlmpydvl601 drmvfltlea gmsprdifda mteefervdn qtmatyivkf fkllfmqwk rdrqapgfhi661 elnsldpkty krfpllssgy qeelafiedn cwmkds (SEQ ID NO: 15)

[0103] In some embodiments, a nicotinamide adenine dinucleotide synthetase (NadE) polynucleotide encodes a NadE polypeptide. An exemplary NadE polynucleotide sequence to be modified is provided at GenBank Accession No. CP101906.1, which is reproduced below:1 gtgaagaaac tgcatattag ctcatgctca ctaaaccaga ctccaatgga ttggagtgga61 aacctgcata acattcaaaa agcaatcaag attgcacatc aagctggagc cgaactgctt121 attacgccag agttgtgtat ttctggttat ggctgtgaag attttttcca tagtcctcat181 gtctctgagc gcgcactgaa aagtgtctct gacctaacgc agtcgattcc caatagcatg241 gcggtatctg ttggcttacc cgtgatgatt aacaatcggg tttacaacgg tgttgcgctg301 gttacgcatg aaggaattca aggcatctct ctaaagcgga atttagctgc gaatggcctt361 cattatgagc aacgttggtt tacgccatgg actcgagata aaaacgcgac ggtggtactc421 aaagaaggga caccacctgt gcgtgttggc aatctggttt acagcgttaa cggtgtcaaa481 gttggctttg aaatctgcga ggatgcctgg gttgccgacc gcacttcaga acgtttcttc541 aaccaaggtg ttgaagtgat tgctaaccca agtgctagtc acttttcgat aggtaaatct601 ctcactcgta agcggctggt ggaagagtca agccgcgtat attcggcctg ttatgtgtat661 tccaatctat cagggtgtga atctggccgg gcaatttatg atgctggcgt gatgattgcg721 gttgatggca gtttggttgc caaaggcgaa cgttttcaca tgagtgatgt ggaggttgta781 acggccgata tcgacttatc ccgcagcagg attggccaaa tcaatagtag tcaacgctatDocket No. 212391-704601841 tatgaggaac atgactttga tacagaggct gtcgtcaaag taacgctcag taaatctctt901 agctctccca agttgcatgt accgccgcta aatcagcctt gggaagatag tgaatatttg961 gaacatgaag aagctttgcg tgcgatagca ataggtttac gtgattggct tcgaaaaacg1021 cacactggtg gctacgcgct ttcattaagt ggcggagcag actctgcttt ggtcgctagt1081 gctgtttata catccgttat cctggaactt tgggagctgg ttaccaaaac agagaaagat1141 gacgagtgtt cactaccaga ccatttgagt caatttttga gcgaagatca aaggagtaaa1201 ttcaaacagg cggggtcctc aaacaaacta gagcaattcg tcagggatac ggcatcagca 1261 ataatggcga acatgctgac aactgcgtat caggccagcg cgaacagcgg ttccgttact1321 cgtactgctg cgcaaaaagt agcggagtca tttggtgcga aatttctaaa cctcagtgtt1381 gccgaggtgg tgaagaatta cgagtcgatg atatcaaaag caaccaatct agagctcaat1441 tggaatgatc atgatattgc gctgcaaaat attcaggcac gtgtgcgctc tccaagtatt1501 tggttcatcg ctaatctgga aaataaactg ctgctgacaa cgagcaacat gtcggaaggg1561 gcggtaggtt actgcacaat ggatggtgat tcttccggag tcctcgcacc tatttccggt1621 gtcactaaaa gccgaattct caagttactg gtatggctag agcaaaaagg gttttattgc1681 actggtaatc acatcatgaa gctagaagcg ctttcttata tcaataatca acgtccaacg1741 gcggagttgc gccccgaaga acaaagtgat gaagaggatt tgatgcctta tgatgtgctc1801 gatcgtatgg tttttttgac cttagaagcc ggtatgtcac caagggatat ttttgatgcg1861 atgacggaag aatttgaacg cgtagacaac caaaccatgg ccacatatat cgtcaaattt1921 tttaagttgc tgtttcgcaa tcaatggaaa cgcgatcgtc aggctccggg gtttcatatc1981 gaactcaata gcctggatcc gaaaacctat aaacgttttc cgcttctaag ctctggatac2041 caagaggagc tagccttcat cgaggataat tgctggatga aagacagcta g (SEQ ID NO: 16)Cell wall genes

[0104] In some embodiments, a genetically-modified bacteria cell can comprise a genetic modification in a gene encoding a polypeptide involved in cell wall formation, relative to an otherwise comparable cell that does not comprise said genetic modification. In some embodiments, the genetic modification is to a mltG gene. Among several lytic transglycosylases (LTs), the mltG gene plays a role in the synthesis of peripheral peptidoglycans, extrachromosomal segments of DNA, known as plasmids. It localizes the remodeled PGs for septum formation and cleavage across the bacterial cell wall during daughter cells separation.

[0105] In some embodiments, a genetically-modified bacterial cell can comprise a genetic modification that results in mltG polypeptide being reduced or disabled. In some embodiments, a gene encoding mltG as described herein is itself modified to eliminate or reduce the expression of a polypeptide encoded by mltG. In some embodiments, a non-coding portion of the mltG gene as described herein is modified to eliminate or reduce the expression of the polypeptide encoded by mltG as described herein, such as a promotor, a polyadenylation site, a 5’ untranslated region, or a 3’ untranslated region. In some embodiments, an upstream or downstream gene that affects expression of the mltG gene as described herein is modified to eliminate orDocket No. 212391-704601reduce the expression of the mltG polypeptide. In some embodiments, a genetic modification to a mltG gene as described herein can be combined with any of theother genetic modifications described herein.Methylase Enzymes

[0106] In some embodiments, a genetically-modified cell can comprise a genetic modification that results in reduced methylation of DNA. When DNA polymerase makes an error resulting in a mismatched base-pair or a small insertion or deletion during DNA synthesis, the cell will repair the DNA by a pathway called mismatch repair. However, the cell must be able to differentiate between the template strand and the newly synthesized strand. In some bacteria, DNA strands are methylated by Dam methylase, and therefore, immediately after replication, the DNA will be hemimethylated. A repair enzyme, MutS, binds to mismatches in DNA and recruits MutL, which subsequently activates the endonuclease MutH. MutH binds hemimethylated GATC sites and when activated will selectively cleave the unmethylated daughter strand, allowing helicase and exonucleases to excise the nascent strand in the region surrounding the mismatch. The strand is then resynthesized by DNA polymerase III.

[0107] Genetically-modified cells and expression systems containing the same are described herein that include a genetically-modified methylase enzyme (e.g., with reduced or disabled activity), as well as uses thereof. In some embodiments, the genetically-modified methylase enzyme is disabled, which thereby disables the mismatch repair pathway. The disabled methylase enzyme can allow for efficient gene editing compared to a comparable cell with a native methylase enzyme present. In other words, a gene edit in a cell with a disabled methylase may persist longer in the cell without being repaired by a mismatch repair pathway compared to a cell comprising a native methylase enzyme.

[0108] In some embodiments, a gene encoding a methylase as described herein is itself modified to eliminate or reduce the expression of the methylase. In some embodiments, a non-coding portion of a gene encoding a methylase as described herein is modified to eliminate or reduce the expression of the methylase, such as a promotor, a polyadenylation site, a 5’ untranslated region, or a 3’ untranslated region. In some embodiments, an upstream or downstream gene that affects expression of the methylase as described herein is modified to eliminate or reduce the methylase.

[0109] In some embodiments, a genetically-modified methylase enzyme comprises aDocket No. 212391-704601modified adenine methylase enzyme or modified cytosine methylase enzyme. In some embodiments, a modified methylase enzyme comprises a modified Class I methylase, or a modified class II methylase. In other embodiments, a modified methylase can comprise a modified histone methylase, a modified N-terminal methylase, a modified DNA adenine methylase (Dam), a modified RNA methylase, a modified natural product methylase, a modified non-S-adenosyl methionine (SAM) dependent methylase, or a modified radical SAM methylase. In some embodiments, the modified methylase is an RNA methylase.

[0110] In some embodiments, a DNA adenine methylase (Dam) polypeptide to be modified has at least 85% amino acid sequence identity to GenBank Accession No. ANQ18149.1 or a fragment thereof having methylase activity. An exemplary DNA adenine methylase amino acid sequence follows:1 mkkqraflkw aggkyglved iqrhlppark Ivepfvgags vflntdydqy lladinpdli61 nlynlikarp eeyiseakrw fvaennrkea ylsiraefnk tddvmyrsla flymnrfgfn121 glcrynkkgg fnvpfgsykk pyfpeaelef faekakkatf vcegypetfr rarkgsvvyc181 dppyaplsnt anftsyagng ftlddqaala diaertater gipvlisnhd ttltrrlyhg241 adlsvvkvkr tisrngsgrn kvdellalfn tpdsdsaas (SEQ ID NO: 17)[OHl] In some embodiments, a DNA adenine methylase (Dam) polynucleotide encodes a DNA adenine methylase polypeptide. An exemplary DNA adenine methylase polynucleotide sequence to be modified is provided at GenBank Accession No. CPO 16347.1, which is reproduced below:1 ctatgaagca gcgctgtctg aatcaggggt attaaaaagc gccagcagtt catcaacttt61 atttcgacca ctgccattac ggctgatggt gcgcttcact tttaccacgc tcaaatccgc121 tccgtggtat aaacgacgcg ttaatgttgt atcgtggttt gaaatcagta ccggaatgcc181 gcgttcagtg gcggttcttt ccgcgatatc ggccagtgcc gcctgatcat cgagcgtaaa241 cccatttcct gcataagagg tgaagtttgc ggtatttgaa agcggcgcat acggtggatc301 gcagtaaaca acactgcctt tacgcgcacg gcgaaacgtc tcgggatagc cttcacaaac361 aaacgtggct ttcttggctt tttctgcaaa gaactccagt tcagcttcag ggaaatacgg421 tttcttgtat gacccaaacg ggacattgaa accgcctttt ttgttgtaac ggcacaggcc481 attaaaacca aaacggttca tgtaaagaaa agcaagtgag cgatacatca cgtcgtcagt541 cttgttgaac tcagcgcgaa tactcagata agcttctttg cggttatttt cggccacgaa601 ccagcgcttc gcctcagaga tatattcctc cggacgcgct ttaataaggt tatacagatt661 gatcaaatcc gggttgatat cagccagtaa atactgatcg taatctgtat tcaaaaaaac721 agagccagcg ccaacaaaag gttcaactag ctttcgagcc ggtggtaaat gacgttggat781 gtcttcaacc agtccgtatt ttcctcctgc ccattttaga aaggctcgtt gctttttcat(SEQ ID NO: 18)Deoxyribonucleases

[0112] In some embodiments, a genetically-modified bacteria cell can comprise a genetic modification that results in results in less phosphodiester cleavage of DNA, relative to an otherwise comparable cell that does not comprise said genetic modification that results in less phosphodiester cleavage of DNA. In someDocket No. 212391-704601embodiments, the genetic modification that results in less phosphodiester cleavage of DNA comprises a modification to a Deoxyribonuclease (Dns) enzyme. DNS is an enzyme that catalyzes the hydrolytic cleavage of phosphodiester linkages in the DNA backbone, thus degrading DNA. A wide variety of deoxyribonucleases are known, which differ in their substrate specificities, chemical mechanisms, and biological functions.

[0113] Some DNases cut, or "cleave", only residues at the ends of DNA molecules (exodeoxyribonucleases, a type of exonuclease). Others cleave anywhere along the chain (endodeoxyribonucleases, a subset of endonucleases). Some DNases are fairly indiscriminate about the DNA sequence at which they cut, while others, including restriction enzymes, are very sequence-specific. Some cleave only double-stranded DNA; others are specific for single-stranded molecules; and still others are active toward both.

[0114] In some embodiments, a genetically-modified cell can comprise a genetic modification that results in reduction or elimination of a polypeptide encoded by one or more deoxyribonuclease genes. In some embodiments, the one or more disabled Dns genes are replaced by one or more catalase genes.

[0115] In some embodiments, a gene encoding a methylase as described herein is itself modified to eliminate or reduce the expression of a deoxyribonuclease gene described herien. In some embodiments, a non-coding portion of the deoxyribonuclease gene as described herein is modified to eliminate or reduce the expression of the deoxyribonuclease gene as described herein, such as a promotor, a polyadenylation site, a 5’ untranslated region, or a 3’ untranslated region. In some embodiments, an upstream or downstream gene that affects expression of the deoxyribonuclease gene as described herein is modified to eliminate or reduce expression of the deoxyribonuclease gene.

[0116] In some embodiments, a catalase polypeptide to be added has at least 85% amino acid sequence identity to GenBank Accession No. EPM39386.1 or a fragment thereof having catalase activity. An exemplary catalase amino acid sequence follows:1 mailqigagg vgwvvahkaa qnndvlgdit iasrtvgkce kiiesiqkkn nlkdstkkle61 aravnaddvd slvalikevk pdlvinagpp wvnmpimeac yqakvsyldt svavdlcseg 121 qqvpqaydwq wgyrekfeea gitgilgagf dpgvvsvfaa yavkhlfdei dtidvmdvna 181 gdhgkkfatn fdpetnmlei qgdsfyweng ewkqvpchsr mlefefpncg shkvysmahd 241 evrsmkefip akriefwmgf gdrylnyfnv mrdigllspd pltlhdgtvv qplhvlkall 301 pdptslapgy tgltcigtwv qgkkdgkers vfiynnadhe vayedvehqa isyttgvpaiDocket No. 212391-704601361 taalqffrge wadkgvfnme qlnpdpflet mpsigldwhv qeleagqglp vihelkk (SEQ ID NO: 19)

[0117] In some embodiments, a catalase polynucleotide encodes a catalase polypeptide. An exemplary catalase polynucleotide sequence to be added is provided at GenBank Accession No. ATFJ01000037.1, which is reproduced below:1 ttacttttta agttcgtgga taactggaag tccctgacct gcttcaagct cttgaacatg61 ccaatccaga ccgatagaag gcatggtttc caggaacgga tctgggttta gctgttccat121 attgaacaca cctttatccg cccactcgcc acggaagaat tgcagtgccg cagtgatcgc181 tggtacacct gtggtgtaag agatcgcctg gtgctctacg tcttcgtatg ccacttcgtg241 gtcagcattg ttatagatga agacactgcg ctctttaccg tctttcttac cttgaaccca301 agtaccgata cacgttagac cggtgtagcc tggtgcaaga gaagttggat ctggtagtag361 cgctttcaat acgtgcagag gctgtactac tgtaccatcg tgcagcgtta gtggatctgg421 gctcaatagg ccgatatcac gcattacatt gaagtagttt aggtaacggt caccgaaacc481 catccagaat tcaatgcgtt ttgcagggat gaattccttc attgaacgaa cttcatcgtg541 cgccattgag tacactttgt gtgaaccaca gttagggaat tcaaactcaa gcatacgaga601 gtgacaaggt acttgtttcc actcgccatt ttcccagtag aaagagtcgc cttggatctc661 tagcatgttg gtttctgggt cgaagtttgt cgcaaacttc ttaccgtggt caccagcgtt721 tacgtccatt acgtcgatag tatcgatttc atcgaacaga tgcttaactg cgtacgctgc781 aaataccgat actacgcctg gatcgaaacc agcacctagg atacctgtga tgcccgcttc841 ttcgaacttc tcacggtaac cccactgcca atcataagcc tgaggtactt gctgaccttc901 agaacacagg tcaactgcca ctgatgtatc caggtatgac actttcgctt ggtaacatgc961 ttccatgatt ggcatgttta cccatggagg accagcgttg atcacaagat caggcttcac1021 ttctttaata agagcaacaa gagaatctac gtcgtcagca ttaactgctc tagcttctaa1081 tttcttagtt gaatctttca ggttgttttt cttctgaata gattcgatga ttttctcaca1141 cttacctacg gtacgtgatg cgattgtgat atcacccaga acgtcgttgt tttgtgctgc1201 tttgtgtgca actacccagc caacgccgcc tgcaccaatc tgtagaattg ccat (SEQ ID NO: 20)

[0118] In some embodiments, a deoxyribonuclease (Dns) polypeptide to be modified has at least 85% amino acid sequence identity to GenBank Accession No.ANQ 17872.1 or a fragment thereof having nuclease activity. An exemplary deoxyribonuclease amino acid sequence follows:1 mklfdthchf dfdvfqddfe hnlalaqeqg vsrilipsvg psnwsriqtl aekyshlyya61 Igfhpyflee nfeqhlaele hylkqkppqc vaigecgldf aidvdpqlqe kvletqfela121 rrfdlpvilh srkahnrlvq mvkaaklpkg gvvhafagsy qqamewvrlg ffigvggtit181 ypraqktrda iqklalenll ietdapdmpi Igyqgqpnhp aklihvlnvl velrrgekqs241 iasqlwknsn fafsice (SEQ ID NO: 21)

[0119] In some embodiments, a deoxyribonuclease (Dns) polynucleotide encodes a deoxyribonuclease polypeptide. An exemplary deoxyribonuclease polynucleotide sequence to be modified is provided at GenBank Accession No. CP016347.1, whichDocket No. 212391-704601is reproduced below:1 ctattcacat attgagaagg caaaattgct atttttccac agttgcgacg caatcgattg61 cttttctcct ctacgcaact ctacgagcac atttaataca tgaatgagtt tcgccgggtg121 gttgggctgc ccctgatatc caagtatagg catatctgga gcgtctgttt cgataagtag181 gttttctagg gctaattttt gaattgcgtc gcgggttttt tgggctcgtg ggtaggtaat241 agtaccccct acaccgatga aaaaacctaa tctgacccac tccatcgctt gctgatagct301 accagcaaaa gcatgtacga caccgccttt aggtagcttc gccgctttga ccatttgaac361 aagtcgattg tgtgcttttc ggctatgtaa aataaccgga aggtcgaaac gtctggcgag421 ctcaaattga gtttcaagca ccttttcttg caattgggga tcgacgtcaa tagcaaaatc481 taatccgcac tcgcctattg caacgcactg tggcggcttt tgtttgagat aatgctccag541 ctcagcaagg tgctgctcaa agttctcttc cagaaaatac ggatggaacc cgagcgcata601 gtataagtgt gagtatttct cggctaaggt ttgaatgcgt gaccagtttg aaggtccgac661 tgagggtatc aggattcggc tcaccccttg ttcttgagca agagccaggt tgtgctcaaa721 atcatcctga aacacgtcaa aatcaaaatg acagtgcgta tcaaaaagct teat (SEQ ID NO: 22) RecA recombinase

[0120] In some embodiments, a genetically-modified bacteria cell can comprise a genetic modification that results in less DNA repair, relative to an otherwise comparable cell that does not comprise said genetic modification that results in less DNA repair. In some embodiments, the genetic modification is to a recombinase A (RecA) gene. RecA recombinase has multiple functions, all related to DNA repair. E. coli strains are often genetically-modified to contain a mutant RecA allele and thereby ensure the stability of extrachromosomal segments of DNA, known as plasmids. In a process called transformation, plasmid DNA is taken up by the bacteria under a variety of conditions (e.g., heat shock, electroporation). Bacteria containing exogenous plasmids are called “transformants”. Transformants retain the plasmid throughout cell divisions such that the plasmids can be recovered and used in other applications. Without a functional RecA polypeptide, the exogenous plasmid DNA is left unaltered by the bacteria.

[0121] In some embodiments, a genetically-modified bacterial cell can comprise a genetic modification that results in RecA recombinase polypeptide being reduced or disabled, which can increase the stability of an unaltered plasmids. In other embodiments, a disabled RecA recombinase polypeptide can enable purification of the unaltered plasmid from bacterial cultures, which can then allow for use in other applications such as, for example, high-fidelity PCR amplification of the original plasmid sequence. In other embodiments, the one or more disabled RecA genes are replaced by one or more catalase genes, such as the exemplary catalase sequences provided herein.

[0122] In some embodiments, a gene encoding RecA as described herein is itselfDocket No. 212391-704601modified to eliminate or reduce the expression of a polypeptide encoded by RecA. In some embodiments, a non-coding portion of the RecA gene as described herein is modified to eliminate or reduce the expression of the polypeptide encoded by RecA as described herein, such as a promotor, a polyadenylation site, a 5’ untranslated region, or a 3’ untranslated region. In some embodiments, an upstream or downstream gene that affects expression of the RecA gene as described herein is modified to eliminate or reduce the expression of the RecA polypeptide.

[0123] In some embodiments, a RecA recombinase polypeptide to be modified has at least 85% amino acid sequence identity to GenBank Accession No. AAO 18662.1 or a fragment thereof having DNA repair activity. An exemplary RecA recombinase amino acid sequence follows:1 mdenkqkala aalgqiekqf gkgsimrlgd nramdvetis tgslsldial gagglpmgri61 vevygpessg kttltlelia aaqregktca fidaehaldp vyakklgvdi dallvsqpdt121 geqaleicda larsgaidvm vvdsvaaltp kaeiegemgd shmglqarml sqamrkltgn 181 Ikqsncmcif ikqirmkigv mfgnpetttg gnalkfyasv rldirrtgai kegdevvgne241 trikvvknki aapfkeantq imygqgfnre gelvdlgvkh klvekagawy syngdkigqg 301 kanacnylre htevaqtidk klremllspa vaegpeagem pekkeeef (SEQ ID NO: 23)

[0124] In some embodiments, a genetically-modified bacterial cell can comprise a deletion of the RecA recombinase polypeptide sequence set forth as follows:MDENKQKALAAALGQIEKQFGKGSIMRLGDNRAMDVETISTGSLSLDI ALGAGGLPMGRIVEVYGPESSGKTTLTLELIAAAQREGKTCAFIDAEH ALDPVYAKKLGVDIDALLVSQPDTGEQALEICDALARSGAIDVMVVD SVAALTPKAEIEGEMGDSHMGLQARMLSQAMRKLTGNLKQSNCMCI FINQIRMKIGVMFGNPETTTGGNALKFYASVRLDIRRTGAIKEGDEVV GNETRIKVVKNKIAAPFKEANTQIMYGQGFNREGELVDLGVKHKLVE KAGAWYSYNGDKIGQGKANACNYLREHTEVAQTIDKKLREMLLSPA VAEGPEAGEMPEKKEEEF (SEQ ID NO: 24)

[0125] In some embodiments, a RecA recombinase polynucleotide encodes a RecA recombinase polypeptide. An exemplary RecA recombinase polynucleotide sequence (promoter region and complete coding sequence) to be modified is provided at GenBank Accession No. AY198129.1, which is reproduced below:1 cgtgataagc tctgcggcaa agttatacgt agatcagcta aagttttttc tatacaggta61 tagacactgt atgaatcaac agtataataa ctttcattgc tgagcgatta actgctcaag121 aaaagtttaa tgactattcg tcgcccaaaa agatgaataa atcggagaaa gtaatggacg181 agaacaaaca gaaagcgctc gccgctgcgc taggtcaaat tgaaaaacaa ttcggtaaag241 gctcaatcat gcgccttggc gataaccgcg caatggacgt agaaaccatc tcaacgggtt301 ctctttctct tgatatcgct ttgggtgctg gtggcttacc gatgggccgt attgttgaag361 tatacggtcc ggaatcttcg ggtaaaacga cactaactct ggaacttatt gcagcagcac421 agcgtgaagg caaaacttgt gcgtttatcg atgcggagca cgctctggat cctgtatacgDocket No. 212391-704601481 cgaagaagct tggcgtagat atcgatgcac ttttggtttc tcagcctgat acgggtgagc541 aagcgctaga aatctgtgac gcattagcgc gctctggtgc tatcgacgta atggttgtcg601 actctgtggc agcactgact ccaaaagcag aaatcgaagg cgaaatgggc gacagccaca 661 tgggtctcca agctcgtatg ctttctcaag cgatgcgtaa gctaacaggt aacctgaagc721 agtctaactg tatgtgtatc ttcatcaagc aaatccgtat gaagattggt gtgatgttcg781 gtaacccaga aacaacaact ggcggtaacg cacttaaatt ctacgcatcg gttcgtcttg841 atatccgtcg tactggcgca atcaaagaag gcgacgaagt tgtaggtaac gaaactcgca901 tcaaagtcgt taagaacaag attgcagcac catttaaaga agcaaacacg cagatcatgt961 atggtcaagg ctttaaccgc gaaggtgagc tggtagactt aggcgtgaag cacaaactgg1021 ttgaaaaagc aggtgcttgg tacagctaca atggcgacaa gatcggtcag ggcaaagcaa 1081 atgcttgtaa ttacctgcgt gaacatacag aagttgctca gactatcgac aagaaacttc1141 gtgagatgct tttgtctcca gctgtagctg agggacctga agccggtgaa atgccagaga1201 agaaagaaga agagttttaa (SEQ ID NO: 25)

[0126] In some embodiments, a genetically-modified bacterial cell can comprise a deleted or inactivated RecA increases plasmid yield and integrity by at least 0.2-fold, at least 0.5-fold, at least 0.8-fold, at least 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, as compared to the a comparable bacterial cell without RecA modification.Prophage

[0127] In some embodiments, a genetically-modified bacteria cell can comprise a genetic modification that results in greater resistance against stressors, relative to an otherwise comparable cell that does not comprise said genetic modification that results in less DNA repair. In some embodiments, the genetic modification is to a prophage region, thereby suppressing or eliminating phage production. Bacterial genomes frequently harbor prophages - integrated viral genomes that remain dormant until triggered by environmental cues. Upon activation, these prophages can initiate phage production, which poses a significant risk in industrial and pharmaceutical manufacturing via catastrophic batch failures and costly facility contamination events. In some embodiments, a genetically-modified bacteria cell comprises an inactivation or deletion of (|)pro 1 , (|)pro2, or both to a comparable wildtype bacterial cell. In some embodiments, the inactivation or deletion of (|)pro 1 , (|)pro2, or both increases stability and eliminates the risk of phage-related contamination of the genetically-modified bacteria cell. In some embodiments, a genetically-modified bacterial cell comprising an inactivation or deletion of (|)pro 1 , (|)pro2, or both has decreased phage production by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, atDocket No. 212391-704601least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100%, as compared to a comparable bacterial cell without the(|)pro 1 or (|)pro2 modification. In some embodiments, a genetically-modified bacterial cell comprising an inactivation or deletion of (|)pro 1 , (|)pro2, or both has increased plasmid yield by at least 0.2-fold, at least 0.5-fold, at least 0.8-fold, at least 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, as compared to a comparable bacterial cell without the (|)prol or (|)pro2 modification.Polynucleotides, plasmids, vectors, and replicons

[0128] Disclosed herein are vectors for use with a genetically-modified cell as described herein, which can be any particle (e.g., plasmids, cosmids, Lambda phages) used as a vehicle to artificially carry a foreign nucleic sequence - usually DNA - into another cell, where it can be replicated and / or expressed. The four major types of vectors are plasmids, viral vectors, cosmids, and artificial chromosomes. In some embodiments, a vector, plasmid, or replicon comprising one or more essential genes and a biomolecule is used to transform a host cell.

[0129] Extra-chromosomal DNA (e.g. a plasmid, vector, or replicon) can be transformed into a cell by any suitable method, for example by bacterial conjugation (e.g., E. coli to Vibrio spp.), electroporation of electro-competent cells, chemical transformation into chemically competent cells, biolistics, transduction, or via natural competence. Efficiencies of transformation can be, for example, at least 1 * 105or at least at least 1 x 106at least 1 x 107at least 1 x 108cfu / ug DNA using any of the methods above.

[0130] A plasmid is a small, extrachromosomal DNA molecule within a cell that is physically separated from chromosomal DNA and can replicate independently. Plasmids are considered replicons, units of DNA capable of replicating autonomously within a suitable host.

[0131] In some embodiments, a viral vector is used. In some of those embodiments, the viral vector is an AAV. In some embodiments, the viral vector corresponds to a virus of a specific serotype. In some examples, the serotype is selected from an AAV1 serotype, an AAV2 serotype, AAV3 serotype, an AAV4 serotype, AAV5 serotype, an AAV6 serotype, AAV7 serotype, an AAV8 serotype, an AAV9 serotype, an AAV10 serotype, an AAV11 serotype, an AAV12 serotype, avian AAV, bovine AAV, canine AAV, equine AAV, ovine AAV, and any other AAV now known or later discovered. See, e.g., BERNARD N. FIELDS et al., VIROLOGY, volume 2, chapter 69 (4th ed., Lippincott-Raven Publishers). A number ofDocket No. 212391-704601relatively new AAV serotypes and clades have been identified (see, e.g., Gao et al., (2004) 1 Virology 78:6381-6388; Moris et al., (2004) Virology 33-375-383; and Table 3). In some embodiments the AAV vector is a recombinant vector, a hybrid AAV vector, a chimeric AAV vector, a self-complementary AAV (scAAV) vector, a single-stranded AAV or any combination thereof. scAAV genomes contain both DNA strands which can anneal together to form double-stranded DNA.

[0132] In some embodiments, methods of producing delivery vectors herein comprise packaging an engineered guide disclosed herein in an AAV vector. In some examples, methods of producing the delivery vectors described herein comprise, (a) introducing into a cell: (i) a polynucleotide encoding any engineered guide disclosed herein; and (ii) a viral genome comprising a Replication (Rep) gene and Capsid (Cap) gene that encodes a wild-type AAV capsid protein or modified version thereof; (b) expressing in the cell the wild-type AAV capsid protein or modified version thereof; (c) assembling an AAV particle; and (d) packaging the polynucleotide encoding the engineered polynucleotide in the AAV particle, thereby generating an AAV delivery vector. In some embodiments, an engineered guide disclosed herein, promoters, stuffer sequences, and any combination thereof may be packaged in the AAV vector. In some examples, the AAV vector can package 1, 2, 3, 4, or 5 copies of the engineered guide. In some embodiments, the recombinant vectors comprise one or more inverted terminal repeats and the inverted terminal repeats comprise a 5’ inverted terminal repeat, a 3 ’ inverted terminal repeat, and a mutated inverted terminal repeat. In some examples, the mutated terminal repeat lacks a terminal resolution site.

[0133] In some embodiments, a hybrid AAV vector is produced by transcapsidation, e.g., packaging an inverted terminal repeat (ITR) from a first serotype into a capsid of a second serotype, wherein the first and second serotypes may be not the same. In some examples, the Rep gene and ITR from a first AAV serotype (e.g., AAV2) may be used in a capsid from a second AAV serotype (e.g., AAV9), wherein the first and second AAV serotypes may be not the same. As a non-limiting example, a hybrid AAV serotype comprising the AAV2 ITRs and AAV9 capsid protein may be indicated AAV2 / 9. In some examples, the hybrid AAV delivery vector comprises an AAV2 / 1, AAV2 / 2, AAV 2 / 4, AAV2 / 5, AAV2 / 8, or AAV2 / 9 vector.

[0134] In some embodiments, the AAV vector may be a chimeric AAV vector. In some embodiments, the chimeric AAV vector comprises an exogenous amino acid or an amino acid substitution, or capsid proteins from two or more serotypes. In some examples, a chimeric AAV vector may be genetically engineered to increase transduction efficiency,Docket No. 212391-704601selectivity, or a combination thereof.

[0135] In some examples, the delivery vector may be a eukaryotic vector, a prokaryotic vector (e.g., a bacterial vector) a viral vector, or any combination thereof. In some embodiments, the delivery vehicle may be a non-viral vector. In some embodiments, the delivery vehicle may be a plasmid. In some embodiments, the plasmid comprises DNA. In some embodiments, the plasmid comprises RNA. In some examples, the plasmid comprises circular double-stranded DNA. In some examples, the plasmid may be linear. In some examples, the plasmid comprises one or more genes of interest (e.g., essential genes and biomolecules) and one or more regulatory elements. In some examples, the plasmid comprises a bacterial backbone containing an origin of replication and an antibiotic resistance gene or other selectable marker (e.g., essential gene) for plasmid amplification in bacteria. In some examples, the plasmid may be a minicircle plasmid. In some examples, the plasmid contains one or more genes that provide a selective marker to induce a target cell to retain the plasmid. In some examples, the plasmid may be formulated for delivery via electroporation or heat shock. In some examples, the plasmids may be engineered through synthetic or other suitable means. For example, in some embodiments, the genetic elements may be assembled by restriction digest of the desired genetic sequence from a donor plasmid or organism to produce ends of the DNA which may then be readily ligated to another genetic sequence.

[0136] In some embodiments, the vector is a non-viral vector, and a physical method or a chemical method is employed for delivery into the bacterial cell. Exemplary physical methods include electroporation, heat shock, gene gun, sonoporation, magnetofection, or hydrodynamic delivery. Exemplary chemical methods include delivery of the recombinant polynucleotide via liposomes such as, cationic lipids or neutral lipids; dendrimers; nanoparticles; or cell-penetrating peptides. In some embodiments, a non-viral vector comprises a nanoparticle such as a lipid nanoparticle, a gold nanoparticle, or a combination thereof.

[0137] In some embodiments, a fusion protein as described herein is inserted into a vector. In some embodiments, the vector optionally comprises one or more promoters, enhancers, operators, ribosome binding sites, RNA splice sites, polyadenylation sites, a replication origin, a multiple cloning site (MCS), cap binding sites, a LacZa fragment, M13 forward and reverse priming sites, and / or transcriptional terminator sequences.

[0138] In general, plasmids and vectors described herein comprise at least one promoter. In some embodiments, the promoters are constitutive promoters. In other embodiments, the promoters are inducible promoters. In additional embodiments, the promoters are prokaryoticDocket No. 212391-704601promoters (e.g., drive expression of a gene in a prokaryotic cell). In some embodiments, the promoters are eukaryotic promoters, (e.g., drive expression of a gene in a eukaryotic cell). Exemplary promoters include, but are not limited to, CMV, EFla, SV40, PGK1, Ubc, human beta actin, CAG, TRE, UAS, Ac5, polyhedron, CaMKIIa, GALI-10, TEF1, GDS, ADH1, CaMV35S, Ubi, Hl, U6, CaMV35S, SV40, CMV, and HSV TK promoter. In some embodiments, the promoter is a lac promoter.

[0139] In some embodiments, vectors are bicistronic or polycistronic vector (e.g., having or involving two or more loci responsible for generating a protein) having an internal ribosome entry site (IRES) is for translation initiation in a cap-independent manner.

[0140] In some embodiments, vectors comprise an enhancer. Enhancers are nucleotide sequences that have the effect of enhancing promoter activity. In some embodiments, enhancers augment transcription regardless of the orientation of their sequence. In some embodiments, enhancers activate transcription from a distance of several kilo base pairs. Furthermore, enhancers are located optionally upstream or downstream of a gene region to be transcribed, and / or located within the gene, to activate the transcription. Exemplary enhancers include, but are not limited to, WPRE; CMV enhancers; the R-U5' segment in LTR of HTLV-I (Mol. Cell. Biol., Vol. 8(1), p. 466-472, 1988); SV40 enhancer; the intron sequence between exons 2 and 3 of rabbit P-globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981); and the genome region of human growth hormone (J Immunol., Vol. 155(3), p. 1286-95, 1995).

[0141] In some embodiments, vectors comprise an operator, which are nucleotide sequences that have the effect of repressing transcription upon binding of a repressor element. In some embodiments, the operator is a lac operator.Gene Editing

[0142] The genes disclosed herein can be disabled by genetic modification of any organism (e.g., bacteria) by genome editing. Gene editing makes very specific targeted changes by insertion, deletion or substitution of genetic material in an organism's DNA to obtain the desired changes to the DNA. Examples of gene editing are CRISPR, zinc finger nuclease, transcription activator-like effector nuclease (TALEN), oligonucleotide directed mutagenesis, site specific nucleases, and meganucleases. The genes disclosed herein can also be disabled by using traditional gene knockout methods (e.g., homologous recombination such as natural selection (cotransformation of unlinked genetic markers) or chemi cal / radiologi cal mutagenesis). Other examples of gene editing systems are transposases using signature-Docket No. 212391-704601tagging mutagenesis or insertional inactivation (e.g., sleeping beauty) or argonaute proteins to edit genes of interest. In some embodiments, more than one type of editing system can be used to generate an expression system. For example, natural selection can be used to introduce a gene edit and then a CRISPR (e.g., CRISPR / Cas9) can target the wild type sequence, leading to cell death of unedited cells (Stukenberg, D., Hoff, J., Faber, A. et al. NT-CRISPR, combining natural transformation and CRISPR-Cas9 countersei ection for markerless and scarless genome editing in Vibrio natriegens. Commun Biol 5, 265 (2022)).

[0143] Engineered or genetically-modified bacterial cells edited herein can be screened using selection markers and can be utilized on the altered Chromosome II or on extrachromosomal DNA or any constructs described herein. In some embodiments, the selection marker is a resistance gene, for example a gene conferring resistance to tetracycline, chloramphenicol, ampicillin, bleomycin, carbenicillin, gentamycin, glyphosate, hygromycin, kanamycin, neomycin, nourseothricin, phleomycin, puromycin, spectinomycin, streptomycin, or another antibiotic agent. In some embodiments, the resistance gene is Ampicillin or Kanamycin. The resistance gene can also have an origin of replication from various sources.Methods of Growing Gram-negative Bacteria

[0144] Growth conditions for gram-negative genetically-modified bacterial cell (e.g., Escherichia spp., Vibrio spp.) as described herein or for wild-type gram-negative bacteria, for purposes of measuring growth rates or comparing relative endotoxin concentrations or levels, can be any standardized or corresponding growth conditions accepted in the field as generally equivalent. In one embodiment, growth rates or other activities can be calculated or conducted in LBv2 media or LB (or LB-Miller) media or peptone, animal component free peptone, or yeast extract, at about 30 °C or another suitable temperature (e.g., 25 to 37 °C) with shaking (e.g., 100-300 rpm shaking). The growth conditions can be utilized to compare the growth rates between gram negative or other organisms, as is known and generally accepted in the field. In any of the embodiments a suitable media (including, but not limited to, any of those described herein) having from about 5 g NaCl / L to about or about 30 g NaCl / L or about 1% NaCl can be used. The media can optionally contain functional amounts glucose and / or magnesium, and can contain minimal or no calcium.

[0145] Corresponding growth conditions are those accepted in the field as those suitable for providing comparative measurements. In some embodiments, the growth rate of a Vibrio spp. organism can be compared to an / ■ / coli organism in corresponding conditions by growing Vibrio spp. in LBv2 media and the E. coli in LB (also called LB-Miller) media or peptone,Docket No. 212391-704601animal component free peptone, or yeast extract, since the organisms prefer these respective media. The organisms can be grown at the same temperature, e.g., about 30 °C or about 37 °C or about 25 °C, or Vibrio spp. can be grown at about 30 °C and E. coli can be grown at about 37 °C for corresponding conditions. In one embodiment, Vibrio spp. and / ■ / coli organisms can also be compared by growing both of them in LBv2 media; in another embodiment for comparison Vibrio spp. can be grown in LBv2 media at about 30 °C and E. coli can be grown in LB (or LB-Miller) media at about 37° C for corresponding conditions. Any of these various conditions can be used to compare any properties of the organisms, whether wild type or recombinant organisms.Growth Rate

[0146] Genetic modification (e.g. deletion, inactivation, insertion, attenuation, inversion, disruption, or downregulation) of one or more of the genes disclosed herein in a gramnegative genetically-modified bacterial cell would be expected to result in an organism having a significantly lower growth rate than an unmodified wild type organism. However, in various embodiments the genetically-modified gram-negative bacterial cell described herein have a higher growth rate than a comparable Escherichia spp. and grows at 10% or more or 25% or more or 50% or more or 75% or more or 100% or more or 150% or more or 200% or more or 300% or more or 500% or more or 750% or more of the growth rate of the unmodified or wild type gram-negative bacterial cell, unless the gram-negative bacterial cell has a modified msbA mutation (or “suppressor mutation”) that permits Lipid IV(A) transport. There are various mutations of msbA that permit an increase in growth and they are known to persons of ordinary skill. Yet the present inventors discovered unexpectedly that the engineered Vibrio spp. gram-negative bacterial cell of the present disclosure can have a genetic modifications in one or more of the API, IpxL IpxM, Dns, Dam, and / or RecA genes and nevertheless remain culturable and retain a high growth rate making them useful for the production of biomolecules as described herein. These genetically-modified gram-negative bacterial cells also have the advantage of giving a substantially reduced or eliminated immune response (or are substantially less endotoxic) to humans and other mammals.

[0147] A growing population of bacteria doubles at regular intervals of time. Bacterial growth occurs by geometric progression, e.g. 1, 2, 4, 8, etc. or 2°, 21, 22, 23. . . 2nwhere n is the number of generations. But only part of the bacterial life cycle involves exponential growth, and bacterial growth curves thus typically have an exponential portion and a stationary portion. Growth rate can be calculated during the exponential part of the life cycle.Docket No. 212391-704601The exponential phase of growth involves balanced growth wherein the cells are dividing regularly and growing by geometric progression. The rate of exponential growth (or the growth rate) of a bacterial culture can be expressed as generation time, or doubling time of the bacterial population. Generation time (G) is defined as the time (t) per generation (n=number of generations). Thus, the equation G=time (t) divided by (n) expresses the doubling time or generation time. G can be expressed in minutes (or hours) or any suitable unit of time. For example, a generation time (G) of 10 minutes means that it will take 10 minutes for the population to double in size. In various embodiments, the generation time can be measured by the numbers of organisms, the biomass, the optical density of the cell culture measured at 600 nm optical density (O.D.), or other measurements that are convenient and accepted as scientifically valid. Another common method of describing growth kinetics is the specific growth rate (SGR). The specific growth rate has units of reciprocal hours (per hr or hr1). Specific growth rate (SGR) and generation time (G) are related through the following mathematical formula: G=ln(2) / SGR. Thus, a large SGR will correspond with a small G, and vice versa. SGR can also be converted into doublings / hr by the formula: doubling time=ln(2) divided by the specific growth rate.

[0148] In some embodiments, the engineered Vibrio sp. of the present disclosure exhibits a specific growth rate of at least 0.30 hr1(per hour) or at least 0.40 or at least 0.50 or at least 0.60 or at least 0.70 or at least 0.80 or at least 0.85 hr1or 0.40-0.95 hr1or 0.50-0.95 or 0.60-0.72 or 0.60-0.75 or 0.60-0.95, or 0.65-0.90, or 0.70-0.95, or 0.80-0.95, or 0.85-0.95, or 0.30-0.90, or 0.40-0.90, or 0.50-0.90, or 0.60-0.90, or 0.70-0.90, or 0.80-0.90 hr1(per hour) which can be conveniently measured in any appropriate media and at any appropriate temperature (e.g., as described herein). Thus, growth rate can be expressed in doublings / hr or in minutes / doubling or simply generation time, or specific growth rate (SGR). In one embodiment, the doubling time of the organisms can be measured at 30 °C in LBv2 media. But any suitable media can be used, for example LB media (or LBMiller media) or peptone, animal component free peptone, or yeast extract. Growth can be assessed in any suitable container such as, for example, a fermentor or shake flask, but in one embodiment, the organisms can be assessed in a culture or assay plate (e.g., a 24, 48, 96, 384 well plate). The container can be flat bottomed microtiter plate, a round bottomed microtiter plate, or another appropriate vessel with wells of advantageous shape, for example flower shaped wells (e.g. FlowerPlate® microtiter plates). Any suitable container and conditions can be used to measure the growth rate. The growth rate or specific growth rate can also be assessed at various temperatures, including but not limited to, growth at about 25 °C or at about 30 °C orDocket No. 212391-704601at about 37 °C or at about 40 °C or at about 42 °C or about 25-30 °C or 25-32 °C or 25-37 °C or about 30-37 °C or about 37-42 °C or at any temperature between 16-42 °C. The growth rates disclosed herein are achievable on the media indicated herein and without any further supplementation of the media (e.g., without supplementation by arabinose 5-phosphate or glucose 6 phosphate). In some embodiments, the gram-negative bacterial cells described herein can have all wild type genes and no deletions or genetic mutations to any gene except as otherwise described herein.

[0149] In various embodiments, the genetically-modified gram-negative bacterial cells described herein have a doubling time of about 60 minutes, or 50-90 minutes, or 40-60 minutes, or 30-40 minutes, or less than 30 minutes at 30 °C, or less than 22 minutes at 37 °C, or less than 21 minutes at 42 °C, all in LB or LBv2 media or peptone, animal component free peptone, or yeast extract.

[0150] The genetically-modified Vibrio spp. bacterial cells described herein can grow more quickly than a corresponding or wild type bacterial cell. Thus, in various embodiments, the genetically-modified Vibrio spp. bacterial cells can have a growth rate of at least 40% more or at least 50% more, or at least 55% more, or at least 60% more at least 65% more or at least 70% more or at least 80% more or at least 85% more or at least 90% more or 50-70% more or 55-70% more or 55-65% more or 55-80% more or 55-90% more or 60-70% more or 60-65% more or 60-80% more or 60-90% more or 60-95% more or 65-90% more or 70-90% more or 75-90% more or 55-95% more or 65-95% more or 70-90% more or 70-95% more or 75-95% more of the growth rate (but also optionally more than 100% or more than 95% or more than 90% for any of them) of the corresponding or wild-type bacterial cells under the same or corresponding conditions. For example, if any bacterial cell has a doubling time of 10 minutes, 65% of its growth rate can be calculated as 10 / 0.65=15.4 minute doubling time. Growth rates can be measured over any convenient time period of cultivation during the exponential phase, such as over 4 hours or over 6 hours or 8 hours or 9 hours or 10 hours or 12 hours or 15 hours or 18 hours or 24 hours or only from 0-3 hours or 0-4 hours or 0-6 hours or 0-8 hours or 6-8 hours or from 8-10 hours or from 8-12 hours or from 10-12 hours. Thus, the genetically-modified Vibrio spp. bacterial cells described herein can have a doubling time or generation time or specific growth rate of 50% or greater or 55% or greater or 60% or greater, or 65% or greater, or 70% or greater or 75% or greater or 80% or greater or 85% or greater or 90% or greater, or 95% or greater (or 55-70% or 55-65% or 55-90% or 55-95% or 60-70% or 60-65% or 60-80% or 60-90% or 60-95% or 65-90% or 65-95% or 70-90% or 75-90% or 80-90% or 75-95% or 80-95%) than the doubling time or generation time of the wild-Docket No. 212391-704601type organism, or an organism not having the genetic modification of RecA, Dam, KdsD, gutQ, kdsA, kdsB, waaA, msbA, yhiD, IpxL, (|)pro 1 , (|)pro2 and / or IpxM genes. Doubling time can be expressed as any suitable unit of time, but doublings / hr is convenient and commonly used.

[0151] Any of the recombinant Vibrio spp. bacterial cells described herein can also have a growth rate of at least 100% greater, or at least 200% greater or at least 300% greater or at least 400% greater or at least 500% greater or at least 600% greater or at least 700% greater or at least 900% greater than an E. coli having a deletion of ARecA, ADam, ADns, AKdsD, AgutQ, AkdsA, AkdsB, AwaaA, AmsbA, AyhiD, AlpxLl, AlpxM, A (|)prol, A (|)pro2 genes, and a mutated msbA gene (a suppressor mutation). Such E. coli are commercially available under the trademark name ClearColi®).

[0152] Any of the genetically-modified Vibrio spp. bacterial cells described herein can exhibit sustained growth at higher temperatures, for example at about 40 °C, or above 40 °C, or at about 42 °C, or above 42 °C, or at about 37-42 °C or about 38-42 °C, e.g. for time periods of at least 12 hours or at least 18 hours or at least 24 hours or at least 48 hours. In some embodiments, the cells can be re-cultured after being exposed to the stated conditions.Stress Tolerance

[0153] Reactive oxygen species (ROS) such as singlet oxygen, superoxide anion, hydrogen peroxide, and hydroxyl radicals are a consequence of aerobic metabolism and can cause cellular damage through the oxidation of biological molecules. These oxygen species can be generated in an enhanced amount as a result of various types of cellular stress, including cold stress. In some embodiments, an genetically-modified bacterial cells (e.g., Escherichia spp., Vibrio spp.) comprises one or more nucleotide sequence(s) encoding one or more enzyme(s) from an ROS detoxification system. The one or more enzymes can be selected from one or more of a peroxidase, a dismutase, a reductase, and a transferase, or any combination of them, and which enzyme can be an algal, microalgal, bacterial, cyanobacterial or other type or source of enzyme. The enzyme can be selected from one or more of glutathione peroxidase (which can have reduced monomeric glutathione (GSH) as substrate), superoxide dismutase, guaiacol peroxidase (GPX), enzymes of ascorbate-glutathione (AsA-GSH) cycle ascorbate peroxidase (APX), monodehydroascorbate reductase (MDHAR), dehydroascorbate reductase (DHAR), glutathione reductase (GR), catalase peroxidase (e.g. katG and / or katE), alkyl hydroperoxide reductase, and glutathione S-transferase. The nucleotide sequence(s) can beDocket No. 212391-704601exogenous or heterologous, and the one or more enzymes can be exogenous or heterologous enzymes.

[0154] In some embodiments, genetically-modified bacterial cells (e.g., Escherichia spp., Vibrio spp.) have a heterologous or exogenous nucleic acid sequence encoding at least one enzyme from an ROS detoxification system, which can be present on a plasmid or other vector. The genetically-modified bacterial cells have a greater ability to tolerate cold stress than comparable wildtype bacterial cells and can therefore remain viable and culturable after incubation at lower temperatures and for substantially greater periods of time than nonengineered bacterial cells. An ROS detoxification system can convert any of the reactive oxygen species into one or more of oxygen or water. The enzyme from an ROS system can be operably linked to or under the control of an exogenous or heterologous promoter and / or other regulatory sequences.

[0155] In some embodiments, a vector, cell, expression system or biomolecule produced by said cell or expression system can be cryopreserved for long term storage. In some embodiments, the vector, cell, expression system or biomolecule produced by said cell or expression system is cryopreserved at a temperature less than -4 °C, -20 °C, -80 °C, or -196 °C. In other embodiments, the vector, cell, expression system or biomolecule produced by said cell or expression system is cryopreserved from 1 to 7 days, from 8 to 30 days, from 31 to 90 days, from 91 to 365 days, from 1 year to 5 years, or more than 5 years.Plasmid / T ransgene production

[0156] Disclosed herein are genetically-modified bacterial cells demonstrating increased plasmid or transgene production as compared to plasmid or transgene production in unmodified bacteria. In some embodiments, the genetically-modified bacterial cells demonstrate increased plasmid or transgene production as compared to plasmid or transgene production in a bacterial expression strain lacking the genetic modifications described herein. Also provided herein, are methods of expressing a plasmid in a genetically-modified cell.

[0157] In some embodiments, the genetically-modified bacterial cells replicate a plasmid with at least a 10%, 25%, 50%, 75%, 100%, 125%, 150%, 175%, 200%, 225%, 250%, 275%, or 300% increase in production yield of mg of plasmid as compared to a corresponding production yield of the plasmid in a comparable expression system lacking the genetic modifications described herein. In some embodiments, the genetically-modified bacterial cells replicate a plasmid with 10% or more, 25% or more, 50% or more, 75% or more, 100% or more, 125% or more, 150% or more, 175% or more, 200% or more, 225% or more, 250%Docket No. 212391-704601or more, 275% or more, or 300% or more increase in production yield of mg of plasmid as compared to a corresponding production yield of the plasmid in a comparable expression system lacking the genetic modifications described herein grown in the growth medium for the same amount of growth time. In some embodiments, the comparable expression system comprises wild-type K12 E. coli.

[0158] In some embodiments, genetically-modified bacterial cells replicate a plasmid to produce plasmids with reduced levels of plasmid multimers and / or concatemers. In some embodiments, the genetically-modified bacterial cells produce at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 99% less multimers an / or concatemers as compared to a comparable wildtype bacterial cell. In some embodiments, the genetically-modified bacterial cells produce at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 99% increase in monomeric plasmid species as compared to a comparable wildtype bacterial cell. In some embodiments, the genetically-modified bacterial cells produce at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 99% increase in supercoiled plasmid DNA as compared to a comparable wildtype bacterial cell. In some embodiments, plasmids produced by the genetically-modified bacterial cells described herein can comprise an increased ratio of monomeric and supercoiled plasmid DNA to multimers and concatemers, as compared to a comparable wildtype bacterial cell.

[0159] In some embodiments, the genetically-modified bacterial cells replicate a non-native plasmid with at least a 10%, 25%, 50%, 75%, 100%, 125%, 150%, 175%, 200%, 225%, 250%, 275%, or 300% increase in production yield of mg of plasmid as compared to a corresponding production yield of the non-native plasmid in a comparable expression system lacking the genetic modifications described herein. In some embodiments, the genetically-modified bacterial cells replicate a non-native plasmid with 10% or more, 25% or more, 50% or more, 75% or more, 100% or more, 125% or more, 150% or more, 175% or more, 200% or more, 225% or more, 250% or more, 275% or more, or 300% or more increase in production yield of mg of plasmid as compared to a corresponding production yield of the non-native plasmid in a comparable expression system lacking the genetic modifications described herein grown in the growth medium for the same amount of growth time. In some embodiments, the comparable expression system comprises wild-type K12 E. coli.

[0160] In some embodiments, genetically-modified bacterial cells replicate a non-native plasmid to produce plasmids with reduced levels of plasmid multimers and / or concatemers.Docket No. 212391-704601In some embodiments, the genetically-modified bacterial cells produce at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 99% less multimers an / or concatemers as compared to a comparable wildtype bacterial cell. In some embodiments, the genetically-modified bacterial cells produce at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 99% increase in monomeric plasmid species as compared to a comparable wildtype bacterial cell. In some embodiments, the genetically-modified bacterial cells produce at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 99% increase in supercoiled plasmid DNA as compared to a comparable wildtype bacterial cell. In some embodiments, plasmids produced by the genetically-modified bacterial cells described herein can comprise an increased ratio of monomeric and supercoiled plasmid DNA to multimers and concatemers, as compared to a comparable wildtype bacterial cell.

[0161] In some embodiments, the genetically-modified bacterial provided herein, wherein upon transforming the plasmid into the genetically-modified bacterial cell, the genetically-modified bacterial cell in liquid media reaches a cell density for purification in less than 24 hours that is equivalent to a cell density for purification reached by E. coli DH5a n liquid media after 36 hours, as measured by opticaldensity at 600 nm.

[0162] In some embodiments, the genetically-modified bacterial cell provided herein, upon liquid culturing colonies of the genetically-modified bacterial cell comprising the plasmid, the genetically-modified bacterial cell reaches a cell density for purification in less than 4 hours that is equivalent to a cell density for purificationreach by E. coli DH5a in liquid media after 12 hours, as measured by optical density at 600 nm.

[0163] In some embodiments, the plasmid disclosed herein comprises an origin of replication selected from the group consisting of pUC19, pcDNA3.1, pET, PBR322, pACYC184, RK2, RSF1010, pl 5 A, pNG2, pSClOlts, pSa, pTHT15, pAL5000, pAMBl, pBBRl, pBBRl-UP, pBCl, pBPl, pCB102, pCD6,pIJ101, pIM13, pIP501, pMBl, pSG5, pUBUO, and pWKSl.

[0164] In some embodiments, the plasmid provided herein comprises an antibiotic selection marker selected from the group consisting of kanamycin (KAN),tetracycline (TET), chloramphenicol (CAM), gentamicin (GEN), spectinomycin (SPEC), and erythromycin (ERM), and carbenicillin.Docket No. 212391-704601

[0165] In some embodiments, the non-native plasmid generated by the genetically-modified bacterial cells can be purified. The skilled artisan may look to known plasmid purification steps to provide for a scheme which results in an appropriate grade of DNA plasmid purity. For example, PCT International Application Nos. PCT / US95 / 09749 (WO96 / 02658) and PCT / US96 / 07083 (WO96 / 36706) give guidance as to alternative, chromatography-based downstream steps which may be utilized in combination with the core purification steps mentioned in this paragraph to provide an effective purification protocol.Method of Expressing Biomolecule

[0166] In some embodiments, non-toxic gram-negative genetically-modified bacterial cells are used as hosts for the production of endotoxin free biomolecules. The present disclosure is not limited to particular biomolecules. Traditionally, the production of biomolecules in Gram negative bacteria, whether it be outer membrane vesicles for vaccines, LPS type molecules (such as monophosphoryl lipid A (MPLA)) to be used as adjuvants, recombinant pharmaceutical proteins, macromolecules, or DNA for mammalian cell transfection / gene therapy, is plagued by the presence of endotoxin from the bacterial host. Contamination of the therapeutic molecule with endotoxin is a concern, as the immunogenic potential of LPS is well documented. Current production strategies to alleviate endotoxin contamination include various purification techniques, such as the kits marketed for endotoxin free DNA plasmid purification, followed by assays to measure endotoxin levels. As such, the non-toxic gramnegative bacterial cells of the present disclosure (e.g., the endotoxin-free cells) provide improved methods of isolating endotoxin free biomolecules. Accordingly, as some cells of the present disclosure do not produce endotoxin, such purification steps are not required. For example, the endotoxin-free cell of the present disclosure can be a host for the production of commercially important biomolecules in an endotoxin-free environment using Gram-negative bacteria. Additionally, cells comprising a modification in a gene encoding any one or more of a D-arabinose 5-phosphate isomerase, a KD08P synthase, a CMP- KDO synthetase, a KD08P phosphatase and / or a KDO transferase, an ATP-dependent translocator, an inner membrane protein (e.g., gutQ, kdsD, kdsA, kdsB, waaA msbA, yhjD genes), or modifications in any other biosynthetic, processing (e.g., IpxLl or IpxM), or trafficking bacterial genes can be hosts for the production of commercially important biomolecules in an endotoxin- free environment using Gram-negative bacteria.

[0167] In some embodiments, A method of expressing a biomolecule encoded by a plasmid in a genetically-modified bacterial cell, the method comprising: transforming the plasmid intoDocket No. 212391-704601the genetically-modified bacterial cell provided herein; culturing the genetically-modified bacterial cell comprising the plasmid; expressing the biomolecule from the plasmid using the genetically-modified bacterial cell in culture medium; and purifying the biomolecule from the genetically-modified bacterial cells.

[0168] Systems for replicating the genetically-modified bacterial cells

[0169] Provided herein are systems for replicating the genetically-modified bacterial cells provided herein. In some embodiments, the genetically-modified bacterial cells provided here are cultured in growth medium. In some embodiments, the growth medium is commercially available growth medium, such as LB and TB. In some embodiments, provided herein, are growth medium specifically formulated to meet the growth requirements of the genetically-modified bacterial cells. In some embodiments, the growth media comprises yeast extract and vegetable tryptone as complex nitrogen sources; MgSCL, NaCl, KC1, CaCh, MgCh, and K2HPO4 to provide essential ions; phosphate for plasmid replication, and buffering agent to maintain pH stability. In some embodiments, the yeast extract ranges from about 1 to about 15 g / L. In some embodiments, the vegetable tryptone ranges from about 0.1 to about 25 g / L. In some embodiments, the amount of MgSCU ranges from 0 to about 35 g / L. In some embodiments, the amount of NaCl ranges from about 0 to 30 g / L. In some embodiments, the amount of CaCh ranges from about 0 to 34 mM. In some embodiments, the amount of KC1 ranges from 0 to about 24 mM. In some embodiments, the amount of K2HPO2 ranges from about 0.5 to about 5 g / L. In some embodiments, the amount of Tris ranges from about 110 mM to about 160 mM. In some embodiments, the percentage of NaCl ranges from about 0.75% to about 2.5%, e.g. about 0.75 %, about 1%, about 1.5%, about 1.8%, about 2.0%, about 2.1 %, about 2.2%, about 2.3 %, about 2.4%.

[0170] In some embodiments, the growth media comprises Tris as the bufferingagent. In some embodiments, the amount of Tris ranges from about 110 mM to about 170 mM, e.g., 115 mM, 117mM, 119 mM, 121 mM, 125 mM, 127mM, 130 mM, 140 mM, 150mM, 160 mM, 165 mM, or 170 mM. In some embodiments, the growthmedia is formulated in liquid format or in solid agar format.

[0171] In some embodiments, the growth media provided herein increase the growth kinetics, plasmid yield, or plasmid quality as compared to other commerciallyDocket No. 212391-704601available culturing media, such as a common E-Coli rich media, e.g., LB or TB media. In some embodiments, the growth media provided herein increase the growth rate of the genetically-modified bacterial cells provided herein by at least 0.2-fold, at least 0.5-fold, at least 0.8-fold, at least 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, as compared to other commercially available culture media. In some embodiments, the growth media provided herein increases plasmid yield of the genetically-modified bacterial cells by at least 0.2-fold, at least 0.5-fold, at least 0.8-fold, at least 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, as compared to other commercially available culture media. In some embodiments, the use of the growth media provided herein in combination of the genetically-modified bacterial cell has synergistic effects on bacteria growth, plasmid yield, and integrity.Systems for transforming the genetically-modified bacterial cells

[0172] Provided herein are also systems for transforming the genetically-modified cells. In some embodiments, the system comprises the genetically-modified bacterial cell disclosed herein and a cloning plasmid. In some embodiments, the cloning plasmid are high-copy cloning vectors (pCYC cloning vectors) that facilitate efficient routine cloning of the genetically-modified bacterial cells. In some embodiments, the cloning plasmid comprise a high-copy origin-of-replication, an antibiotic resistance marker, such as AmpR, CmR, or KanR. In some embodiments, the cloning plasmid comprises removed Bsal restriction site from the backbone and a unique Bsal entry site to facilitate rapid cloning by Golden Gate Assembly. In some embodiments, the cloning plasmid comprises a sequence set forth in SEQ ID NO: 39 below:TCCTGGAGACCAGCATGGCTTGCAGTGGCGTTGGTCTCCGGC (SEQ ID NO: 39)

[0173] In some embodiments, provided herein are systems for replicating a genetically-modified bacterial cell, comprising: the genetically-modified bacterial cells disclosed herein; and growth medium for culturing the genetically-modified bacterial cells. In some embodiments, the growth media is solid or liquid. In some embodiments, the systems are for transforming a genetically-modified bacterial cell, comprising: (a) the genetically-modified bacterial cell of disclosed herein; and (b) a cloning plasmid. In some embodiments, the cloning plasmid comprises a backboneDocket No. 212391-704601comprising a high-copy origin of replication, an antibiotic resistance marker, or a unique restriction enzyme site, such as a unique restriction enzyme site. In some embodiments, the cloning plasmid comprises a backbone comprising a high-copy origin of replication that comprises pUC19, pcDNA3.1, pET, PBR322, pACYC184, RK2, RSF1010, pl5A, pNG2, pSClOlts, pSa, pTHT15, pAL5000, pAMBl, pBBRl, pBBRl-UP, pBCl, pBPl, pCB102, pCD6,pIJ101, pIM13, pIP501, pMBl, pSG5, pUBl 10, or pWKSl. In some embodiments, the cloning plasmid comprises a backbone comprising an antibiotic resistance marker that comprises kanamycin (KAN), tetracycline (TET), chloramphenicol (CAM), gentamicin (GEN), spectinomycin (SPEC), erythromycin (ERM), or carbenicillin.

[0174] In some embodiments, the cloning plasmid comprises backbone sequences set forth in SED ID NO: 40, SED ID NO: 41, or SED ID NO: 42. In some embodiments, the pCYC vectors provided herein increases plasmid yield of the genetically-modified bacterial cells by at least 0.2-fold, at least 0.5-fold, at least 0.8-fold, at least 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold as compared to other commercially available vectors. In some embodiments, the pCYC vectors are used together with the genetically-modified bacterial cells and the culture media provided herein, wherein the the genetically-modified bacterial cells, pCYC vectors, and the culture mediaexert synergistic effects in promoting the growth of the genetically-modified bacterial cells and increasing the plasmid yield, thereby providing an accelerated and superior recombinant DNA workflow.EXAMPLESExample 1 — Generation of a genetically-modified bacteria for improved transformation efficiency

[0175] This example describes the generation of a genetically-modified bacteria with a gene knockout for improved transformation efficiency. An exemplary Vibrio natriegens gene having the polynucleotide sequence of SEQ ID NO: 1 was selected for knockout. Using this sequence, this gene sequence was replaced with an antibiotic resistance marker using natural competence-mediated homologous recombination, as previously described. Briefly, V. natriegens cells were rendered naturally competent via expression of the V. cholera tfoX protein from a plasmid, which activated the cell’s natural competence machinery. The naturally competent cells were then transformed with DNA cassettes that contained anDocket No. 212391-704601antibiotic resistance gene bounded by homology sequences, these were used to direct the DNA cassettes to the appropriate locus and enabled a recombination event. This resulted in the replacement of the most of the gene sequence of SEQ ID NO: 1 with the resistance marker, effectively knocking out the gene. The resulting genetically-modified bacteria were screened then by colony PCR to confirm the desired knockout. Finally, the genetically-modified bacteria were then passaged in the absence of antibiotics to remove the tfoX expression plasmid. Collectively, described herein was a method of generating a genetically-modified strain, with a genetic modification that results in the knockout in the gene having the polynucleotide of SEQ ID NO: 1.Example 2 — Transformation efficiency in the genetically-modified bacterial cells This example describes the improvement in transformation efficiency in the genetically-modified bacterial cells. Briefly, plasmid DNA was introduced into the genetically-modified bacterial cell from Example 1. Two different plasmids were used to assess transformation efficiency. The first plasmid was pUC19, a high-copy plasmid that confers resistance to Carbenicillin. The second plasmid was a medium copy, 13.3 kb plasmid with a ColEl origin that conferred resistance to Kanamycin. After transformation, the transformed genetically-modified bacterial cells were plated on agar plates containing either 50 mg / mL Carbenicillin or 100 mg / mL Kanamycin. The agar plates were incubated overnight at 37 °C in a static incubator. After approximately 16 hours, plates were retrieved, and colonies were counted. As each colony on the plate is the result of a successful transformation event, transformation efficiency was then calculated by determining the number of colony forming units per amount of plasmid DNA (reported as CFU / mg DNA). The higher the number indicated increased transformation efficiency. As can be seen from FIGs. 1 A-1B, the genetically-modified bacterial cell that contained the gene knock out of SEQ ID NO: 1 produced an increase in the number of transformants, when compared to the wildtype bacterial cell with the gene sequence of SEQ ID NO: 1 present. Overall, a 1.6 fold increase in the number of transformants was observed for the genetically-modified bacterial cells transformed with the high copy plasmid. Notably, a 2.9-fold increase in the number of transformants was observed for the genetically-modified bacterial cells transformed with the medium copy plasmid. Collectively, this data demonstrates that the genetically-modified bacteria described herein demonstrated an increase in transformation efficiency.Docket No. 212391-704601Example 3 - Generation of a genetically-modified bacterial cell with an exogenous OxyR gene

[0176] This example describes the generation of a genetically-modified bacteria with an exogenous mutant OxyR gene. Briefly the exogenous mutant OxyR gene was generated using a DNA sequence for OxyR containing an exemplary mutation of interest (C208G) (encoded by the polynucleotide of SEQ ID NO: 2) via standard laboratory mutagenesis techniques using synthetic DNA. The polynucleotide of SEQ ID NO: 2 was fused to a spectinomycin antibiotic resistance cassette, which provided a means of selection, and was inserted into the dns locus of an exemplary bacterial strain to generate the dns::oxyR2 mutant. The bacterial strain used was the Vibrio natriegens using natural competence-mediated homologous recombination, as previously described in Example 1. Briefly, V. natriegens cells were rendered naturally competent via expression of the V. cholera tfoX protein from a plasmid, which activated the cell’s natural competence machinery. The naturally competent cells were transformed with DNA cassettes composed of the exogenous mutant OxyR gene bounded by homology sequences to direct the DNA cassette to the dns locus and enabled a recombination event. This resulted in the replacement of the dns gene with the mutant OxyR cassette. Thus, the genetically-modified bacterial cells contained a wildtype OxyR gene and a mutant OxyR gene. The resulting transformants were screened by colony PCR to confirm the desired knock-in of the exogenous mutant gene. Finally, the genetically-modified bacteria were then passaged in the absence of antibiotics to remove the tfoX expression plasmid. Collectively, described herein was a method of generating a genetically-modified strain, with a genetic modification that results in the knock-in of the exogenous mutant OxyR gene having the polynucleotide of SEQ ID NO: 2.Example 4 — Constitutive expression of stress response genes in the genetically-modified bacterial cells that contain the exogenous mutant OxyR gene

[0177] This example describes the effects of knocking in an exogenous mutant OxyR gene in a genetically-modified bacterial cell from Example 3. Briefly, we employed an catalase assay to detect the presence of catalase activity because the nativecatalases are regulated by OxyR. Bacterial cell. V. natriegens was used as anexemplary bacterial cell as it was expected to have constitutively upregulated stress response genes. 50 uL of a liquid culture of the genetically-modified cells containing the exogenous mutant OxyR gene and 50 uL of a liquid culture of the wildtypeDocket No. 212391-704601bacterial cells were pipetted onto a plastic surface. 10 uL of 3% Hydrogen peroxide were added to the sample and mixed by pipetting. Next, the samples were visually observed for bubbles, which indicated of catalase activity (in breaking down the hydrogen peroxide into water and gaseous oxygen). As shown in FIG.2A-2B, the wildtype bacterial strain did not produce any observable bubbles. However, the genetically-modified bacterial cells with the exogenous mutant OxyR gene produced visible bubbles, which indicated a more robust response to oxidative stress.Collectively, this example demonstrated that the inclusion of an exogenous mutant OxyR led to constitutive expression of stress response genes.Example 5 — Genetically-modified bacterial cells that contain the exogenous mutant OxyR gene demonstrated an increase in plasmid yield

[0178] This example describes the improvement in plasmid yield in the genetically-modified bacterial cells. Briefly, plasmid DNA was introduced and transformed into the genetically-modified bacterial cell from Example 3, and comparable wildtype bacterial cells. Agar plates with transformed cells were incubated overnight at 37 °C in a static incubator. After approximately 16 hours, plates were retrieved. Colonies were picked from the agar plates into 2 mL of growth media containing appropriate antibiotics in wells of a 24-well plate. The plate was then incubated at 37 °C in a shaking incubator with agitation at 300 RPM. After 6 hours of cultivation, 200 uL of the cultures were retrieved and plasmid DNA was extracted using a QIAprep Spin Miniprep Kit (Qiagen) following the manufacturer’s instructions. DNA was then quantified using a Qubit fluorometer (Thermo Fisher Scientific). As shown in FIG.3A-3C, the genetically-modified bacterial cell demonstrated a significant increase in plasmid yield of about 60-80%, as compared to a comparable wildtype cell in three different growth media formulations, stress.

[0179] Additionally, plasmid yield and growth characteristics of the stains with and without dns::oxyR2 were measured. Briefly, colonies of strains on agar plates with and without the dns::oxyR2 modification carrying the plasmid pcDNA3.1 were inoculated into 2 mL aliquots of media in 24-well deep-well plates. Cultures grew at 37°C with agitation at 300 RPM and humidity at 80% for 6 hours. Plasmid yield and quality were assessed by extracting DNA via miniprep. Typically, cell pellets were harvested from 100 - 200 pL of culture by centrifugation at 5000 x g for 5 min, followed by removal of the supernatant. Cells were processed through a QiagenDocket No. 212391-704601QIAprep Spin Miniprep column following the manufacturer instructions with the following modifications: the optional PB step was employed, and plasmid was eluted by 2 x 50 pL elutions with TE buffer to ensure high recovery of plasmid from the column matrix. Plasmid volumetric yield was assessed by measuring the concentration of the recovered plasmid DNA on a Qubit™ fluorometer using the lx dsDNA Broad Range Assay Kit, and then adjusting for the amount of culture processed through the column. Plasmids were sequenced by long-read NGS.

[0180] Results for plasmid yield and growth characteristics in dns::oxyR2 stains were shown in FIGs 4A-4C. These figures demonstrated that the presence of the dns::oxyR2 genetic modification increased plasmid growth and yield at early as 6 hr timepoint by about 60% to about 80%. These effects were consistent across different media formulations.

[0181] Collectively, this example demonstrated that the inclusion of an exogenous mutant OxyR resulted in a significant increase in plasmid yield. Further, the increased plasmid yield and growth illustrated that enhancing peroxide detoxification improves the robustness of bacterial cells, such as V. natriegens, for generalized laboratory applications including plasmid DNA production.Example 6 —Enhanced transformation efficiency of genetically-modified bacterial cells with select plasmids

[0182] This example evaluated synergistic effects of modifications to multiple genes on transformation efficiency of the genetically-modified bacterial cells.

[0183] Genetically-modified bacterial cells comprising 1) dns deletion alone, 2) dns, RecA, (|)prol, and (|)pro2 deletions, 3) an insertion of an extra copy of oxyR carrying the C208G mutation inserted at the dns locus (dns::oxyR2), together with RecA, (|)prol, and (|)pro2 deletions, 4) dns::oxyR2, RecA, (jiprol, (|)pro2 deletions, and an mutation to the SEQ ID NO: 1. Briefly, the dns::oxyR2 modification were obtained through the modifications to dns, OxyR, RecA, (jipro 1 , (|)pro2, mlgG genes. Briefly, V. natriegens were cultured in culture media. Gene knockouts were performed by replacing RecA, (jiprol , and (|)pro2 with a chloramphenicol or spectinomycin antibiotic resistance cassette using natural competence-mediated transformation. Successful knockouts were confirmed by colony PCR. In some cases, the antibiotic cassette was flanked on both sides by engineered loxP sites, allowing for the removal of the marker from the genome via Cre-lox recombination. Removal of the antibiotic marker wasDocket No. 212391-704601confirmed first by patch plating on plates with and without antibiotic, followed by colony PCR, and finally by full genome sequencing. Modification of SEQ ID NO: 1 was employed using similar methods according to Example 1. Generation of dns:oxyR2 was conducted according to methods in Example 3-5.

[0184] Competent cells were thawed on ice for 30 minutes. The tube was gently flicked to mix contents and then 50 pL of cells was gently transferred to a pre-chilled 1.5 mL microcentrifuge tube. 1-2 pL of plasmid DNA was added to the cells and gently flicked to mix. Cells were incubated on ice for 20 minutes, heat shocked in a water bath at 42°C for 45 seconds, then returned to ice for 3 min. Cells were recovered by adding 1 mL of room temperature recovery Media and incubating at 37°C with agitation at 250-300 RPM for 1-2 hrs. Appropriate dilutions were made in fresh culturing Recovery Media, followed by plating 50 - 200 pL on pre-warmed agar plates. Plates were incubated between 6 - 16 hrs.

[0185] pUC19, pACYC184, and pCYC-3 plasmids were transformed into the genetically-modified bacteria cells. Transformation efficiency was evaluated according to methods disclosed in Example 2.

[0186] As shown in FIG. 5, deletion of dns gene in the V. natriegens cells consistently increased transformation efficiency of various types of plasmids by at least 1.5 fold as compared to the wildtype V. natriegens cells. Additional increases of transformation efficiency were observed with the deletion of RecA, (|)prol, or (|)pro2, mutation to SEQ ID NO: 1, insertion of an exogeneous copy of mutant oxrR gene, or a combination thereof. Notably, a combination of dns::oxyR2, RecA, <])prol , (|)pro2 deletions, and SEQ ID NO: 1 modification to the wildtype V. natriegens cells increased the transformation efficiency of pUC19 plasmids by about 1 x 104as compared to the wildtype V. natriegens cells.

[0187] Collectively, these results suggest that genetically-modified bacterial cells comprise modifications that increase oxyR2 expression or decrease RecA, (|)prol, <])pro2 or SEQ ID NO: 1 expression increased transformation efficiency of the bacterial cells as compared to the comparable wildtype bacterial cells.Example 7 — Genetically-modified bacterial cells with RecA deletion increase plasmid integrity

[0188] This example demonstrated that the genetically-modified bacterial cells comprising a RecA deletion reduced plasmid concatenation as compared to aDocket No. 212391-704601comparable wildtype bacterial cells.

[0189] Dns and RecA deficient bacterial cells were produced according to Example 1 and Example 6. A pUC plasmid and a 7.4kb lentiviral transfer plasmid containing long terminal repeats (LTRs) were transformed into either a strain lacking only dns gene or a stain lacking both dns and RecA genes.

[0190] The deleted RecA sequence is as follows:MDENKQKALAAALGQIEKQFGKGSIMRLGDNRAMDVETISTGSLSLDIALGA GGLPMGRIVEVYGPESSGKTTLTLELIAAAQREGKTCAFIDAEHALDPVYAKK LGVDIDALLVSQPDTGEQALEICDALARSGAIDVMVVDSVAALTPKAEIEGE MGDSHMGLQARMLSQAMRKLTGNLKQSNCMCIFINQIRMKIGVMFGNPETT TGGNALKFYASVRLDIRRTGAIKEGDEVVGNETRIKVVKNKIAAPFKEANTQI MYGQGFNREGELVDLGVKHKLVEKAGAWYSYNGDKIGQGKANACNYLRE HTEVAQTIDKKLREMLLSPAVAEGPEAGEMPEKKEEEF (SEQ ID NO: 24)

[0191] Two independent colonies of each strain / plasmid combination were cultured in liquid medium followed by plasmid isolation via miniprep. Purified DNA samples were analyzed by agarose gel electrophoresis. Supercoiled gels were run by mixing purified plasmid DNA with 5x gel loading dye (NEB), loading on a hand-poured 1% agarose TAE gel containing SYBR Safe gel stain, and running the gel at 120V for > 1 hr. Gels were visualized in a gel imager equipped with blue light illumination. The monomeric, supercoiled plasmid species is indicated as “Desired plasmid”, while higher-molecular-weight, concatenated species are indicated as “Undesired multimers”. Results were shown in FIGs 5A-5B. Both pUC19 (FIG. 6A) and lentiviral transfer plasmid (FIG. 6B) clones comprising additional RecA deletion significantly reduced undesired multimers and produced greater number of desired plasmids that are monomeric and supercoiled.

[0192] These data suggest that deletion of RecA gene from the bacterial cells is effective in preventing plasmid concatenation and greatly enhances plasmid integrity during transformation.

[0193] The following examples 8-11 used V. natriegens for exemplary purpose and did not exclude similar effects on other genetically-modified bacterial cells disclosed herein.Example 8 — A system for increased plasmid yield and quality of the genetically-modified bacterial cells

[0194] This example provided a system that was developed, inter alia, to provide lowDocket No. 212391-704601cost, animal components-free media for the increase of plasmid yield and quality of the genetically-modified bacterial cells disclosed herein.

[0195] To develop an improved media formulation for plasmid DNA production in V. natriegens, a response surface methodology was employed using a central composite design. Media components were selected based on the nutritional and physiological requirements of this marine bacterium: yeast extract and vegetable tryptone as complex nitrogen sources; MgSCL, NaCl, and K2HPO4 to provide essential ions; phosphate for plasmid replication; and buffer to maintain pH stability. Component concentration ranges were established using existing V. natriegens formulations and common E. coli rich media (LB, TB) as reference points.

[0196] To evaluate the impact of adding a buffering agent to rich media, media (20 g / L yeast extract, 5 g / L tryptone, 41 mM MgSO4, 428 mM NaCl, 21 mM potassium phosphate) was prepared with either no buffering agent or 150 mM of MES, MOPS, PIPES, or TRIS buffer. All types of media were pH adjusted to ~6.4. Colonies of genetically-modified V. natriegens transformed with pcDNA3.1 were picked into 2 mL of each growth media in wells of a 24-well deep-well plate. The plate was incubated at 37°C with shaking at 300 RPM for 6 hours. Each media was tested in triplicate. 0.3 mL of each culture was harvested and processed through a Qiagen miniprep column as described in the materials and methods section. Plasmid yields were determined using the Qubit fluorometer. The results showed that Tris buffer was better to maintain pH stability and increased plasmid yield by at least 32% as compared bacterial cell cultured without buffer or with other buffering agents, (see FIG. 7)

[0197] A design-of-experiments (DOE) approach was employed to determine both liquid and solid agar media components and their concentrations. For the liquid media, plasmid yield after 4 h of growth was used as the primary response variable. For the solid agar media, transformation efficiency and colony growth were used as the primary response variables. Systematic evaluation of main effects, interactions, and quadratic relationships between components and plasmid yield were also evaluated.A. Increased plasmid yield and quality of the genetically-modified bacterial cells in animal component-free liquid media

[0198] 32 conditions were formulated, and 2 mL was added to wells of 24-well deepwell plates (2 plates total; each condition n=l, center point n=6 to assess variability).Docket No. 212391-704601Carbenicillin was added to a concentration of 50 pg / mL. The wells were inoculated with 5 pL of an overnight culture of genetically-modified V. natriegens harboring plasmid pcDNA3.1 grown in the media with Tris described in Supplementary Text 6. The cultures were grown for 4 hours at 37°C with shaking at 300 RPM and humidity at 80%. At 4 hours, 0.2 mL of each culture was harvested and processed through a Qiagen miniprep column as described in the materials and methods section. Plasmid yields were determined using the Qubit fluorometer. OD600 was measured spectroscopically on a Nanodrop UV / Vis spectrophotometer using the cuvette setting.

[0199] The results were shown in the Table 1 below:Table 1. OD600 and plasmid yield under different culture conditions at 4 hours Yeast Tryptone MgSO4 NaCl K2HPO4 Tris OD600 Plasmid Extract (g / L) (g / L) (g / L) (g / L) (mM) Yield (g / L) (mg / L)2.5-7.5 4-8 7.5- 1-3 150 0.6-5.6 0.5-1.32 15-3022.5

[0200] The results showed a strong statistically significant model was created with an R2 = 0.96, RMSE of 0.078 mg / L, and P-value <0.0001. Among the 14 significant model terms, NaCl concentration exhibited the strongest linear effect, followed by a significant quadratic term for NaCl, indicating an optimal concentration range. The MgSO4 x K2HPO4 interaction was the third most influential factor, suggesting synergistic or antagonistic effects between these salt components on plasmid yield. The quadratic term for K2HPO4 was excluded due to low P value (0.2).Counterintuitively, both yeast extract and tryptone showed negative linear effects on plasmid yield at 4 hours, with optima at about 7.5 g / L and 0 g / L, respectively. This indicates that moderate nutrient limitation enhances early plasmid accumulation in this fast-growing marine bacterium, possibly by reducing acetate or other metabolic byproducts that accumulate during rapid growth on rich media, or by shifting the balance between cell division and plasmid replication.B. Increased plasmid yield and quality of the genetically-modified bacterial cells in animal component free solid agar media

[0201] For the solid agar media, similar approaches were taken as liquid media. Transformations of competent cells with pUC19 were plated and incubated at 37°CDocket No. 212391-704601for 16 hours on the respective agar designs in Table 2 . Colony size (scored 1-4, with 4 corresponding to fastest growth) and transformation efficiency (number of colonies from 3 pL of transformation plated) were recorded for each plate. Colony size and transformation efficiency were evaluated as response variables in the model, enabling systematic evaluation of main effects, interactions, and quadratic relationshipsbetween growth rate (colony size) and transformation efficiency (number of colonies).Table 2. Growth rate of genetically-modified V. natriegens in various solid agarmedia conditions.Tryptone MgSCU NaCl KC1 CaCh MgCh Colonies Yeast(g / L) (g / L) (g / L) (mM) (mM) (mM) (mg / L)Extract(g / L)1-9 1-19 23-46 0-18.8 0- 0-18.8 0-58 0-78018.8

[0202] The results showed that inclusion of KC1 and CaC12 negatively affected transformation efficiency and colony growth.

[0203] These results together suggest the animal components-free growth media further enhanced plasmid yield and growth of the genetically V. natriegens, adding additional benefit to overcome the bottleneck of synthetic biology and modern biotechnology by accelerating molecular cloning and plasmid production workflows.Example 9 Accelerated recombinant DNA workflows using the genetically-modified bacteria cells and animal component-free media

[0204] Briefly, high-copy mammalian expression plasmid pcDNA3.1 was transformed into each of the genetically-modified bacterial cells disclosed herein, E. coli DH5a, and E. coli NEB® Turbo via chemical transformation and plated on agar plates provided herein. DH5a served as a benchmark strain due to its widespread use as for molecular cloning and plasmid production, whereas NEB® Turbo was included as a commercially available E. coli strain marketed for accelerating recombinant DNA workflows due to rapid growth rate. Agar plates were incubated overnight, followed by colony picking into 2 mL aliquots of liquid media with carbenicillin in wells of a 24-well deep-well plate. Transformed colonies were used to inoculate 2 mL cultures and cultivated for 6 hours before harvest. Growth curves measured directly in the 24-well plate via an Essitech mtpOD online biomass monitor. Average volumetric yields (in mg / L) of pcDNA3.1 after 6 hours of cultivation isolated by QiagenDocket No. 212391-704601miniprep columns and measured by Qubit double-stranded DNA assay. Averages were calculated from yields from four independent colonies (n=4) from each strain. Plasmid topology was also assessed, as recombination events within the host can lead to undesirable truncations, rearrangements, or plasmid concatenation (multimer formation). Large-scale recombination events (such as large deletions or concatenation) are readily detected by supercoiled agarose gel electrophoresis, in which plasmid DNA is analyzed on an agarose gel without prior restriction digestion to preserve topological differences. As such, plasmid quality assessed by a supercoiled agarose gel stained with SYBRsafe stain, allowing visualization of other plasmid topologies such as undesired concatenated isoforms.

[0205] Growth kinetics, plasmid yield, and plasmid quality were presented in FIGs. 8A-8C.FIG. 8A demonstrated that the growth rate of the genetically-modified V. natriegens substantially exceeded that of both E. coli strains, including the fast-growing NEB® Turbo. Similarly, volumetric plasmid yields (FIG. 8B) mirrored the growth trends, with genetically-modified V. natriegens producing the highest yield, NEB® Turbo showing an intermediate yield, and DH5a the lowest. Additionally, the supercoiled gel revealed that plasmids isolated from genetically-modified V. natriegens and A. coli DH5a were predominantly monomeric and supercoiled, whereas plasmid from NEB® Turbo contained an appreciable percentage of material in higher-order concatenates (FIG. 8C). This finding is consistent with the RecA + genotype of NEB® Turbo, which enhances growth by restoring DNA repair capacity. These findings further explain the faster growth rate compared to other E. coli strains, but at the cost of increasing plasmid recombination events.

[0206] To further evaluate the performance of our new strain, 15 additional plasmids representing different antibiotic resistances, origins of replication, sizes, and downstream applications were transformed into genetically-modified V. natriegens and DH5a.Transformation reactions were plated out on agar plates and incubated overnight. On the following morning colonies were inoculated into 2 mL cultures and cultivated in a shaking incubator for 6 hours before harvest. Due to the lack of biomass from the E. coli cultivations, only the genetically-modified V. natriegens samples were moved forward for plasmid extraction (along with four additional plasmids that were not tested in E. coli).

[0207] To explore the flexibility of cultivation format, plasmid yields from cultures at 4, 6, and 8 hours in 96-well, 24-well, and 125 mL shake flask formats were also examined.Briefly, individual colonies of genetically-modified V. natriegens transformed with pUC19 were inoculated into different growth formats (25 mL culture volume in 125 mL baffled flask; 4 mL or 2 mL in a 24-well deep-well plate; and 1 mL or 0.5 mL in a 96-well deep-wellDocket No. 212391-704601plate). Each condition was tested in triplicate. All cultures were incubated in at 37°C for 4, 6, or 8 hours. The flask was agitated at 250 RPM with a 2.5 cm orbit, the 24-well deep-well plate at 300 RPM with a 2.5 cm orbit, and the 96-well deep-well plate at 1000 RPM with a 3 mm orbit.

[0208] As a result, all genetically-modified V. natriegens cultures showed significant growth, while only a few E. coli DH5a cultures showed any measurable growth (FIG. 9). Moreover, as shown in FIG. 10, usable amounts of DNA can be generated in this shortened timeframe regardless the culturing format, saving considerable time in a typical design-build-test cycle.FIGs 11A-11C show that even the smallest culture volumes (0.5 - 4 mL) produced several micrograms of plasmid in 4 hours (sufficient for standard miniprep workflows), with yields increasing as culture time is extended. Larger-volume cultures (25 mL) achieved midiprep-scale yields after 6-8 hours.

[0209] Collectively, the findings demonstrated that genetically-modified V. natriegens supports rapid, scalable plasmid production across common laboratory formats.Example 10. Molecular cloning using the genetically-modified V. natriegens

[0210] Having established that the genetically-modified V. natriegens accelerated the growth-related steps in recombinant DNA workflows, the compatibility of genetically-modified V. natriegens with common molecular cloning workflows were evaluated. Briefly, plasmid assembly reactions were performed using Gibson Assembly, Golden Gate Assembly, and Ligation-independent Cloning (LIC), and assemblies were transformed into the genetically-modified V. natriegens by chemical transformation.

[0211] Plasmid assembly: Gibson assemblies were performed in PCR tubes bymixing 0.025 pmol of each fragment together and bringing volume up to 5 pL with molecular biology grade water, and then adding 5 pL of 2x HiFi NEBuilder Master Mix (NEB). Reactions were incubated at 50°C in a thermocycler for 30 - 60 min.Golden Gate assemblies using Bsal sites were performed with the NEB ridge® Golden Gate Assembly Kit BsaI-HF®v2 (NEB #E1601). Reactions (20 pL total) contained 1 pL backbone plasmid normalized to 10 ng / kbp, insert DNA (from plasmids orpurified PCR amplicons) at 30 ng / kbp to achieve a 3:1 insert-to-backbone molar ratio of fragments, 2 pL T4 DNA Ligase Buffer, 2 pL Golden Gate Assembly EnzymeMix, and nuclease-free water. Assemblies were cycled 30 times between 37 °C for 1 min and 16 °C for 1 min, followed by 60 °C for 5 min and a 4 °C hold. 3 pL of completed reactions were used in transformations. LIC reactions were performedDocket No. 212391-704601following the procedure.

[0212] Briefly, primers LIC-vector-F and LIC-vector-R in Table 3 were used toamplify the backbone of pCYC02. Primers LIC-insert-F and LIC-insert-R in Tablexx were used to amplify a GFP-expression cassette from an internal plasmid(pCYC03-GFP).Primers used for LIC:Primer LIC homology Primer region Full primer (5’ to 3’) Name regionLIC-insert-F GAGAGTGAGGTA CTATTCAGGGATT GAGAGTGAGGTATTGA TTGAGGGT (SEQ GGTAAAAC(SEQ GGGTCTATTCAGGGATT ID NO: 27) ID NO: 28) GGTAAAAC(SEQ ID NO:29)LIC-insert-R GAGGTTAGAGGA CATCCACGCCTGA GAGGTTAGAGGAGAGT GAGTTAGAG(SEQ GATCTAG(SEQ ID TAGAGCATCCACGCCTG ID NO: 30) NO: 31) AGATCTAG(SEQ ID NO:32)LIC-vector-F ACCCTCAATACCT GGCGTAATCATGG ACCCTCAATACCTCACT CACTCTC(SEQ ID TCATAGC(SEQ ID CTCGGCGTAATCATGGT NO: 33) NO: 34) CATAGC(SEQ ID NO: 35) LIC-vector-R CTCTAACTCTCCT GTATATCTGGCCC CTCTAACTCTCCTCTAA CTAACCTC(SEQ GTACAT(SEQ ID CCTCGTATATCTGGCCCID NO: 36) NO: 37) GTACAT(SEQ ID NO: 38)

[0213] Q5 Hot Start High-Fidelity 2X master mix was used in both PCR reactions.The amplicons from both reactions were gel-purified. The pCYC02 amplicon (0.1 pmole) was mixed 2.5 mM dCTP, 5 mM DTT, 0.5 pL T4 DNA polymerase (NEB) inIX NEB Buffer 2.1. The GFP amplicon (0.1 pmole) was mixed with 2.5 mM dGTP,5 mM DTT, 0.5 pL T4 DNA polyemerase in IX NEB Buffer 2.1. Both of the T4DNA polymerase reactions were incubated at 23 °C for 40 min, followed by 20 min at 75°C. 3 pL of the GFP-T4 DNA polymerase reaction was mixed with 1 pL of the pCYC02-T4 DNA polymerase reaction and incubated at 23°C for 25 min. 2 pL of 50 mM EDTA was then added to the mixture and incubated at 23 °C for 5 additional min.3 pL of this assembly was used to transform genetically-modified V. natriegenschemical competent cells.

[0214] To compare LIC assembly to Gibson assembly, the pCYC02 ampliconamplified with LIC-vector-F and -R, and the GFP amplicon amplified with LIC-insert-F and -R were also assembled via Gibson Assembly using the NEBuilder HiFiDocket No. 212391-704601DNA Assembly protocol (the primer design used in this experiment was intentionally designed to be compatible with both LIC and Gibson Assembly). The assemblyproduct was transformed into genetically-modified V. natriegens chemicallycompetent cells.

[0215] Various dilutions of the recovery reaction were plated to ensure pickable,well-isolated colonies. 8 colonies from each transformation were randomly picked to inoculate 2-mL of genetically-modified V. natriegens media with chloramphenicol.The cultures were incubated at 37°C at 250 RPM for 5 hours, after which 1 mL ofcells were spun down. Agar plates and pellets were visualized under a blue light transilluminator for GFP expression:

[0216] In all cases, transformations resulted in significant colonies (see FIGs. 12A-12D), suitable for routine cloning and library construction applications. Plasmid isolation and analysis confirmed that the recovered constructs matched the expected assemblies, demonstrating that the genetically-modified V. natriegens supports efficient and reliable cloning workflows.Example 11. Cloning plasmid backbone

[0217] To facilitate efficient routine cloning in the genetically-modified V. natriegens, we designed a set of standardized high-copy cloning vectors collectively referred to as the pCYC series. These vectors were developed to provide flexibility in selection and assembly while maintaining compatibility with modern cloning workflows. Each vector incorporates a distinct antibiotic resistance marker, such as AmpR, CmR, and KanR, to enable parallel cloning applications, and features a high-copy origin of replication to support robust plasmid yields. To ensure seamless Golden Gate compatibility, all internal Bsal recognition sites were eliminated, and a unique Bsal entry site was introduced to allow rapid and directional DNA assembly. The Bsal sites can also be used for rapid linearization of the backbone for use with Gibson Assembly workflows. The overall architecture of these plasmids is shown in FIG. 13. The plasmid pCYC sequences are provided as follows:

[0218] >pCYC01 AmpR

[0219] TTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACC ACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCG AAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGC CGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCT GCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGDocket No. 212391-704601TTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGG GGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATAC CTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGAC AGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCC AGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTT GAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCC AGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTT CTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAG CTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGG AAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTC ATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCA ACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTAT GCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGA AACAGCTATGACCATGATTACGCCAAGCTCCTGGAGACCAGCATGGCTTGCAGT GGCGTTGGTCTCCGGCAACGCGTATATCTGGCCCGTACATCGCGAAGCAGCGCA AAACGCCTAACCCTAAGCAGATTCTTCATGCAATTGTCGGTCAAGCCTTGCCTTG TTGTAGCTTAAATTTTGCTCGCGCACTACTCAGCGACCTCCAACACACAAGCAGG GAGCAGATACTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCA CCATAGGGGATCGGGAGATCTCCCGATCCGTCGACGTCAGGTGGCACTTTTCGGG GAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTAT CCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAG AGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTG CCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGAT CAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATC CTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTC TGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCG CCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAG CATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATG AGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAG CTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGG AACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTG TAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGC TTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACT TCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTDocket No. 212391-704601GAGCGTGGCTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCC GTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATA GACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACC AAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGG ATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGT TTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTC (SEQ ID NO: 39)

[0220] >pCYC02 CmR

[0221] TTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACC ACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCG AAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGC CGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCT GCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGG TTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGG GGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATAC CTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGAC AGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCC AGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTT GAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCC AGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTT CTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAG CTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGG AAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTC ATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCA ACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTAT GCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGA AACAGCTATGACCATGATTACGCCAAGCTCCTGGAGACCAGCATGGCTTGCAGT GGCGTTGGTCTCCGGCAACGCGTATATCTGGCCCGTACATCGCGAAGCAGCGCA AAACGCCTAACCCTAAGCAGATTCTTCATGCAATTGTCGGTCAAGCCTTGCCTTG TTGTAGCTTAAATTTTGCTCGCGCACTACTCAGCGACCTCCAACACACAAGCAGG GAGCAGATACTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCA CCATAGGGGATCGGGAGATCTCCCGATCCGTCGACGTCAGGTGGCACTTTTCGGG GAAATGTGTGATCGGCACGTAAGAGGTTCCAACTTTCACCATAATGAAATAAGA TCACTACCGGGCGTATTTTTTGAGTTATCGAGATTTTCAGGAGCTAAGGAAGCTADocket No. 212391-704601AAATGGAGAAAAAAATCACTGGATATACCACCGTTGATATATCCCAATGGCATC GTAAAGAACATTTTGAGGCATTTCAGTCAGTTGCTCAATGTACCTATAACCAGAC CGTTCAGCTGGATATTACGGCCTTTTTAAAGACCGTAAAGAAAAATAAGCACAA GTTTTATCCGGCCTTTATTCACATTCTTGCCCGCCTGATGAATGCTCATCCGGAAT TCCGTATGGCAATGAAAGACGGTGAGCTGGTGATATGGGATAGTGTTCACCCTTG TTACACCGTTTTCCATGAGCAAACTGAAACGTTTTCATCGCTCTGGAGTGAATAC CACGACGATTTCCGGCAGTTTCTACACATATATTCGCAAGATGTGGCGTGTTACG GTGAAAACCTGGCCTATTTCCCTAAAGGGTTTATTGAGAATATGTTTTTCGTCTCA GCCAATCCCTGGGTGAGTTTCACCAGTTTTGATTTAAACGTGGCCAATATGGACA ACTTCTTCGCCCCCGTTTTCACCATGGGCAAATATTATACGCAAGGCGACAAGGT GCTGATGCCGCTGGCGATTCAGGTTCATCATGCCGTTTGTGATGGCTTCCATGTC GGCAGAATGCTTAATGAATTACAACAGTACTGCGATGAGTGGCAGGGCGGGGCG TAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTT TTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATC CCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAG GATCTTC (SEQ ID NO: 40)

[0222] >pCYC03_KanR TTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCG CTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGG TAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTA GTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTA ATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGG ACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTT CGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTAC AGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGG TATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGG GGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAG CGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGC AACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTT TCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTG ATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAA GCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATT AATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGDocket No. 212391-704601CAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTT CCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAAC AGCTATGACCATGATTACGCCAAGCTCCTGGAGACCAGCATGGCTTGCAGTGGC GTTGGTCTCCGGCAACGCGTATATCTGGCCCGTACATCGCGAAGCAGCGCAAAA CGCCTAACCCTAAGCAGATTCTTCATGCAATTGTCGGTCAAGCCTTGCCTTGTTGT AGCTTAAATTTTGCTCGCGCACTACTCAGCGACCTCCAACACACAAGCAGGGAG CAGATACTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCA TAGGGGATCGGGAGATCTCCCGATCCGTCGACGTCAGGTGGCACTTTTCGGGGA AATGTGAGTGGCCAATTTTGCGGCCGCCCTATTTGTTTATTTTTCTAAATACATTC AAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGA AAAAGGAAGAGTATGAGCCATATTCAACGGGAAACGTCTTGCTCTAGGCCGCGA TTAAATTCCAACATGGATGCTGATTTATATGGGTATAAATGGGCTCGCGATAATG TCGGGCAATCAGGTGCGACAATCTATCGATTGTATGGGAAGCCCGATGCGCCAG AGTTGTTTCTGAAACATGGCAAAGGTAGCGTTGCCAATGATGTTACAGATGAGAT GGTCAGACTAAACTGGCTGACGGAATTTATGCCTCTTCCGACCATCAAGCATTTT ATCCGTACTCCTGATGATGCATGGTTACTCACCACTGCGATCCCTGGGAAAACAG CATTCCAGGTATTAGAAGAATATCCTGATTCAGGTGAAAATATTGTTGATGCGCT GGCAGTGTTCCTGCGCCGGTTGCATTCGATTCCTGTTTGTAATTGTCCTTTTAACA GCGATCGCGTATTTCGTCTCGCTCAGGCGCAATCACGAATGAATAACGGTTTGGT TGATGCGAGTGATTTTGATGACGAGCGTAATGGCTGGCCTGTTGAACAAGTCTGG AAAGAAATGCATAAACTTTTGCCATTCTCACCGGATTCAGTCGTCACTCATGGTG ATTTCTCACTTGATAACCTTATTTTTGACGAGGGGAAATTAATAGGTTGTATTGAT GTTGGACGAGTCGGAATCGCAGACCGATACCAGGATCTTGCCATCCTATGGAAC TGCCTCGGTGAGTTTTCTCCTTCATTACAGAAACGGCTTTTTCAAAAATATGGTAT TGATAATCCTGATATGAATAAATTGCAGTTTCATTTGATGCTCGATGAGTTTTTCT AACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTT TAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCC CTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGG ATCTTC (SEQ ID NO: 41)

[0223] In sum, provided herein are systems that combines exceptional growth rate, genetic stability, and compatibility of the genetically-modified bacterial cells with standard molecular biology tools. When paired with advanced media formulations and / or high-copy cloning vectors provided herein, the genetically-modified bacterial cells consistently outperformed benchmark E. coli strains, achieving higher plasmidDocket No. 212391-704601yields, and markedly faster cultivation times. Accordingly, the genetically-modified bacterial cells represent a next-generation host for molecular cloning and plasmid DNA production by shortening the growth-dependent steps that dominate the molecular cloning workflow.While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims

Docket No. 212391-704601CLAIMS WHAT IS CLAIMED IS:

1. A genetically-modified bacterial cell of species Vibrio natriegens comprising a genetic modification to an mltG gene that results in reduced expression of mltG polypeptide encoded by the mltG gene, as compared to an amount of mltG polypeptide expressed from the mltG gene prior to the genetic modification.

2. The genetically-modified bacterial cell of claim 1, wherein the genetic modification results in increased transformation efficiency of a plasmid transformed into the genetically-modified bacterial cell after the genetically-modified bacterial cell is made chemically competent, as compared to transforming the plasmid into a comparable chemically competent wildtype bacterial cell.

3. The genetically-modified bacterial cell of claim 2, further comprising an additional modification to a gene selected from the group consisting of RecA, DAM, DNS, KDO, KdsD, gutQ, kdsA, kdsB, waaA, msbA, yhiD, IpxL, IpxM, (|)prol , (|)pro2, and any combination thereof.

4. A genetically-modified bacterial cell comprising a genetic modification that results in reduced expression of a polypeptide encoded by a gene having a polynucleotide sequence ofSEQ ID NO: 1, as compared to an amount of expression of the polypeptide encoded by the gene having the polynucleotide sequence of SEQ ID NO: 1 by a comparable chemically competent wildtype bacterial cell, wherein the genetic modification results in increased transformation efficiency of a plasmid transformed into the genetically-modified bacterial cell after the genetically-modified bacterial cell is made chemically competent, as compared to transforming the plasmid into a comparable chemically competent wildtype bacterial cell.

5. The genetically-modified bacterial cell of claim 4, wherein the genetic modification that results in reduced expression of a polypeptide encoded by the gene having the polynucleotide sequence ofSEQ ID NO: 1 comprises a deletion of the gene having the polynucleotide sequence ofSEQ ID NO: 1.

6. The genetically-modified bacterial cell of claims 4 or 5, wherein the genetic modification results in at least a l.O-fold, a 1.1-fold, a 1.2-fold, a 1.3-fold, a 1.4-fold, aDocket No. 212391-7046011.5-fold, a 1.6-fold, a 1.7-fold, a 1.8-fold, a 1.9-fold, a 2.0-fold, a 2.1-fold, a 2.2-fold, a 2.3-fold, a 2.4-fold, a 2.5-fold, a 2.6-fold, a 2.7-fold, a 2.8-fold, a 2.9-fold, or a 3.0-fold increase in transformants, as compared to the comparable chemically competent wildtype bacterial cell.

7. The genetically-modified bacterial cell of any one of claims 4-6, wherein the genetically- modified bacterial cell further comprises a second genetic modification.

8. The genetically-modified bacterial cell of claim 7, wherein the second genetic modification results in reduced expression of a polypeptide encoded by a gene having a polynucleotide sequence of SEQ ID NO: 3 in the chemically competent genetically- modified bacterial cell, as compared to the comparable chemically competent wildtype bacterial cell.

9. The genetically-modified bacterial cell of claim 7, wherein the second genetic modification that results in the reduced expression of the polypeptide encoded by the gene having the polynucleotide sequence SEQ ID NO: 3 comprises a deletion of the gene having the polynucleotide sequence of SEQ ID NO: 3.

10. The genetically-modified bacterial cell of any one of claims 4-9, wherein the genetically- modified bacterial cell further comprises a third genetic modification to one or more genes selected from the group consisting of: DAM, DNS, KDO, KdsD, gutQ, kdsA, kdsB, waaA, msbA, yhiD, IpxL, IpxM, (|)prol , (|)pro2, and any combination thereof.

11. The genetically-modified bacterial cell of claim 10, wherein the genetically-modified bacterial cell comprises a genetic modification to a DNS gene.

12. The genetically-modified bacterial cell of claim 11, wherein upon transformation of the plasmid into the genetically-modified bacterial cell, the genetically-modified bacterial cell expresses the plasmid with a reduced amount of plasmid multimers or concatemers, relative to an amount of plasmid multimers or concatemers produced in the same amount of time upon transformation of the plasmid into the comparable chemically competent wildtype bacterial cell.

13. The genetically-modified bacterial cell of claim 10, wherein the genetically-modified bacterial cell comprises a genetic modification to a DAM gene.Docket No. 212391-70460114. The genetically-modified bacterial cell of claim 10, wherein the genetically-modified bacterial cell comprises a genetic modification to a KdsD gene.

15. The genetically-modified bacterial cell of claim 10, wherein the genetically-modified bacterial cell comprises a genetic modification to a IpxL gene.

16. The genetically-modified bacterial cell of claim 10, wherein the genetically-modified bacterial cell comprises a genetic modification to a IpxM gene.

17. The genetically-modified bacterial cell of any one of claims 1-16, wherein upon culturing the genetically-modified bacterial cell in a growth medium, the genetically- modified bacterial cell replicates with reduced secretion of endotoxin into the growth medium, as compared to an amount of endotoxin secreted by a comparable bacterial strain lacking the genetic modification that is replicated in the growth medium for the same amount of time.

18. The genetically-modified bacterial cell of claim 7, wherein the genetically- modified bacterial cell comprises an inactivation or a deletion of (|)pro 1 or (|)pro2.

19. The genetically-modified bacterial cell of any one of claims 2-18, wherein the genetically-modified bacterial cell:(a) transforms the plasmid at an increased level;(b) replicates the plasmid at an increased level;(c) reduces an amount of plasmid multimers or concatemers;(d) expresses a transgene encoded by the plasmid at an increased level; or(e) a combination of (a), (b), (c), or (d);relative to a level of plasmid transformation, plasmid replication, plasmid multimers or concatemers, or transgene expression, respectively, produced in the same amount of time upon transformation of the plasmid into a comparable wildtype bacterial cell.

20. The genetically-modified bacterial cell of claim 19, wherein upon transformation of the plasmid into the genetically-modified bacterial cell, the genetically-modified bacterial cell replicates the plasmid at an increased level, relative to the level of plasmid replication produced in the same amount of time upon transformation of the plasmid into the comparable wildtype bacterial cell.Docket No. 212391-70460121. The genetically-modified bacterial cell of claim any one of claims 2-20, wherein upon transformation of the plasmid into the genetically-modified bacterial cell, the genetically-modified bacterial cell replicates the plasmid at a level that is at least 200% greater than the level of template plasmid replication produced in the same amount of time upon transformation of the plasmid into the bacterial cell of a comparable bacterial strain lacking the genetic modification.

22. The genetically-modified bacterial cell of claim 1, wherein upon culturing the genetically-modified bacterial cell in growth medium, the genetically-modified bacterial cell reaches a target density at least 150% faster than a replication rate of a bacterial cell of a comparable bacterial strain lacking the genetic modification that is replicated in the growth medium for the same amount of time, as measured by optical density at 600 nm.

23. The genetically-modified bacterial cell of claim 22, wherein upon culturing the genetically-modified bacterial cell in the growth medium, the genetically-modified bacterial cell replicates with a doubling time of about at least about 5 minutes, at least about 10 minutes, at least about 15 minutes, at least about 20 minutes, at least about 25 minutes or at least about 30 minutes, as measured by optical density at 600 nm.

24. The genetically-modified bacterial cell of claim 22, wherein upon culturing the genetically-modified bacterial cell in the growth medium, the genetically-modified bacterial cell replicates with a doubling time of less than 30 minutes, less than 29 minutes, less than 28 minutes, less than 27 minutes, less than 26 minutes, less than 25 minutes, less than 24 minutes, less than 23 minutes, less than 22 minutes, less than 21 minutes, less than 20 minutes, less than 19 minutes, less than 18 minutes, less than 17 minutes, less than 16 minutes, or less than 15 minutes, as measured by optical density at 600 nm.

25. The genetically-modified bacterial cell of claim 3, wherein upon transforming the plasmid into the genetically-modified bacterial cell, the genetically-modified bacterial cell in liquid media reaches a cell density for purification in less than 24 hours that is equivalent to a cell density for purification reached by E. coli DH5a in liquid media after 36 hours, as measured by optical density at 600 nm.

26. The genetically-modified bacterial cell of claim 3, wherein upon liquid culturing colonies of the genetically-modified bacterial cell comprising the plasmid, the genetically-modified bacterial cell reaches a cell density for purification in lessDocket No. 212391-704601than 4 hours that is equivalent to a cell density for purification reach by E. coli DH5a in liquid media after 12 hours, as measured by optical density at 600 nm.

27. The genetically-modified bacterial cell of claim 4, wherein the genetically-modified bacterial cell is Escherichia spp., Shigella spp., Salmonella spp., Campylobacter spp., Neisseria spp., Haemophilus spp., Aeromonas spp., Francisella spp., Yersinia spp., Klebsiella spp., Bordetella spp., Legionella spp., Citrobacter spp., Chlamydia spp., Brucella spp., Pseudomonas spp., Helicobacter spp., Moraxella spp., Stenotrophomonas spp., Bdellovibrio spp., Acinetobacter spp., Enterobacter spp., and Vibrio spp.

28. A genetically-modified bacterial cell comprising a genetic modification that results in increased and / or constitutive expression of one or more bacterial stress genes as compared to a comparable wildtype bacterial cell, wherein the genetic modification comprises an insertion of a modified oxyR gene into the genetically-modified bacterial cell, and wherein the modified oxyR gene is exogenous to the genetically-modified bacterial cell prior to the insertion, and wherein the increased and / or constitutive expression of the one or more bacterial stress genes results in an increase in plasmid yield after transformation, as compared to the comparable wildtype bacterial cell.

29. The genetically-modified bacterial cell of claim 28, wherein the modified oxyR gene has a polynucleotide sequence with at least 95% identity to the polynucleotide sequence of SEQ ID NO:

230. The genetically-modified bacterial cell of claim 28, wherein the modified oxyR gene has the polynucleotide sequence of SEQ ID NO: 2.

31. The genetically-modified bacterial cell of any one of claims 28-30, wherein the genetic modification results in the increased expression of OxyR polypeptide encoded by the modified oxyR gene.

32. The genetically-modified bacterial cell of claim 31, wherein the OxyR polypeptide encoded by the modified oxyR gene has at least 1 amino acid substitution with respect to a wildtype OxyR polypeptide encoded by an oxyR gene sequence of SEQ ID NO: 7.

33. The genetically-modified bacterial cell of any one of claims 28-32, wherein the genetic modification results in increased expression of the one or more bacterial stress genes, as compared to the comparable wildtype bacterial cell.Docket No. 212391-70460134. The genetically-modified bacterial cell of any one of claims 28-33, wherein the genetically-modified bacterial cell further comprises a second genetic modification.

35. The genetically-modified bacterial cell of claim 34, wherein the second genetic modification results in reduced expression of a polypeptide encoded by a gene having a polynucleotide sequence of SEQ ID NO: 3 in the genetically-modified bacterial cell, as compared to the comparable wildtype bacterial cell.

36. The genetically-modified bacterial cell of claim 34, wherein the second genetic modification that results in a reduced expression of a polypeptide encoded by the gene having a polynucleotide sequence set forth in SEQ ID NO: 3 comprises a deletion of the gene having the polynucleotide sequence of SEQ ID NO: 3.

37. The genetically-modified bacterial cell of any one of claims 28-36, wherein the genetically-modified bacterial cell further comprises a third genetic modification to one or more genes selected from the group consisting of DAM, KDO, KdsD, gutQ, kdsA, kdsB, waaA, msbA, mltG, yhiD, IpxL, IpxM, (|)prol, (|)pro2, and any combination thereof.

38. The genetically-modified bacterial cell of claim 37, wherein the genetically-modified bacterial cell comprises a genetic modification to a DAM gene.

39. The genetically-modified bacterial cell of claim 37, wherein the genetically-modified bacterial cell comprises a genetic modification to a KdsD gene.

40. The genetically-modified bacterial cell of claim 37, wherein the genetically-modified bacterial cell comprises a genetic modification to a IpxL gene.

41. The genetically-modified bacterial cell of claim 37, wherein the genetically-modified bacterial cell comprises a genetic modification to a IpxM gene.

42. The genetically-modified bacterial cell of any one of claims 28-41, wherein upon culturing the genetically-modified bacterial cell in a growth medium, the genetically- modified bacterial cell replicates with reduced secretion of endotoxin into the growth medium, as compared to an amount of endotoxin secreted by a comparable bacterial strain lacking the genetic modification that is replicated in the growth medium for the same amount of time.Docket No. 212391-70460143. The genetically-modified bacterial cell of claim 37, wherein the genetically-modified bacterial cell comprises an inactivation or a deletion of (|)pro 1 or (|)pro2.

44. The genetically-modified bacterial cell of any one of claims 28-43, wherein the genetically-modified bacterial cell:(a) replicates the plasmid at an increased level; or(b) expresses a transgene encoded by the plasmid at an increased level, relative to a level of plasmid replication or transgene expression, respectively, produced in the same amount of time upon transformation of the plasmid into the comparable wildtype bacterial cell.

45. The genetically-modified bacterial cell of claim 44, wherein upon transformation of the plasmid into the genetically-modified bacterial cell, the genetically-modified bacterial cell replicates the plasmid at the increased level, relative to the level of plasmid replication produced in the same amount of time upon transformation of the plasmid into the comparable wildtype bacterial cell.

46. The genetically-modified bacterial cell of claim any one of claims 28-45, wherein upon transformation of the plasmid into the genetically-modified bacterial cell, the genetically-modified bacterial cell replicates the plasmid at a level that is at least 200% greater than the level of template plasmid replication produced in the same amount of time upon transformation of the plasmid into the bacterial cell of a comparable bacterial strain lacking the genetic modification.

47. The genetically-modified bacterial cell of any one of claims 28-46, wherein upon culturing the genetically-modified bacterial cell in growth medium, the genetically- modified bacterial reaches a target density 150% faster than a replication rate of a bacterial cell of a comparable bacterial strain lacking the genetic modification that is replicated in the growth medium for the same amount of time, as measured by optical density at 600 nm.

48. The genetically-modified bacterial cell of claim 47, wherein upon culturing the genetically-modified bacterial cell in the growth medium, the genetically-modified bacterial cell replicates with a doubling time of about at least about 5 minutes, at least about 10 minutes, at least about 15 minutes, at least about 20 minutes, at least about 25 minutes or at least about 30 minutes, as measured by optical density at 600 nm.Docket No. 212391-70460149. The genetically-modified bacterial cell of claim 47, wherein upon culturing the genetically-modified bacterial cell in the growth medium, the genetically-modified bacterial cell replicates with a doubling time of less than 30 minutes, less than 29 minutes, less than 28 minutes, less than 27 minutes, less than 26 minutes, less than 25 minutes, less than 24 minutes, less than 23 minutes, less than 22 minutes, less than 21 minutes, less than 20 minutes, less than 19 minutes, less than 18 minutes, less than 17 minutes, less than 16 minutes, or less than 15 minutes, as measured by optical density at 600 nm.

50. The genetically-modified bacterial cell of claim 28, wherein the genetically-modified bacterial cell is Escherichia spp., Shigella spp., Salmonella spp., Campylobacter spp., Neisseria spp., Haemophilus spp., Aeromonas spp., Francisella spp., Yersinia spp., Klebsiella spp., Bordetella spp., Legionella spp., Citrobacter spp., Chlamydia spp., Brucella spp., Pseudomonas spp., Helicobacter spp., Moraxella spp., Stenotrophomonas spp., Bdellovibrio spp., Acinetobacter spp., Enterobacter spp., and Vibrio spp.

51. The genetically-modified bacterial cell of any one of claims 2-48, wherein the plasmid comprises an origin of replication selected from the group consisting of pUC19, pcDNA3.1, pET, PBR322, pACYC184, RK2, RSF1010, pl 5 A, pNG2, pSClOlts, pSa, pTHT15, pAL5000, pAMBl, pBBRl, pBBRl-UP, pBCl, pBPl, pCB102, pCD6,pIJ101, pIM13, pIP501, pMBl, pSG5, pUBUO, and pWKSl.

52. The genetically-modified bacterial cell of any one of claims 2-48, wherein the plasmid comprises an antibiotic selection marker selected from the group consisting of kanamycin (KAN), tetracycline (TET), chloramphenicol (CAM), gentamicin (GEN), spectinomycin (SPEC), erythromycin (ERM), and carbenicillin.

53. A genetically-modified bacterial cell of species Vibrio natriegens comprising a genetic modification to a gene selected from the group consisting of mltG, RecA, DAM, DNS, KDO, KdsD, gutQ, kdsA, kdsB, waaA, msbA, yhiD, IpxL, IpxM, (|)prol , (|)pro2, and any combination thereof.

54. An expression product produced by the genetically-modified bacterial cell of any one of claims 1-53.

55. A system for replicating a genetically-modified bacterial cell, comprising:Docket No. 212391-704601(a) the genetically-modified bacterial cell of any one of claims 1-53; and(b) growth medium.

56. The system of claim 55, wherein the growth medium comprises yeast extract, vegetable tryptone, MgSC>4, NaCl, K2HPO4, and a buffering agent.

57. The system of claim 56, wherein the buffering agent is Tris.

58. The system of claim 55, wherein the growth medium is in a liquid or a solid agar format.

59. The system of claim 55, wherein the growth medium increases growth kinetics of the genetically-modified bacterial cell, or plasmid yield or plasmid quality of a plasmid replicated using the genetically-modified bacterial cell, as compared to a LB or a TB media.

60. A method of making a genetically-modified bacterial cell, the method comprising:(a) obtaining a wildtype bacterial cell; and(b) performing a modification that results in altered expression of a polypeptide encoded by at least one gene having a polynucleotide sequence of SEQ ID NO: 1 - SEQ ID NO: 2, wherein the altered expression of the polypeptide comprises an increase in expression of the polypeptide or a decrease in expression in the polypeptide as compared to the wildtype bacterial cell prior to the modification, thereby generating the genetically-modified bacterial cell.

61. A method of expressing a biomolecule encoded by a plasmid in a genetically-modified bacterial cell, the method comprising:(a) transforming the plasmid into the genetically-modified bacterial cell ofany one of claims 1-53;(b) culturing the genetically-modified bacterial cell comprising the plasmid;(c) expressing the biomolecule from the plasmid using the genetically- modified bacterial cell in culture medium; and(d) purifying the biomolecule from the genetically-modified bacterial cells.

62. A biomolecule produced by the method of claim 61.

63. A system for transforming a genetically-modified bacterial cell, comprising:(a) the genetically-modified bacterial cell of any one of claims 1-53; and(b) a cloning plasmid.Docket No. 212391-70460164. The system of claim 63, wherein the cloning plasmid comprises a backbone comprising a high-copy origin of replication, an antibiotic resistance marker, or a restriction enzyme site.

65. The system of claim 64, wherein the cloning plasmid comprises a backbone comprising a high-copy origin of replication selected from the group consisting of pUC19, pcDNA3.1, pET, PBR322, pACYC184, RK2, RSF1010, pl 5 A, pNG2, pSClOlts, pSa, pTHT15, pAL5000, pAMBl, pBBRl, pBBRl-UP, pBCl, pBPl, pCB102, pCD6,pU101, pIM13, pIP501, pMBl, pSG5, pUBUO, and pWKSl.

66. The system of claim 64, wherein the cloning plasmid comprises a backbone comprising an antibiotic resistance marker selected from the group consisting of kanamycin (KAN), tetracycline (TET), chloramphenicol (CAM), gentamicin (GEN), spectinomycin (SPEC), erythromycin (ERM), and carbenicillin.

67. The system of claim 63, wherein the cloning plasmid comprises a backbone comprising SEQ ID NO: 39.

68. The system of claim 63, wherein the cloning plasmid comprises a backbone sequence set forth in any one of SEQ ID NOs 40-42.